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	Summary	
	
The	 discovery	 of	 the	 connection	 between	Wnt/β-catenin	 signaling,	 APC	 and	 colon	 cancer	
two	decades	ago	created	fertile	ground	for	research	in	the	field	of	Wnt/β-catenin	signaling.	
The	 hope	 was	 that	 by	 elucidating	 all	 the	 elements	 of	 the	 cascade,	 one	 might	 discover	
inhibitors	 of	 this	 pathway	 that	 help	 treating	 cancer	 patients.	 This	 work	 has	 revealed	 a	
picture	 of	Wnt/β-catenin	 signaling’s	 pivotal	 involvement	 in	 virtually	 every	 developmental	
process	as	well	as	in	adult	tissue	homeostasis;	moreover,	Wnt-signaling	is	involved	in	many	
forms	of	cancer.	Unfortunately,	one	aspect	that	also	became	clear	over	the	years	was	that	
targeting	 the	 pathway	 is	 not	 a	 simple	matter.	 Apart	 from	 the	 fact,	 that	 inhibition	 of	 the	
pathway	is	associated	with	severe	side	effects	due	to	its	crucial	role	in	gut	homeostasis,	it	is	
also	a	notoriously	difficult	cascade	to	target.	This	difficulty	arises	mainly	because	there	are	
no	pathway	specific	kinases	known	against	which	an	inhibitor	could	be	developed.	Another	
problematic	aspect	is	the	dual	role	the	main	pathway	effector	b-catenin	has	in	transducing	
the	Wnt	signal	as	well	as	maintaining	adherens	junctions.	Nevertheless,	the	last	years	have	
shown	 several	 possible	 ways	 to	 tackle	 these	 issues.	 Besides	 the	 discovery	 of	 Porcupine	
inhibitors,	which	hinder	palmitoylation	of	 the	Wnt	 ligands,	 thereby	blocking	secretion	and	
shutting	down	the	pathway,	the	idea	to	block	b-catenin’s	interaction	with	transcriptional	co-
factors	has	gained	some	merit.	 In	 this	work,	we	set	out	 to	 test	 the	advantages	and	draw-
backs	of	Porcupine	inhibitors.	Furthermore,	we	wanted	to	clarify	the	tissue	specific	roles	of	
b-catenin’s	 transcriptional	 co-factors	with	 regards	 to	 their	 ability	 to	 transduce	 the	 signal.	
This	 information	 will	 be	 crucial	 to	 judge	 the	 feasibility	 of	 using	 an	 inhibitor	 in	 a	 specific	
setting.		
Here	 we	 show	 that	 Porcupine	 is	 overexpressed	 in	 a	 murine	 cutaneous	 squamous	 cell	
carcinoma	model	(cSCC)	model,	as	well	as	in	human	cSCCs.	This	gave	us	the	incentive	to	test	
Porcupine	 inhibitors	 in	 this	 cSCC	 model,	 where	 we	 found	 that	 this	 hinders	 tumor	
development	 and	 reduces	 the	 cancer	 stem	 cell	 compartment	 of	 established	 tumors.	 This	
leads	to	increased	differentiation	and	a	reduction	of	markers	for	tumor	invasiveness.	
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	In	an	effort	to	further	characterize	the	specific	roles	of	b-catenin’s	transcriptional	co-factors,	
we	used	mouse	models	with	specific	domain	deletions	inhibiting	the	binding	of	b-catenin	to	
the	N-terminal	 co-factors	 (Bcl9	and	Pygopus)	 and	 the	 co-factors	 to	each	other.	We	 found	
that	 the	 integrity	 of	 these	 interactions	 is	 specifically	 needed	 in	 the	 development	 of	 the	
embryonic	 heart	 and	 limbs.	 Loss	 of	 Bcl9-Pygo-b-catenin	 binding	 in	 mouse	 embryos	
phenocopies	human	congenital	heart	disorders	by	disrupting	a	molecular	cascade	necessary	
for	 the	 correct	 specification	 of	 the	 heart	 outflow	 tract	 and	 valves.	We	 thus	 uncovered	 a	
novel	role	for	Wnt/b-catenin	signaling	in	heart	development	and	possibly	human	congenital	
heart	disorders.			
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	Zusammenfassung	
Die	 Erkenntnis	 in	 den	 Neunzigerjahren,	 dass	 zwischen	 der	 Wnt/b-catenin	 Signalkaskade,	
APC	 und	 Darmkrebs	 ein	 Zusammenhang	 besteht,	 liess	 die	 Forschung	 im	 Wnt/b-catenin	
Gebiet	aufleben.	Das	Ziel	dieser	Forschungstätigkeit	war,	durch	besseres	Verständnis	aller	
Elemente	der	 Signalkaskade	neue	 Inhibitoren	 zu	entdecken,	um	Darmkrebs	 zu	heilen.	Die	
Studien	 damals	 haben	 gezeigt,	 dass	 die	 Wnt/b-catenin	 Signalkaskade	 in	 praktisch	 allen	
entwicklungsbiologischen	 Schritten	 als	 auch	 in	 der	 Gewebehomöostase	 eine	 Rolle	 spielt.	
Unglücklicherweise	 wurde	 auch	 immer	 klarer,	 dass	 es	 nicht	 einfach	 werden	 würde	 diese	
Signalkaskade	 zu	 inhibieren.	 Abgesehen	 davon,	 dass	 die	 Inhibition	 der	 Kaskade	 schwere	
Nebenwirkungen	 hervorrufen	 kann	 wegen	 der	 wichtigen	 Rolle,	 die	 die	 Wnt/b-catenin	
Signalkaskade	in	der	Homöostase	des	Darmes	spielt,	 ist	es	generell	extrem	schwierig	diese	
Kaskade	 zu	 inhibieren.	 Dies	 kommt	 vor	 allem	 daher,	 dass	 keine	 Kaskaden-spezifischen	
Kinasen	 bekannt	 sind,	 welche	 als	 Ziel	 eines	 Inhibitors	 verwendet	 werden	 könnten.	 Ein	
anderer	sehr	problematischer	Aspekt	der	Kaskade	ist	die	Doppelrolle	des	Haupteffektors	b-
catenin	 als	 Signalgeber	 sowie	 als	 Teil	 der	 Adhärenzverbindungen	 zwischen	 zwei	 Zellen.	
Trotzdem	 wurden	 in	 den	 letzten	 Jahren	 verschiedene	 Möglichkeiten	 gezeigt,	 wie	 das	
Problem	 angegangen	 werden	 könnte.	 Einerseits	 wäre	 da	 die	 Entdeckung	 von	 Porcupine	
Inhibitoren	zu	erwähnen,	welche	die	Palmytoylierung	der	Wnt-Liganden	verhindern,	was	zur	
kompletten	 Blockade	 jeglicher	 Sekretion	 der	 Wnt-Moleküle	 führt,	 womit	 die	 Kaskade	
blockiert	wird.	Des	Weiteren	wird	die	Idee	in	Erwägung	gezogen,	die	Bindung	von	b-catenin	
mit	transkriptionellen	Hilfsfaktoren	zu	blockieren.	In	dieser	Arbeit	wollten	wir	die	Vor-	und	
Nachteile	 der	 Inhibierung	 von	 Porcupine	 klären.	 Zusätzlich	 versuchten	 wir	 klarzustellen,	
welche	 gewebsspezifische	 Aufgabe	 die	 b-catenin	 Hilfsfaktoren	 haben	 in	 Bezug	 auf	 ihre	
Fähigkeit,	das	Signal	zu	übermitteln.	Diese	Informationen	werden	imminent	wichtig	sein	um	
zu	beurteilen,	ob	ein	Inhibitor	in	einem	spezifischen	Fall	erfolgsversprechend	sein	kann.		
In	 dieser	 Studie	 konnten	 wir	 zeigen,	 dass	 Porcupine	 in	 einem	 Plattenepithelkarzinom-	
Modell	 von	Mäusen	 überexprimiert	 ist.	 Interessanterweise	 trifft	 diese	 Beobachtung	 auch	
auf	menschliche	Tumore	zu.	Diese	Entdeckung	gab	uns	den	Anreiz,	Porcupine	Inhibitoren	in	
einem	Mausmodell	zu	testen.	Wir	entdeckten	dabei,	dass	diese	Inhibitoren	die	Entstehung	
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	der	Tumore	behindern	und	die	Stammzell-Nische	der	schon	etablierten	Tumore	verkleinert.	
Dies	 führt	 zu	 erhöhter	 Differenzierung	 und	 einer	 Reduktion	 von	 Markern	 der	
Tumorinvasion.	 In	 einem	 Versuch,	 die	 spezifische	 Rolle	 von	b-catenin’s	 transkriptionellen	
Hilfsfaktoren	 zu	 charakterisieren,	benützten	wir	Mausmodelle	mit	 spezifischen	Deletionen	
um	die	Bindung	von	b-catenin	mit	den	N-terminalen	Hilfsfaktoren	(Bcl9	und	Pygopus)	und	
der	Hilfsfaktoren	zueinander	zu	verunmöglichen.	Wir	entdeckten,	dass	die	Integrität	dieser	
Interaktionen	 spezifisch	 während	 der	 Entwicklung	 des	 embryonalen	 Herzens	 und	 der	
Extremitäten	 gebraucht	 wird.	 Der	 Verlust	 dieser	 Interaktionen	 unterbindet	 molekulare	
Signalkaskaden,	 welche	 für	 die	 korrekte	 Spezifikation	 des	 Herzens	 essentiell	 sind,	 was	 zu	
Phänotypen	 führt,	 welche	 an	 häufig	 auftretende	 Herzfehler	 in	 menschlichen	 Patienten	
erinnern.	 Somit	 haben	 wir	 eine	 neue	 Aufgabe	 der	 Wnt/b-catenin	 Signalkaskade	 in	 der	
Herzentwicklung	sowie	in	der	Entstehung	von	humanen	Herzfehlern	gefunden.	  
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	Introduction	
In	the	nineties,	the	discovery	of	the	connection	between	Wnt/β-catenin	signaling,	APC	and	
colon	cancer,	sparked	intense	research	in	the	field	of	Wnt/β-catenin	signaling.	The	hope	was	
that	by	elucidating	all	the	possible	elements	of	the	cascade,	one	might	discover	inhibitors	of	
this	pathway	that	could	help	treating	cancer	patients	(Kahn,	2014).	The	work	has	revealed	a	
picture	 of	Wnt/β-catenin	 signaling’s	 pivotal	 involvement	 in	 virtually	 every	 developmental	
process	as	well	as	in	adult	tissue	homeostasis	and	many	forms	of	cancers.		
Depending	 on	 which	 Wnt	 binds	 to	 what	 Frizzled-co-receptor	 combination,	 different	
downstream	cascades	 are	 induced.	Adding	 to	 the	 complexity	 there	 are	19	different	Wnts	
and	10	Frizzled	receptors	(Kahn,	2014).		
In	this	work,	we	focus	on	the	Wnt/β-catenin	signaling	cascade,	which	 is	most	prominently	
triggered	by	Wnt	binding	to	Frizzled	and	the	co-receptors	Lrp5/6.	This	binding	event	leads	to	
recruitment	and	inactivation	of	the	destruction	complex,	a	large	protein	complex	containing	
APC	 (Adenomatous	 polyposis	 coli),	 Axin	 and	 Ck1	 (Casein	 kinase1)	 among	 others,	 to	 the	
membrane.	 When	 active	 this	 multiprotein	 complex	 marks	 β-catenin	 for	 degradation	 via	
phosphorylation	in	the	absence	of	a	Wnt	ligand.	Destruction	complex	inactivation	upon	Wnt	
binding	leads	to	β-catenin	stabilization,	promoting	its	translocation	to	the	nucleus,	where	it	
associates	with	its	transcription	factors	of	the	Tcf	family.	For	efficient	transcription	to	occur,	
several	other	co-factors	binding	to	β-catenin	are	needed,	such	as	a	Bcl9-Pygo	complex	at	the	
N-terminal	end	of	β-catenin	and	at	the	C-terminus	histone	modifiers	like	CREB	and	p-300,	as	
well	 as	 several	 other	 transcriptional	 co-activators	 (Valenta	 et	 al.,	 2012).	 The	 exact	
requirement	for	specific	co-factors	in	certain	cell	types	and	developmental	stages	is	an	open	
question,	which	we	are	 trying	 to	address	with	 this	work.	Many	direct	 target	genes	of	 the	
cascade	 are	 negative	 feedback	 regulators,	 ensuring	 that	 the	 pathway	 activation	 does	 not	
overshoot.		
Curiously,	 in	D.	melanogaster,	 one	 of	 the	 bona	 fide	Wnt	 target	 genes	 is	 Frizzled	 3,	while	
Arrow	(the	homologue	of	Lrp5/6)	seems	to	be	a	negative	target.	A	Frizzled	protein	being	a	
positive	target	was	mysterious,	since	one	would	associate	a	positive	rather	than	a	negative	
role	 for	 a	 receptor	 of	 the	 pathway,	 which	 would	 make	 it	 a	 positive	 feedback	 regulator.	
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	Therefore,	we	 set	out	 to	 investigate	 the	 specific	 roles	of	 Frizzled	3	as	well	 as	Arrow	 in	D.	
melanogaster	development	as	well	as	how	their	regulation	by	the	Wnt/β-catenin	signaling	
cascade	works	(Schilling	et	al.,	2014),	manuscript	inserted	below.	
As	noted	above,	 impetus	 for	 therapeutic	modulation	of	 the	Wnt/β-catenin	 cascade	arises	
from	 its	 role	as	a	key	player	 in	most	epithelial	cancer	types,	 foremost	among	them	colon,	
breast	and	lung	carcinoma,	as	well	as	its	involvement	in	other	diseases	such	as	osteoporosis,	
fibrosis	 and	 neurological	 diseases.	 The	 task	 has	 been	 herculean	 because	 of	 the	 lack	 of	
kinases	to	target,	as	well	as	the	multi-functionality	of	many	of	the	key	pathway	components,	
especially	β-catenin.	To	remedy	this,	a	better	understanding	of	the	molecular	mechanisms	
of	the	cascade	as	well	as	of	the	specific	biological	consequences	of	Wnt/β-catenin	signaling	
in	 different	 tissues	 is	 of	 utmost	 importance.	 Only	 in	 recent	 years,	 due	 to	 a	 better	
understanding	 of	 the	 pathway,	 some	 promising	 attempts	 at	 inhibiting	 this	 cascade	 have	
been	made	(Zimmerli	et	al.,	2017).		
One	such	avenue	is	inhibiting	Porcupine,	which	is	necessary	for	all	Wnts	to	be	secreted.	It	is	
also	 the	 only	 known	 enzyme	 that	 is	 specific	 to	 the	Wnt	 cascade	 (Herr	 et	 al.,	 2012).	 The	
usefulness	 of	 Porcupine	 inhibition	 is	 unclear	 in	 cancers	 with	 activating	 mutations	
downstream	of	 the	 ligands,	 like	APC	 in	 colon	 carcinoma.	However	 there	 are	 cancers	with	
increased	 secretion	of	Wnts	 like	 certain	 SCCs	 and	mammary	 carcinomas.	We	 investigated	
this	 in	 a	 study	 looking	at	 the	 role	of	Wnt	 ligands	 in	 the	progression	of	human	papilloma-
virus-driven	cSCCs	(Zimmerli	et	al.,	2017,	included	below),	(Manuscript:	WNT	ligands	control	
initiation	 and	 progression	 of	 human	 papilloma-virus-driven	 squamous	 cell	 carcinoma;	 in	
revision,	attached	below).	 
Another	 therapeutic	 target	 might	 be	 β-catenin’s	 N-terminal	 co-activators	 Bcl9	 and	 Pygo.	
They	are	especially	interesting,	since	a	single	amino	acid	mutation	in	β-catenin	can	abrogate	
the	 binding	 of	 β-catenin	 to	 these	 co-factors.	 The	 drawback	 is	 the	 relatively	 scarce	
knowledge	about	their	exact	function	in	the	Wnt/β-catenin	cascade	in	mammals.		
A	reason	for	this	is,	that	when	Pygo	and	Bcl9	were	discovered	in	Drosophila	as	components	
of	the	Wnt/β-catenin	signaling	cascade,	crucial	for	any	β-catenin	mediated	outputs	(Kramps	
et	 al.,	 2002),	 the	 enthusiasm	 in	 the	 field	 reached	 its	 zenith.	 But	when	 it	 became	obvious	
from	studies	using	mouse	models,	 that	 these	 factors	were	not	needed	 to	 transduce	all	β-
catenin	mediated	signaling	 in	mammals,	 the	attention	paid	 to	 these	proteins	got	declined	
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	abruptly.	Nevertheless,	recent	studies	take	up	the	cudgels	for	the	validity	of	N-terminal	β-
catenin	 interactors	 as	 drug	 targets.	 In	 these	 studies,	 it	 was	 shown	 that	 these	 N-terminal	
factors	are	negligible	in	normal	gut	homeostasis,	but	loss	of	them	reduces	colon	carcinoma	
invasiveness	(Deka	et	al.,	2010,	Moor	et	al.,	2015).		
Therefore,	we	decided	to	revisit	the	function	of	these	proteins	in	mammalian	development.	
Fuel	 for	this	 idea	were	the	findings,	that	Pygo	as	well	as	Bcl9	 loss	of	 function	are	 lethal	 in	
developing	 mouse	 embryos,	 despite	 not	 being	 necessary	 for	 all	 Wnt/β-catenin	 signaling	
outputs.	 This	 led	 us	 to	 question	 if	 the	 cause	of	 this	 lethality	was	Wnt/β-catenin	 signaling	
related,	 indicating	 tissue	 specificity	 for	 a	 role	 of	 these	 proteins	 as	 β-catenin	 co-factors	 in	
mammals,	 or	 if	 they	 acquired	 novel,	 β-catenin	 independent	 functions	 in	 the	mammalian	
kingdom.	 A	 possibility	which	 should	 not	 be	 neglected	 is	 that	 these	 functions	 are	 actually	
conserved	in	flies	as	well,	but	were	so	far	overlooked,	because	the	Wnt-induced	lethality	is	
too	early.		
In	 our	 lab,	 we	 have	 shown	 that	 Bcl9	 and	 Pygo	 indeed	 do	 have	 β-catenin	 independent	
functions,	specifically	 in	the	developing	eye	as	well	as	teeth	(Cantù	et	al.,	2014),	(Cantù	et	
al.,	2017),	but	the	observed	lethality	of	the	embryos	upon	loss	of	these	β-catenin	N-terminal	
co-factors	is	most	likely	β-catenin	dependent	(Manuscript:	Mutations	in	the	Wnt/b-catenin	
cofactors	Bcl9	and	Pygo	cause	congenital	heart	malformations,	below).		
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that a causative link between aberrant Wnt signalling and many types of human cancers was established more than a decade ago,
no Wnt signalling inhibitors have made it into the clinic so far. One reason for this is that no pathway‐speciﬁc kinase is known.
Additionally, targeting the protein–protein interactions needed to transduce the signal has not met with success so far.
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reported in mouse models of disease. In this review, we summarize possible roads to follow during the quest to pharmacologically
modulate the Wnt signalling pathway in cancer.
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Introduction
Wnts activate diverse signalling cascades
Mammalian genomes encode for 19 different Wnt
molecules, which can bind to 10 different Frizzled (FZD)
receptors (Koike et al., 1999; Langton et al., 2016). FZDs
belong to the family of seven‐pass transmembrane GPCRs.
When bound by Wnt proteins on their extracellular cysteine
rich domain, they activate the cytosolic protein Dishevelled
to transduce the signal inside the cell (reviewed in
Dijksterhuis et al., 2014). Several independentWnt signalling
cascades are activated in response to Wnts binding to their
cognate receptors. The best studied and perhaps the most
important is the β‐catenin‐dependent signalling cascade,
mediated by β‐catenin (Figure 1). The β‐catenin‐dependent
cascade is of foremost importance for normal development
and tissue homeostasis. When deregulated, it causes the
initiation and progression of a myriad of different tumour
types. Besides the β‐catenin‐mediated cascade, there are other
β‐catenin‐independent outputs, such as the planar cell
polarity and the Wnt/Ca2+ signalling pathway. The nature
of the pathway transduced depends on the receptors/co‐
receptors present (He et al., 1997; van Amerongen et al.,
2008). To transduce the β‐catenin‐dependent signal, FZD
proteins bind the co‐receptors low‐density lipoprotein 5
(LRP5) or LRP6. Why in each speciﬁc context a particular
Wnt/receptor combination activates one cascade or another
is not entirely clear. However, some Wnts are thought to be
preferentially β‐catenin dependent (e.g. Wnt3a) or
independent (e.g. Wnt5a). Wnt5a normally binds to FZD
receptors and Ror/Ryk instead of Lrp5/6 and activates, among
others, JNK signalling (Yamanaka, 2002). β‐Catenin‐
independent signalling is often associated with the
regulation of cell adhesion, migration and polarity (reviewed
in Veeman et al., 2003). Furthermore, it is also thought to
suppress β‐catenin‐dependent signalling (Yuzugullu et al.,
2009). The β‐catenin‐independent cascade has received
increasing attention in recent years due to its role in
melanoma formation and metastasis (Weeraratna et al.,
2002; Chien et al., 2009).
While the search for therapeutic targets has long focused
on the transduction of the signal in the receiving cell, it is
increasingly evident that an alternative strategy to modulate
the Wnt signalling cascade is at the level of the ligands, for
example, inhibiting their secretion.
Wnt secretion is dependent on Porcupine and
Wntless
To be fully active, Wnts must undergo glycosylation and lipid
modiﬁcation (Figure 2). Whereas Wnt glycosylation
enhances but is not essential for secretion and signalling,
the lipid modiﬁcations are necessary for both functions.
Wnts are acylated on two conserved residues, corresponding
to cysteine 77 and serine 209 in mouse Wnt3a (Harterink
and Korswagen, 2012). The enzyme responsible for these
lipid modiﬁcations is the O‐acyl‐transferase Porcupine
(PORCN). This is demonstrated by the fact that the genetic
loss of PORCN, or the impairment of its activity, leads to
Wnt molecules being retained in the endoplasmic reticulum
(ER). The acylation of Drosophila Wnts in position Ser209 (or
the mammalian homologue position) is required for the
interaction of Wnts with Wntless (Wls), which is another
protein critical for Wnt secretion (Herr and Basler, 2012).
Wls is a multipass transmembrane protein that is an absolute
requirement for the secretion of all Wnts (Bänziger et al.,
2006; Bartscherer et al., 2006). The puzzle of how Wls
promotes Wnt secretion remains unresolved; however, many
pieces have already been put together. These include the
unearthing of the role of the retromer complex in the
retrieval of Wls, which establishes a trafﬁcking loop from
the ER to the plasma membrane via the Golgi (Herr et al.,
2012). While our understanding of Wls function is not
sufﬁcient to generate small molecule inhibitors, suitable
inhibitors for the enzyme PORCN have been discovered.
Porcupine is an attractive target because it seems to be
exclusively required for Wnt secretion. Moreover, we have
also found that PORCN, which is the sole enzyme known to
be speciﬁc to the Wnt cascade, is up‐regulated in murine
cancer models. Additionally, elevated PORCN expression is
an indicator for a bad prognosis in head and neck squamous
cell carcinomas (the cancer genome atlas, unpublished
observations by Dario Zimmerli).
Wnt signalling initiated by the Wnt–FZD
interaction is highly regulated
Wnt signalling transduction is tightly regulated at the level of
the ligand–receptor interaction. This is achieved by titration
of the ligands and/or of the receptors.
Ligand availability can bemodulated by the production of
secreted FZD‐related proteins (SFRPs). SFRPs are secreted
molecules with no direct signalling activity, but they possess
a Wnt‐binding domain through which they sequester
extracellular Wnts (Leyns et al., 1997; Wang et al., 1997).
Another way to modulate Wnt signalling is to alter the level
and/or availability of the receptors or co‐receptors. The four
secreted Dickkopf (DKK) proteins are a well‐studied class of
molecules that act in this way. In the Wnt cascade, DKKs act
by binding to the FZD co‐receptors LRP5/6, thereby
inhibiting the binding of the Wnts (Mao et al., 2001). Three
of the DKK proteins (DKK1, 2 and 4) appear to be speciﬁc
for the Wnt pathway and act by binding to LRP5/6 (Mao
et al., 2001). Interestingly, DKK2 and DKK4 can act as either
activators or as repressors of the pathway, depending on the
abundance of the cofactor Kremen 2 (Mao and Niehrs,
2003). In contrast to the three other members of the DKK
family, DKK3 acts in the TGF‐β signalling cascade (Pinho
and Niehrs, 2007; Nakamura and Hackam, 2010). In addition
to above‐mentioned mechanisms, there is a variety of other
transmembrane or secreted inhibitors with various modes of
action, such as WIF, WISE/SOST, CERBERUS, IGFBP, TIKI1,
SHISA, WAIF1 and APCDD1 (reviewed in Cruciat and Niehrs,
2013).
Besides LRP proteins, there are other receptor‐co‐receptor
pairs such as Ryk, which can enhance Wnt signalling (Lu
et al., 2004). Additionally, there are ancillary receptor
complexes, which regulate the levels of available Wnt
receptors. Most prominent among them are LGR4/5/6. Those
proteins came to fame as Wnt target genes expressed in the
intestine and were found to mark various stem cell
populations (Barker et al., 2007). Later on, it was revealed that
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Figure 1
(A) The β‐catenin‐dependent Wnt signalling cascade in the ON‐state. Upon binding of the Wnts to the receptors of the FZD family and the co‐
receptors LRP5/6, Dishevelled (Dvl) is recruited to the membrane, thus disassembling the destruction complex consisting of Axin, GSK3β, APC
and CK1, preventing phosphorylation and thus protecting β‐catenin from proteasomal degradation. This allows β‐catenin to accumulate and
translocate to the nucleus to initiate target gene transcription. Tankyrases can further increase the signal by marking Axin for degradation.
Furthermore, when ZNRF3 and RNF43 are bound by R‐spondin and LGR5 and, therefore, unable to target FZD receptors for degradation, Wnt
signalling is enhanced in the Wnt‐ON state. A further step protecting β‐catenin from degradation is the inhibition of E3 ubiquitin ligases such
as βTRCP by Armless, at least in D. melanogaster. A selection of Wnt‐pathway inhibitors currently used in research are shown in red; red bars
indicate the interaction they inhibit. (B) The Wnt signalling cascade in the OFF‐state. Without Wnts binding to the FZD and LRP receptors, the
destruction complex is active and phosphorylates β‐catenin, thus marking it for proteasomal degradation. In the absence of LGR5, a Wnt target
gene, the FZD receptor is also targeted for degradation by ZNRF3 and RNF43. Furthermore, E3 ubiquitin ligases, like βTRCP, promote proteasomal
turnover of β‐catenin.
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they greatly increase Wnt signal transduction when they are
bound by the extracellular R‐spondin. They act by inhibiting
the ubiquitination of FZD receptors and their subsequent
degradation by ZNRF3 and RNF43 (de Lau et al., 2014).
The diversity of mechanisms by which Wnt signalling is
initiated by the Wnt‐FZD receptor interaction is regulated is
both a bane and a boon. There are many potential targets,
but their diversity also means that redundancy could affect
the efﬁcacy of any intervention.
β‐catenin is the central scaffold transducing the
β‐catenin‐dependent Wnt signal
The central node of the β‐catenin‐dependent pathway is β‐
catenin. β‐Catenin was discovered as a membrane‐associated
protein that binds E‐cadherin (Kemler, 1993). Later, it was
found that it regulates Wnt‐dependent transcription via the
recruitment of different transcriptional cofactors to the
regulatory regions of Wnt target genes. In a signalling ‘off
state’, the so‐called ‘destruction complex’ [consisting of
adenomatous polyposis coli (APC), Axin and the kinases
responsible for the phosphorylation of β‐catenin – glycogen
synthase kinase (GSK3β) and casein kinase (CK1)] marks
cytosolic β‐catenin for proteosomal degradation (Stamos
and Weis, 2013). Upon activation of this pathway, the rate
limiting factor of the destruction complex, Axin, together
with GSK3β, is recruited to the so‐called Wnt signalosome –
consisting of WNT/FZD/LRP and multimer Dishevelled (Bilic
et al., 2007). This destabilizes the destruction complex,
leaving β‐catenin free to accumulate and to translocate into
the nucleus, where it binds to the transcription factors of
the TCF/LEF family. Acting together with a plethora of
N‐ and C‐ terminal binding transcriptional co‐activators,
β‐catenin and TCF/LEF facilitate target gene expression.
In the pathway, ‘off‐state’ TCFs are thought to silence
target genes by recruiting co‐repressors such as Groucho.
These co‐repressors are displaced by β‐catenin and its cohort
of transcriptional activators (Clevers, 2006; Städeli et al.,
2006; Mosimann et al., 2009; Valenta et al., 2012).
Recently, it was discovered that even if β‐catenin escapes
degradation by the destruction complex, it can still be
degraded by the proteasome unless rescued by Armless, a
pathway component recently identiﬁed in Drosophila
melanogaster. Armless protects Arm/β‐catenin from
degradation by inhibiting the function of Ter94 in facilitating
protein turnover (Reim et al., 2014). This discovery is
interesting in light of this review, as it might represent a so
far overlooked mechanism for therapeutic intervention.
The Wnt/β‐catenin transcriptional pathway is
executed by N‐ and C‐ terminal co‐activators
β‐catenin facilitates transcription by recruiting several N‐ and
C‐ terminal binding co‐activators.
The factors directly binding the N‐terminus of β‐catenin
are Bcl9 and Bcl9l (the two mammalian paralogues of the
Drosophila Legless); they in turn recruit Pygopus (Pygo1 and
2 inmammals). Bcl9/9l and Pygo are thought to form a ‘chain
of adaptors’ extending from β‐catenin. The simple model
arising from Drosophila is that Legless and Pygo are essential
for the Wnt transcriptional output (Kramps et al., 2002;
Thompson et al., 2002; reviewed in Mosimann et al., 2009
Figure 2
The secretory pathway of the ligands of the Wnt pathway. Wnts need to be coupled to fatty acids to be secreted. This happens in the ER by the
acyltransferase Porcupine, which is a prime target for a small molecule inhibitor, since it is the only known enzyme speciﬁc to the pathway.
Acylation of Wnts allows them to bind to Wntless (Wls) in the Golgi apparatus, which in turn facilitates secretion of the mature Wnts. Wls is a
transmembrane protein required for the secretion of all Wnts.
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and Valenta et al., 2012). In mammals, although also required
for a maximal Wnt output, the relative importance of Bcl9/9l
and Pygo seems to be context‐dependent. In the mouse loss
of function mutations in these genes do not replicate loss of
β‐catenin‐dependent Wnt signalling (i.e. by mutations in
β‐catenin). For example, β‐catenin signalling mutants die at
E6.5, whereas Bcl9/9l knockout (KO) animals die at E10.5,
while Pygo KO animals survive at least to E13.5. Moreover,
recent work has demonstrated that the Pygo‐Bcl9 complex
can also act independently of β‐catenin (Cantù et al., 2014;
Cantù et al., 2017). We therefore speculate that the role of
Bcl9 as well as Pygo is to act as a booster of the signal and
facilitate transcription of speciﬁc target genes in a subset of
cells with active Wnt signalling. As described later, the
context‐dependent requirement of the so‐called N‐terminal
chain of adaptors for facilitating the Wnt transcriptional
output presents an exciting therapeutic target.
Another series of cofactors bind to β‐catenin’s
C‐terminus. This ensemble of cofactors comprises a diverse
group of proteins, which have a more general role in
transcription initiation and progression (reviewed in
MacDonald et al., 2009; Mosimann et al., 2009). The most
prominent among them are p300 and CBP, members of the
basal transcriptional machinery, which were thought to have
redundant modes of action in transcriptional activation
(Hecht, 2000; Takemaru and Moon, 2000). However, recent
studies suggest that although they are redundant in certain
tissues, p300 and CBP can play critical roles and determine
the nature of the transduced Wnt transcriptional
programme. In lung ﬁbrosis, the differential utilization of
CBP or p300 seems to determine whether to execute alveolar
repair or promote the ﬁbroproliferation associated with
ﬁbrosis (Gottardi and Königshoff, 2013; Kahn, 2014).
Wnt signalling in cancer
Since Wnt signalling plays a role in nearly all developmental
processes, it does not come as a surprise that it is also
implicated in many cancers. There are several possibilities
for a cancer cell to hijack this pathway. It can either
inactivate/decrease the expression of an inhibitory
component or activate/increase the expression of an
activating factor. When, in 1991, mutations in the APC gene
were discovered in 80% of colorectal cancers, efforts to ﬁnd a
drug acting on this protein were initiated, so far with limited
success (Groden et al., 1991; Powell et al., 1992). In addition
to mutations in APC, which is a fundamental component of
the β‐catenin destruction complex, other Wnt pathway
mutations have been found: rarely inactivating mutations
in Axin and activating mutations in the gene encoding for
β‐catenin (10%). Whereas in colon cancer APC mutations
and β‐catenin are prevalent, in other cancer types, such as
hepatocellular carcinoma, mutations in Axin predominate.
Oncogenic ctnnb mutations occur in melanoma and in solid
tumours such as thyroid tumours (Kahn, 2014; Mazzoni and
Fearon, 2014). The fact that in different tumours, alternate
Wnt signalling activating mutations occur means that
distinctive strategies may need to be employed in each case.
This will be further discussed in the speciﬁc sections for the
different targets.
As shown in colon cancers, the Wnt pathway is also
activated in some tumours through epigenetic silencing of
inhibitors of the cascade (Suzuki et al., 2004). Some of these
epigenetic changes affect the secreted inhibitors that regulate
transduction at the level of theWnt pathway ligand–receptor
interaction: for instance, methylation of SFRP genes has been
reported in colon, breast, lung, prostate and other cancers
(Caldwell et al., 2004; Suzuki et al., 2004; Fukui et al., 2005).
Mutations in inhibitory factors like ZNRF43 and RNF43 have
also been reported. These proteins act as negative regulators
by decreasing FZD protein abundance at the membrane.
When they are lost, receptor levels increase, thereby
increasing signalling. In fact, mutations in these proteins
were found to be common in the extremely aggressive
pancreatic ductal adenocarcinomas (Jiang et al., 2013).
Another way by which Wnt signalling can be increased is by
boosting ligand expression: the discovery of Int1 as a murine
mammary tumour oncogene, as well as being a participant of
theWnt signalling ﬁeld, is a prime example of this (Nusse and
Varmus, 1982; Kahn, 2014).
While activating Wnt signalling is often a driver of
tumour initiation, the evolution of a tumour to a fully
malignant form seems in some cases to correlate with
mutations that shut down the β‐catenin‐dependent Wnt
cascade. A prime example of this is melanoma, where
increased β‐catenin‐dependent Wnt signalling actually
correlates with a better prognosis (Chien et al., 2009).
Therefore, blocking β‐catenin‐dependent Wnt signalling
should not be considered a cure‐all and different strategies
will have to be applied in different diseases.
Therapeutic inhibitors of the Wnt pathway
Despite the challenges, especially the pivotal role of the
pathway in tissue homeostasis, the Wnt pathway can be
therapeutically targeted. An example is the targeting of the
bone‐derivedWnt inhibitor Sclerostin to treat osteoporosis.
The use of a humanized, anti‐sclerostin antibody is currently
in phase III clinical trials (Appelman‐Dijkstra and
Papapoulos, 2016). The approach is successful because of
the tissue (bone)‐speciﬁc function of sclerostin. Discovering
and exploiting the tissue‐ and disease‐speciﬁc features is
likely to be the key to the wider application of Wnt pathway
modulators. Below, we describe different targets and their
potential usefulness.
Porcupine: a promising target for effective Wnt
pathway inhibition
One of the most promising ways for targeting Wnt signalling
is to block ligand production. Although, as noted above,
many cancers, especially colon carcinomas, have activating
mutations in components of theWnt cascade in the receiving
cell, there is a growing body of evidence that additional
signalling induced by the presence of Wnts is critical for
tumour progression (Lavergne et al., 2011; Koo et al., 2015).
Currently, the best way to interfere with Wnt secretion is to
inhibit the acyl‐transferase Porcupine (Figure 2).
One such inhibitor – Lgk974 – was identiﬁed in a high‐
throughput screen performed on living cells. To achieve this,
2.4 million compounds were tested for their ability to
suppress the activity of a transcriptionalWnt reporter in a cell
line co‐cultured with another cell line overexpressingWnt3a.
Lgk974 binds directly to and inhibits Porcupine (Liu et al.,
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2013). Currently, it is being tested in a stage 1 dose escalation
clinical trial (Lum and Clevers, 2012). Another small‐
molecule inhibitor of Porcupine, ETC‐159, has also just
entered the phase of clinical trials (Madan et al., 2016; Nile
and Hannoush, 2016).
In mouse tumour models, Porcupine inhibitors (Table 1)
showed very promising results in treating various types of
cancer. The primary candidates for these studies were
cancers known to be dependent on Wnt secretion, for
example, due to RNF43 mutations (Liu et al., 2013). Studies
were conducted in murine models of mammary carcinomas,
basal cell carcinoma, keratoacanthomas, colon cancer and
head and neck squamous cell carcinomas (Liu et al., 2013;
Profﬁtt et al., 2013; Zito et al., 2014; Larsimont et al., 2015;
Madan et al., 2016). Another scenario where inhibiting the
secretion of ligands might be beneﬁcial is when a cancer
exploits them to inﬂuence the surrounding tissue to create
its own niche.
There are several aspects that need to be considered when
evaluating the therapeutic potential of globally blocking the
secretion of all Wnts. The ﬁrst is that systemic abolishion of
Wnt secretion will result in defects in gut homeostasis
(Valenta et al., 2016). It is, therefore, essential to either target
inhibitors directly to their site of action or to use smaller
doses that do not attenuate Wnt signalling to the extent that
tissue homeostasis is affected. The existence of a useful
therapeutic window is demonstrated by studies showing that
treatment with the Porcupine inhibitor Lgk974 resulted in
cancer regression, but gut homeostasis was unaffected (Liu
et al., 2013).
The possibility that blocking Wnt secretion will affect
both β‐catenin‐dependent and ‐independent Wnt signalling
also needs to be taken into account. The consequences of
applying Porcupine inhibitors will therefore depend on
what Wnts are present and what pathways are activated.
Since β‐catenin‐dependent and ‐independent Wnt signalling
seem to inﬂuence each other, predicting the outcome is not
easy (Yuzugullu et al., 2009; Grumolato et al., 2010). An
illustrative example is melanoma, where the relative
contribution of β‐catenin‐dependent and ‐independent
signalling is unclear, particularly in the later stages such as
metastases formation. The loss of the β‐catenin‐independent
Wnt5a has been found to inhibit tumour growth and
metastasis (Weeraratna et al., 2002; Anastas et al., 2014);
however, it also seems to lead to activation of β‐catenin‐
dependent signalling, which in different studies has positive
or negative effects on tumour progression (Damsky et al.,
2011; Yang et al., 2012; Caramel et al., 2013). While this
might seem to restrict the utility of Porcupine inhibitors, it
may be an advantage to block all Wnt‐dependent outputs,
β‐catenin‐dependent and ‐independent, and thereby
simplify the playing ﬁeld.
Table 1
Selected Wnt pathway inhibitors and their use in mouse tumour models
Compound name Mode of action Tested applications
Publications for in vivo
inhibitor use if applicable
Lgk974 Inhibits Porcupine Cell lines, div. murine cancermodels, phase 1 clinical trial
Liu et al., 2013 Clinical trial
identiﬁer: NCT01351103
ETC‐159 Inhibits Porcupine
Rspo3 translocations in CRC
xenografts Madan et al., 2016
Wnt‐C59 Inhibits Porcupine Cell lines, murine cancer models Profﬁtt et al., 2013
IWP‐2 Inhibits Porcupine
Murine keratoacanthoma model,
cell lines Zito et al., 2014
Xav939 Tankyrase 1 + 2 Cell lines, xenografts Huang et al., 2009,
Arques et al., 2016
ICG‐001 Inhibits β‐catenin‐ CBPinteraction Diverse murine tumour models Emami et al., 2004
PRI‐724 (2nd
generation
of ICG‐ 001)
Inhibits β‐catenin‐ CBP
interaction Clinical trial phase 1
Clinical trials identiﬁer:
NCT01764477, NCT01606579
OMP‐18R5 (mAB) Antibody against FZDreceptors
Various xenograft models,
clinical trial phase 1
Gurney et al., 2012 Clinical
trials identiﬁers: NCT01973309,
NCT01345201
OMP‐54F28
(Fzd8‐Fc fusion)
Competes with FZDs
for Wnts
Various xenograft models,
clinical trial phase 1
Wei et al. 2011 Clinical
trial identiﬁer: NCT02092363
FJ9
Inhibits Dishevelled
PDZ domain interaction
with FZD
Cell lines, xenograft models Fujii et al. 2007
SAH‐BCL9
Inhibits Bcl9‐β‐catenin
interaction Cell lines, xenograft models Takada et al., 2012
1,4‐Dibenzoylpiperazines Inhibits Bcl9‐β‐catenin
interaction
Cell lines Wisniewski et al., 2016
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A further critical open question with regard to the
therapeutic application of Porcupine inhibitors is their
effect on the immune system and how those effects will
impinge on the efﬁcacy of treatments. Since the inhibitors
are typically applied orally, the possibility that the loss of
Wnt secretion will affect the tumour micro‐environment
or the proliferation and differentiation of the inﬁltrating
immune cells cannot be excluded.
However, the above‐mentioned challenges necessitate
further work to understand the consequences of globally
blocking Wnt production and ﬁnd solutions in order to
circumvent challenges such as the paramount importance
of Wnt signalling for tissue homeostasis.
Alternatives to small molecules are neutralizing
antibodies or biologicals to inhibit the receptors
The development of small molecule inhibitors against
components of the Wnt pathway is a challenging task,
especially due to the lack of easily targetable enzymes speciﬁc
for the pathway. An alternative is to use either antibodies
against surface molecules like FZD or LRP, or more simply
exploit ‘natural’ inhibitors of the cascade.
The difﬁculty of targeting FZDs with antibodies is the
sheer number of them with poorly deﬁned roles in
transducing the signal. This raises the problem of the
speciﬁcity of the antibody to speciﬁc receptors, as well as
possible alternative routes for the cell to transduce the signal
if only one speciﬁc receptor is blocked. Despite these
challenges, promising results have been reported with the
use of FZD antibodies: one example is the antibody OMP‐
18R5 that, even though it targets ﬁve different FZDs, appears
to speciﬁcally hamper tumour growth without affecting
normal tissues (Gurney et al., 2012).
Another approach, shown to be promising in mice, is the
use of biologically occurring inhibitors. A prime example for
this is the injection of SFRP proteins, which are ‘natural’
inhibitors of the pathway (Polesskaya et al., 2003). Instead
of using existing SFRPs, it is also possible to engineer new
ones by simply removing the transmembrane domain of an
FZD of interest, thus rendering the Wnt binding part soluble.
These engineered proteins can then act as an artiﬁcial soluble
SFRP (Wei et al., 2011). An additional possibility is to use
other soluble inhibitors like DKK (Aicher et al., 2008).
Surprisingly, antibodies against DKK1 have anti‐
tumourigenic effects in cancer cell lines and xenograft
models, which are thought to be Wnt signalling‐dependent
(Sato et al., 2010). This has to be carefully evaluated, as it
points to a broader role for DKK1 in cancer than simply being
a negative feedback regulator of theWnt pathway.With these
results in mind, it might not be advisable to increase the
DKK1 dose to inhibit theWnt pathway, since this might have
unexpected effects.
Tankyrase inhibitors
Tankyrase is a member of the PARP superfamily of enzymes
that add ADP‐ribose onto target proteins. With respect to
Wnt signalling, tankyrase PARylates Axin and targets it for
proteasomal degradation. Inhibition of tankyrase thus leads
to an increased abundance of Axin and consequently to an
overactivated destruction complex, the ﬁnal effect being
inhibition of the pathway (Huang et al., 2009).
Initial results with tankyrase inhibitors seemed to be
promising: in particular, the combined administration of
Akt, PI3K and tankyrase inhibitors to human colon
carcinoma cell lines xenografted into mice and rats
induced apoptosis in cells escaping the therapy targeting
only Akt and PI3K. This combined therapy was
particularly effective in those cases where the
accumulation of nuclear β‐catenin was observed in the
tumours (Arques et al., 2016).
An impasse of this strategy is that tankyrase has multiple
substrates and is critical for many basic cellular processes,
for example, in telomere maintenance, mitosis and insulin‐
mediated glucose uptake; inhibiting it may therefore lead to
severe side effects (Riffell et al., 2012).
The β‐catenin – TCF interaction is an attractive
but elusive target
Another possibility for modulating the β‐catenin‐dependent
Wnt signalling cascade very downstream is to target the
nuclear function of β‐catenin, more speciﬁcally by
inhibiting the TCF‐β‐catenin interaction (Valenta et al.,
2012). This would be especially efﬁcacious in colon
carcinoma, where the majority of the mutations affect the
destruction complex. However, there are a number of
hurdles that to date have proven insurmountable. Firstly,
β‐catenin plays an important role in cell adhesion where,
in association with E‐cadherin, it forms the adherens
junctions, and the interaction sites of TCF and E‐cadherin
overlap. Secondly, the binding afﬁnity of β‐catenin to TCF
is quite high (ca. 20 nM). Nevertheless, several screens have
been performed with the aim of disrupting this interaction.
Although several compounds were identiﬁed that reduced
Wnt signalling in reporter assays and inhibited the growth
of colon cancer cell lines, the mechanisms of action of the
molecules remained unclear and their speciﬁcity was
limited (Kahn, 2014).
However, as mentioned above, β‐catenin interacts with
various transcriptional cofactors via its C‐ and N‐terminus.
Targeting these interactions represents an interesting
alternative strategy.
Targeting the interaction between β‐catenin and
its C‐terminal cofactors – a difficult case
Various screens have been conducted in order to ﬁnd suitable
inhibitors of β‐catenin’s interaction with C‐terminal
cofactors like CBP and p300. Even though some of these
screens yielded efﬁcacious inhibitors, none of them seem to
speciﬁcally inhibit the interaction with β‐catenin. ICG‐001,
which does inhibit Wnt signalling, generally interferes with
CBP’s activity and does not inhibit the binding of CBP to β‐
catenin. Interestingly, ICG‐001 does not inhibit the very
closely related p300. Since the inhibitor is effective in colon
cancer mouse xenograft models, there may be a tissue‐speciﬁc
requirement for CBP in the colon (Emami et al., 2004;
McMillan and Kahn, 2005). However, because ICG‐001
inhibits CBP, which is part of the general transcriptional
machinery, administering this compound could result in
severe side effects. Several phase 1 clinical trials are currently
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being conducted to study the efﬁcacy and side effects of this
inhibitor in patients.
Targeting β‐catenin’s N‐terminal interaction
partners is the promising alternative
The only known N‐terminal binding partners of β‐catenin are
the paralog proteins Bcl9and Bcl19l and indirectly
Pygo1/Pygo2 (Figure 1) (Kramps et al., 2002). While in
D. melanogaster these proteins seem to be mandatory for all
Wnt signalling outputs, in the mouse this appears not to be
the case and their function seems to be more restricted
(Kramps et al., 2002; Song et al., 2007; Cantù et al., 2014).
For example, in the intestinal epithelia, N‐terminal co‐
activators are not needed for normal maintenance of
homeostasis, but only during inﬂammation‐induced
regeneration. Moreover, colon carcinomas heavily depend
on Bcl9/9l to become malignant (Deka et al., 2010).
Importantly, preventing the binding between β‐catenin and
Bcl9/9l has exactly the same effect as the complete deletion
of Bcl9/9l; therefore, this genetically very well‐deﬁned
interaction represents an ideal target for the development of
small molecule inhibitors (Moor et al., 2015). In terms of
speciﬁcity, the context‐dependent requirement of the N‐
terminal activators makes it an exciting therapeutic target.
Several studies exploring this possibility have been recently
published (Hoggard et al., 2015; Wisniewski et al., 2016).
Also promising seems to be the use of stapled peptides.
This technology exploits the fact that the Bcl9‐β‐catenin
interaction is mediated by a helical segment of Bcl9, which
binds a large groove of β‐catenin’s structure. Metabolically
stable triazole‐stapled Bcl9 α‐helical peptides seem to be an
effective approach for inhibiting this interaction (Kawamoto
et al., 2012; Takada et al., 2012). These stapled peptides appear
to be good inhibitors in vitro and in mouse xenograft models,
but the efﬁcacy of such molecules in the clinic has not yet
been tested. A possible drawback of inhibiting Bcl9/Bcl9l
functions is suggested by recent ﬁndings, which show that a
dysfunctional Bcl9l impairs caspase 2 expression, thus
permitting higher aneuploidy tolerance in colorectal cancer
cells (López‐García et al., 2017). Whether this is also the case
when Bcl9l‐β‐catenin binding is inhibited will have to be
investigated carefully.
Another attractive target is the Bcl9/9l partner, Pygo2.
From a developmental viewpoint, the requirement for Pygo2
seems to be even more restricted than that of Bcl9/9l: for
example, mouse embryos lacking Pygo2 die at E13.5, while
Bcl9/9l loss of function is lethal at earlier stages, between
E9.5 and E10.5 (Cantù et al., 2014). Pygo1 seems to be
negligible; so far, no phenotype could be observed upon its
loss. Interestingly, Pygo2 plays crucial roles in mammary
gland outgrowth as well as in mammary cancer stem cells.
Furthermore, it may also play a role in some models of
intestinal tumour initiation and progression (Talla and
Brembeck, 2016). Additionally, there is evidence that Pygo’s
chromatin binding ability is required for mammary gland
outgrowth (Watanabe et al., 2014). Chromatin binding is
not essential for Wnt signal transduction in the development
and normal homeostasis of mice, suggesting that targeting
this interaction will have few side effects (Cantu et al.,
2013). Therefore, Pygo’s chromatin binding capability is a
promising target for drug development. The therapeutic
potential of targeting the binding of Pygo to Bcl9/91 requires
further exploration of when and where this interaction is
required; the interaction is also relevant in Wnt‐independent
contexts (Cantù et al., 2014).
Delivering inhibitors directly to malignant cells
via carrier molecules
In the adult organism Wnt signalling is critical for stem cell
maintenance and tissue homeostasis, systemically blocking
Wnt signalling will therefore be problematic (Valenta et al.,
2016). One way of circumventing this is to use the inhibitors
at sub‐lethal doses, where only theWnt signalling‐dependent
cancer cells are affected. An alternative is to develop strategies
to deliver the inhibitors directly and exclusively to the
tumour tissue. This could be done by linking an
inhibitor/toxin to a compound, which is attracted by the
tumour, as for example was described by Krall et al., 2014
(Wichert et al., 2015) for acetazolamide, a ligand with speciﬁc
receptors in cancerous lesions in clear‐cell renal cell
carcinomas. If such molecules also exist in Wnt driven
tumours, these would be needed to be established. Other
strategies to deliver the drug via nanoparticles to a speciﬁc
tissue/cancer have also been proposed: one method would
be to exploit chemical gradients, such as differences in pH
or in oxygen concentration. Tumours are often hypoxic, thus
the redox potential in the vicinity of the tumours is altered.
Additionally, liposomes could be used to deliver the
inhibitors (Muller and Keck, 2004; Allen and Cullis, 2013).
All these methods have potential, but testing their practical
implementation will be an important step in modulating
the Wnt‐pathway in disease.
Round up and looking forward
Wnt signalling is of paramount importance both in disease
and in tissue maintenance; therefore, any therapeutic
intervention involving Wnt signalling must solve this
conundrum. Targeting inhibitors to the afﬂicted tissue is a
promising but underexplored option. Other possible
solutions have emerged and will continue to emerge, as our
understanding of the complexities of Wnt signalling in
cancer improves.
An exciting target is the Bcl9/9l‐Pygo branch of β‐catenin‐
dependent Wnt signalling, since it is not essential for adult
tissue homeostasis but, in the case of colorectal cancer, is
required for tumour progression. Blocking the β‐catenin‐
Bcl9/9l interaction is one targetable interface. Although
targeting a protein–protein interaction is challenging,
recently, there have been some very promising results using
stapled peptides as well as small molecule inhibitors. Further
work is needed to determine other cancer types where
impinging on the chain of adaptors could be harnessed.
Therefore, further scrutiny of the developmental and disease
relevance of the chain of adaptors is important. Basic research
that reﬁnes our understanding of the intricacies of β‐catenin‐
dependent Wnt signalling will reveal other opportunities –
the identiﬁcation of additional context‐ and tissue‐speciﬁc
factors is critical.
Another promising avenue is to target Wnt production by
inhibiting Porcupine, which is speciﬁcally required for the
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production and secretion of active Wnts. In cancers where
Wnt secretion or receptor turnover is over‐activated,
Porcupine inhibition can be effective, for example, in head
and neck squamous cell carcinoma with Notch mutations
(Liu et al., 2013). One future challenge to this is to gauge the
consequences of the combined effect of blocking β‐catenin‐
dependent and ‐independent Wnt signalling. More work is
needed to understand the interplay of these signalling
cascades. In tumours with downstream mutations in the
Wnt cascade, the utility of treatment with Porcupine
inhibitors is less obvious; however, as mentioned earlier in
such cases, ligand‐mediated augmentation of the signalling
also probably plays a role in the later stages of tumour
progression. Furthermore, β‐catenin‐independent Wnt
signalling, which is also blocked by Porcupine inhibition, is
known to play a role in the later stages of tumourigenesis,
for example, Wnt5a signalling in melanoma metastases. It is
critical to get a better understanding of the biology and the
genetics of the tumours that we aim to treat. Given the
diversity of the mutational landscapes found in different
tumours, a therapy, which does not work in colorectal cancer
or melanoma, might well work in mammary tumours.
The practical solution for effective inhibition of Wnt
signalling is probably going to be to combine the above‐
mentioned approaches and, thereby, gain a decisive
advantage over the tumour. One would need to carefully
weigh the effect of a multifarious approach on homeostasis
against the potential enhanced efﬁcacy in killing cancer cells.
An additional advantage of a varied strategy would be that it
takes away alternative routes for the cancer to escape therapy.
Further efﬁcacy from a treatment point of view could also be
achieved by using Wnt signalling inhibition as an adjunct
therapy to other molecular medicine approaches,
chemotherapy, radiology and/or surgery.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY
(Southan et al., 2016), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2015/16
(Alexander et al., 2015a,b).
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	ABSTRACT  
Human papilloma virus (HPV)-driven cutaneous squamous cell carcinoma (cSCC) is the 
most common cancer in immunosuppressed patients. Despite indications suggesting that 
HPV promotes genomic instability during cSCC development, the molecular pathways 
underpinning HPV-driven cSCC development remain unknown. We compared the 
transcriptome of HPV-driven mouse cSCC with normal skin and observed higher amounts of 
transcripts for Porcupine and WNT ligands in cSCC, suggesting a role for WNT-signaling in 
cSCC progression. We confirmed increased Porcupine expression in human cSCC samples. 
Blocking the secretion of WNT-ligands by the Porcupine inhibitor LGK974 significantly 
diminished initiation and progression of HPV-driven cSCC. Administration of LGK974 to 
mice with established cSCC resulted in differentiation of cancer cells and significant 
reduction of the cancer stem cell compartment. Thus, WNT/b-catenin signaling is essential 
for HPV-driven cSCC initiation and progression as well as for maintaining the cancer stem 
cell niche. Interference with WNT-secretion may thus represent a promising approach for 
therapeutic intervention. 
 
INTRODUCTION 
 
cSCC develops from basal keratinocytes in sunlight-exposed skin and is the second most 
frequent cancer in fair-skinned individuals. HPV-driven cSCC is the most common cancer in 
immunosuppressed organ transplant recipients (OTR), up to 50% of those patients develop 
cSCCs within 10 years after transplantation (Connolly et al., 2014). Thus, 
immunosuppression increases the risk to develop cSCC by 250-fold (Chockalingam et al., 
2015) (Hofbauer et al., 2010). In addition, 80% of cSCC in OTR are positive for HPV 
compared to 40% in non-OTR (Accardi and Gheit, 2014), suggesting a role for HPV in the 
initiation and/or progression of cSCC particularly in immunosuppressed individuals. This is 
underscored by a recent report showing that vaccination against HPV protects against 
keratinocyte-derived cancers (Nichols et al., 2017). While the main driver mutations of HPV-
negative cSCCs are found in the RAS-MAPK signaling pathway (Nassar et al., 2015), a role 
for WNT/β-catenin signaling has been reported as well (Malanchi et al., 2008a).  
The WNT/β-catenin signaling cascade is essential in many developmental processes but is 
also involved in initiation and progression of many cancer types. Signaling is initiated by the 
binding of secreted WNT-ligands (WNTs) to the Frizzled/LRP receptor complexes. Secretion 
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	of WNT ligands fully depends on their acylation by the acyl-transferase Porcupine (PORCN) 
(Herr and Basler, 2012), (Zimmerli et al., 2017a). Binding of WNTs to Frizzled/LRP triggers 
a cascade of events, which culminates in cytoplasmic stabilization and subsequent nuclear 
translocation of β-catenin. In the nucleus, β-catenin associates with TCF/LEF transcription 
factors to drive expression of WNT-target genes (Nusse and Clevers, 2017). WNTs also 
initiate various β-catenin independent outputs, some of which may play a role in cSCC 
(Pourreyron et al., 2012).  
To investigate the molecular mechanisms underlying the initiation and progression of HPV-
driven cSCC, we used a mouse model in which UV-induced overexpression of the HPV8-
derived E6 oncogene in keratinocytes drives the development of a progressive cSCC (Krt14-
HPV8(E6); (Schaper, 2005), (Marcuzzi et al., 2009a)). We found increased expression of 
WNTs and PORCN in cSCCs. Furthermore, blocking WNT secretion by a small-molecule 
inhibitor of PORCN, LGK974 decreased the cSCC stem cell compartment and inhibited 
induction and progression of cSCC.  
 
RESULTS AND DISCUSSION 
 
Increased expression of WNT ligands and elevated WNT/β-catenin signaling are 
hallmarks of HPV8-E6 driven cSCC 
Aberrantly active WNT/β-catenin drives various epithelial cancers, including non-viral cSCC 
(Malanchi et al., 2008b), (Powell et al., 1992), (Zimmerli et al., 2017b). The importance of 
WNT/b-catenin signaling in HPV-driven tumors is unknown. To investigate this, we used the 
Krt14-HPV8(E6) transgenic mouse model for cSCC in which tumor induction can be 
triggered by UV-irradiation (Marcuzzi et al., 2009b). We observed nuclear localization of b-
catenin, a hallmark for active WNT/b-catenin signaling, in established cSCC (Fig 1A, left 
panels) and confirmed elevated WNT/β-catenin signaling by in situ hybridization for the 
WNT/b-catenin target gene Axin2 (Jho et al., 2002) (Fig 1A, right panels).  
In non-viral cSCCs, CSC reside at the tumor-stroma interface in close proximity to the 
vasculature (Beck et al., 2011) and express, besides EpCAM, several integrins including 
integrin b1 (CD29), a6 (CD49f) (Schober and Fuchs, 2011), as well as CD34 (Schober and 
Fuchs, 2011), (Malanchi et al., 2008b), (Lapouge et al., 2012). We found a population of 
EpCAM+, CD34+, CD49f+ cells at the tumor-stroma interface in HPV-driven cSCCs 
(supplementary Figure 1A), which are putative CSCs. Importantly, these EpCAM+ CD34+ 
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	CSCs expressed a higher amount of the WNT/β-catenin target gene and stem cell marker 
Lgr5 (Haegebarth and Clevers, 2009), when compared to non-stem cell tumor cells 
(EpCAM+ CD34-) or stromal cells (EpCAM- CD34-) (Fig 1B). Thus as in non-viral cSCC and 
colorectal cancer (Malanchi et al., 2008b), (de Sousa e Melo and Vermeulen, 2016) elevated 
WNT signaling and expression of LGR5 seem to mark the CSC pool. 
To better understand the involvement of WNT/β-catenin signaling in HPV-driven cSCCs, we 
compared the transcriptome of established cSCC to that of healthy skin. Gene ontology 
analysis (The Gene Ontology Consortium, 2015) suggested that differentially expressed 
genes are associated with increased cell motility, altered cell-matrix adhesion and 
inflammation (supplementary Figure 1B). Several transcripts that have previously been 
associated with non-viral cSCC, such as Fosl1 (encoding Fos-like antigen 1), Ptprz1 
(encoding protein tyrosine phosphatase, receptor type Z1) (Schober and Fuchs, 2011), (Latil 
et al., 2017) as well as transcripts encoding for metalloproteases (Mmp), were also 
upregulated in HPV-driven cSCC (supplementary Figure 1C), suggesting the existence of 
common pathways in cSCC that are independent of its etiology.  
Although no mutations in Hras were reported in the Krt14-HPV8(E6) cSCC tumor model 
(Marcuzzi et al., 2009a), we found a significant upregulation of the RAS-MAPK-ERK 
signaling pathway (supplementary Figure 1B and supplementary Figure 1E). Therefore, 
RAS-MAPK-ERK activation seems to represent a common mechanism associated with cSCC 
progression together with elevated WNT/b-catenin signaling. 
We did not detect an increase of expression of WNT/β-catenin signaling target genes. This 
was not unexpected because of the very high activity of the WNT pathway in hair follicles, 
especially during the hair growth (anagen) phase (Huelsken et al., 2001b).  
However, consistent with the presence of activated WNT/b-catenin signaling in HPV-driven 
cSCCs, we observed decreased expression of extracellular WNT-inhibitory factors, including 
members of the Sfrp (encoding secreted frizzled-like protein)-family, Notum and Dkk 
(encoding Dickkopf). We also observed increased expression of transcripts of some Wnts and 
Porcn, whose product is essential for WNT-secretion (supplementary Figure 1D). We found 
significantly increased expression of Wnt16 transcripts in HPV-induced cSCCs. Using in situ 
hybridization, we confirmed the increased Wnt16 expression in tumor tissue compared to 
healthy skin (Fig 1E). This is interesting because in prostate cancer elevated WNT16 
expression correlated with enhanced WNT/b-catenin signaling, leading to cell survival and 
therapy resistance (Sun et al., 2016), (Sun et al., 2012).  
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	Recent studies have highlighted the importance of PORCN for establishment and 
maintenance of a CSC niche (Tammela et al., 2017). We found that cells at the tumor-stroma 
interface strongly expressed PORCN (Fig. 1C). The PORCN+ cells included CD34+ and 
CD34- cells (Fig. 1D). Thus, PORCN expression may mark the niche rich in WNTs needed 
by CSCs as was described recently for lung adenocarcinomas (Tammela et al., 2017).  
The clinical relevance of these findings is underscored by the enhanced expression of 
PORCN along the invasive front also in human cSCC samples (Fig. 1F). 
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	Figure 1: Elevated WNT/β-catenin signaling and increased expression of WNT ligands are hallmarks of 
HPV8-E6 driven cSCC. 
(A) Left panel: Nuclear accumulation of β-catenin in the invasive front of HPV-driven cSCCs (black 
arrowheads). Healthy skin shows membranous expression of β-catenin (gray arrowhead). Scale bar = 50 µm. 
Right panel: In situ hybridization for Axin2 (red stain) shows increased expression of this WNT/b-catenin 
signaling target in tumors in comparison to healthy skin. Nuclei are counterstained with hematoxylin (blue 
stain). Scale bar = 100µm. 
 (B) Enhanced amount of Lgr5 transcripts in CSCs (EpCAM+ CD34+ CD49f+) compared to non-CSC tumor 
cells (EpCAM+ CD34-) (unpaired Student’s t-test, ***p<0.001) and stromal cells (EpCAM- CD34- CD49f-) 
(unpaired Student’s t-test, **p<0.01). Cells from 2 HPV-driven cSCC from different mice were sorted and 
expression was quantified by qRT-PCR.  
(C) PORCN (red) staining in healthy skin and HPV-driven cSCC. E-cadherin (green) marks epithelial cells, 
DAPI (blue) marks nuclei. Scale bar = 100µm. PORCN is mostly expressed along the tumor-stroma interphase 
of the tumor, while it is absent in healthy epidermis. Insets show a larger magnification of the region marked by 
the white square.  
(D) Overlapping expression of PORCN (green) and CD34 (red) in healthy skin with hair follicles and tumor 
tissue is indicated by arrowheads. Scale bar = 50 µm. Insets show a larger magnification of the region marked 
by the white square. 
(E) In situ hybridization of healthy skin and HPV-driven cSCC for Wnt16 (red), shows higher expression of 
Wnt16 in tumors compared to healthy skin. The section is counterstained with hematoxylin. Scale bar = 50 µm. 
(F) Increased expression of PORCN (red) in human cSCC in comparison to healthy human skin. E-cadherin 
(green) marks epithelial tissue, nuclei are counterstained in blue. Scale bar = 100 µm. Insets show a larger 
magnification of the region marked by a white square. 
Krt14-HPV8(E6) mice were described previously (Marcuzzi et al., 2009b) and were bred to FVB mice (Harlan 
Laboratories, Envigo) in house. Mice were kept under specific pathogen-free conditions at the Laboratory 
Animal Services Center at the University of Zurich.  
To induce cSCC, approximately 4 cm2 of shaved dorsal skin was irradiated with UVA (5 J/cm2) plus UVB (1 
J/cm2) using the UV 802 L Waldmann device.  
Murine tumor samples were collected 4 weeks after tumor induction. Representative samples from at least 3 
biologically independent replicas are shown in the immunohistochemistry, immunofluorescence and in situ 
hybridization. 
Experiments were performed in accordance with the Swiss federal and cantonal regulations on animal protection 
and were approved by the Cantonal Veterinary Office Zurich. 
Human SCC samples were obtained from biobanks managed by the University Research Priority Project 
“Translational Cancer Research” and the research project “Skintegrity”. All material were surplus biopsies from 
patients who had signed an informed consent that was approved by the cantonal ethics commission Zurich 
(EK647 and EK800). 
For flow cytometry and sorting, tumors were collected in PBS and digested for 2 h at 37°C in 2.4 mg/ml 
Dispase (Roche), cut into pieces and digested again for one hour at 37°C in 1 mg/ml collagenase Type IV 
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	(Worthington Biochemical Corporation) and 0.1 mg/ml DNase (Sigma-Aldrich). Antibodies against the 
following proteins were used: CD45.1 (clone A20, BioLegend), CD31 (clone MEC13.3, BioLegend), EpCAM 
(clone GoH3, BioLegend), CD34 (clone RAM34, eBioscience). Dead cells were excluded using Zombie Violet 
Fixable Viability Kit (BioLegend). Doublets were excluded by FSC-A versus FSC-H and SSC-A versus SSC-H 
gating.  
Immunohistochemistry on frozen sections was performed on tissue fixed in 4% PFA for 1 h, left to sink in 30% 
sucrose and embedded in OCT. Ten-µm thick cryosections were blocked for 1h at RT with 2.5% Hings and 
2.5% BSA in 0.1% Tween in PBS (PBST) (blocking buffer), and then stained with biotin-conjugated anti-CD34 
(clone RAM34, eBioscience) and unconjugated rabbit anti-PORCN (clone ab105543, Abcam) over night at 4°C 
in blocking buffer. Secondary antibodies (see below) were added for 1 h in blocking buffer at RT, then samples 
were mounted in fluor save (CalBiochem). 
Standard protocols were used for embedding and cutting Formalin-fixed paraffin-embedded (FFPE) tissue. 
After deparaffinization, on both mouse and human samples, antigen retrieval was performed in 10mM 
Trisodium citrate buffer pH 6. Staining was performed as described above for frozen sections.  
The following antibodies were used for mouse and human FFPE samples: Mouse-anti-b-catenin (clone14, BD 
transduction labs), mouse-anti-E-cadherin (BD transduction labs), rabbit-anti-PORCN (Abcam ab105543), 
rabbit-anti-Ki67 (Abcam), rabbit-anti-HMGA2 (SantaCruz), rabbit-anti-MMP13 (clone 3H13L17, 
ThermoFisher) and rabbit-anti-phospho-ERK (Cell Signaling).  
Secondary antibodies used were goat-anti-mouse AlexaFluor 488 and goat-anti-rabbit AlexaFluor 555. For the 
PORCN staining a biotin-labeled goat-anti-rabbit secondary antibody was used, followed by the ABC kit 
(VectaShield), and the Cy3 tyramide amplification kit (PerkinElmer). 
Stainings for nuclear b-catenin were performed with biotin-labeled secondary antibodies, followed by DAB 
staining (VectorLabs). 
When mouse primary antibodies were used on murine tissues, VectorLabs MOM kit was used to block 
endogenous antigens.  
In situ hybridization was performed using the RNAscope kit (Advanced Cell Diagnostics) according to the 
manufacturer’s instructions. Probes for Axin2 and Wnt16 were obtained from the same company. 
For qRT-PCR, RNA was isolated from sorted cells using the NucleoSpin RNA XS kit (Machery-Nagel) 
according to the manufacturer’s instructions. qRT-PCRs using SybrGreen were performed on cDNA 
synthesized with the Roche Transcriptor High Fidelity cDNA Synthesis Kit after RNA isolation by standard 
TRI-Reagent protocols. Reactions were performed in triplicates and monitored with the ABI Prism 7900HT 
system (Applied Biosystems). The following 5’-3’ primers (Microsynth) were used for qRT-PCR. Gapdh, fwd 
AACTTTGGCATTGTGGAAGG, rev ATCCACAGTCTTCTGGGTGG; Lgr5, fwd 
CTCCACACTTCGGACTCAACAG, rev AACCAAGCTAAATGCACCGAAT. 
  
29
	  
Krt10
Fn1
Dlc1
Tgfbr2
Krt1
Lamb1
Nfatc1
Kras
Ccnd1
Tnf
Ccne1
Ereg
Casp3
Cd44
Mmp11
Mmp12
Dsg1b
Mmp24
Ptprz1
Mmp8
Fosl1
Mmp13
Mmp10
Cxcr2
Krt6a
Krt16
skin_vs_SCC
−2.5
0.0
2.5
5.0
7.5
log2 fold change
Skin vs Tumor
Sfrp4
Sfrp5
Wisp2
Notum
Wnt9a
Wnt2
Wnt6
Sfrp2
Wnt10b
Dkk2
Sfrp1
Dkkl1
Dkk3
Wnt3a
Wnt5b
Wls
Wnt5a
Wnt9b
Wnt3
Wnt11
Wnt7b
Wnt7a
Wnt4
Wisp1
Wnt10a
Porcn
Wnt16
skin_vs_SCC
−5.0
−2.5
0.0
2.5
log2 fold change
Skin vs Tumor
Supplementary Figure 1
WNT secretory factors
Tumor vs Skin
GO biological process 
complete
Gene number Expected
number
Fold 
Enrichment
P value
positive regulation of MAPK 
cascade 66 29.91 2.21 4.54E-05
regulation of cell migration 98 47.94 2.04 5.45E-07
inflammatory response 63 27.09 2.33 1.74E-05
p-Erk
Selected GO terms of first 1500 hits skin vs tumor
A
C EMalignancy markers
Tumor vs Skin
D
H
ea
lth
y 
sk
in
Tu
m
or
C
D
34
/K
er
at
in
6/
D
AP
I
B
30
	Supplementary Figure 1: Secretion of WNTs is elevated in HPV-driven cSCCs in comparison to healthy 
skin, leading to active WNT/b-catenin signaling. Relates to Figure 1. 
(A) Gene ontology analysis of RNA-sequencing data comparing HPV-driven cSCCs with healthy skin. Four 
independent samples for each condition were sequenced and analyzed. 
(B) Heatmap showing expression of selected malignancy-associated genes in cSCC compared to healthy skin. 
Malignancy markers are upregulated, while differentiation markers are downregulated in cSCC.  
(C) Heatmap showing expression of transcripts for Wnts and factors implicated in WNT secretion or availability 
in cSCC compared to healthy skin; tumor tissue shows increased expression of transcripts associated with WNT 
production and decreased expression of transcripts for WNT inhibitory factors. 
(D) Staining for phosphorylated ERK (p-ERK, brown) in HPV-driven cSCC four weeks after tumor induction. 
P-ERK was not detected in healthy skin. 
(E) Staining for CD34 (red) in HPV-driven cSCC shows expression at tumor-stroma interphase in the invasive 
front of the tumors. Cells are counterstained with DAPI, Keratin6 marks epithelial tumor cells. Scale bar = 
100µm. 
Protocols were as described for the main figures. 
For RNA-sequencing, RNA was isolated from healthy skin (n=4) and tumors from LGK974-treated (n=4) and 
vehicle-treated (n=4) mice using TRI-Reagent combined with the Ambion PureLink RNA mini Kit. Each 
sample was obtained from an individual mouse. Single-stranded 100-bp read sequencing was performed on an 
Illumina HiSeq2500 machine at the Genomics Platform of the University of Geneva. The reads were mapped 
with the TopHat v.2 software to the Ensembl GRCm38.p4 reference on new junctions and known junction 
annotations. Biological quality control and summarization were performed with PicardTools1.141. EdgeR was 
used for normalization and differential expression testing. 
Clustering analysis was performed using the online tool described in (Babicki et al., 2016), other heatmaps were 
generated in R-studio. The top-ranked genes for the clustering analysis and other heatmaps were chosen 
according to p<0.05 (general linear model with negative binomial distribution, (quasi-likelyhood F-test)). False 
discovery rate was too stringent due to the high variability between different tumors and low number of 
changing transcripts. qRT-PCR and immunohistochemistry was used to confirm the findings.  
 
Inhibition of WNT secretion impairs the initiation of HPV-driven cSCC 
To address whether WNT-secretion and -signaling are essential for the initiation of HPV-
driven cSCC, we administered a small-molecule inhibitor of PORCN (LGK974), which 
blocks the secretion of all WNTs (Liu et al., 2013a). LGK974 (or vehicle) was administered 
daily per os, starting one week prior to tumor induction (Fig. 2A). Administration of LGK974 
or vehicle did not affect the general wellbeing of mice and the dose used here did not affect 
the intestinal stem cell compartment, which is most sensitive to perturbations of WNT/b-
catenin signaling (Valenta et al., 2016), (data not shown).  
Treatment with LGK974 prior to the tumor induction resulted in a significant reduction in 
tumor size in comparison to the vehicle-treated control mice (Fig 2B), suggesting an essential 
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	role of PORCN and by extension WNTs for the initiation of HPV-driven cSCC. Analysis of 
haematoxylin and eosin (H&E) stained sections confirmed that UV-induced skin 
inflammation failed to progress to carcinoma in LGK974-treated mice, whereas characteristic 
cSCC lesions were observed in vehicle-treated mice (Fig 2C). In contrast, the lesions in 
LGK974-treated mice (Fig 2B) consisted mainly of keratin whorls reminiscent of 
differentiation and in some cases of hair follicles with normal morphology (supplementary 
Figure 2).  
Expression of CSC markers is indicative for malignancy and loss of stem cells often results in 
differentiation and ultimately regression of tumors (Singh and Settleman, 2010). WNT/b-
catenin signaling is one of the key pathways defining the stem cell niche in many epithelial 
tissues and cancers of epithelial origin (de Sousa e Melo and Vermeulen, 2016), (Shiokawa et 
al., 2017). As a next step we therefore investigated whether inhibition of WNT-secretion has 
an impact on CSCs in HPV-driven cSCCs. Thus, we quantified transcripts by qRT-PCR that 
are expressed in cSCC stem cells (Schober and Fuchs, 2011), (Malanchi et al., 2008b), 
(Lapouge et al., 2012). We focused on Pthlh (encoding parathyroid hormone-like hormone), 
Ptprz1 and Cd44 because of their association with CSC in a chemically induced model of 
cSCC (Schober and Fuchs, 2011), (Oshimori et al., 2015). Blocking WNT-secretion via 
LGK974 administration resulted in significantly reduced expression of all these cancer stem 
cell markers (Fig 2D). Therefore, WNT-ligands are presumably essential for the stem cell 
niche in HPV-driven cSCCs. In support of these findings, inhibition of PORCN inhibited also 
basal cell carcinoma (BCC) (Larsimont et al., 2015) as well as keratoacanthoma development 
(Zito et al., 2014).  
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Figure 2: Inhibition of WNT secretion by the PORCN-inhibitor LGK974 impairs the initiation of HPV-
driven cSCC. 
(A) Experimental design. Treatment with LGK974 (6 mg/kg) or vehicle was started 7 days prior to tumor 
induction by UV-irradiation. Mice were treated daily until the endpoint at day 28. Control mice were treated 
with vehicle. 
(B) Representative macroscopic display of a control (left panel) and LGK974-treated (middle panel) tumor. 
Tumor weight at endpoint (right panel). Unpaired Student’s t-test, *p<0.05. 
(C) H&E staining of control (left panel) and LGK974-treated (right panel) tumors. Scale bar = 100 µm.  
(D) Quantification of transcripts for Pthlh, Ptprz1 and Cd44 in vehicle- and LGK974-treated tumors shows 
significant reduction of markers for tumor malignancy upon treatment. Unpaired Student’s t-test, *p<0.05. 
The Porcupine-inhibitor LGK974 was applied as described in (Liu et al., 2013b). Briefly, LGK974 was 
dissolved in DMSO and diluted in citrate buffer pH 3 to a final concentration of 1mg/ml. Mice were treated 
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	daily with 6 mg/kg LGK974 or vehicle (20% DMSO in citrate buffer pH 3) per os.  
This experiment was performed once with groups consisting of 4 untreated and 5 treated mice, representative 
images are shown.  
Staining and qPCR Protocols were as described above. The primers used were Pthlh, fwd 
ATCCCCGACGCCTATGTAA, rev GGGGAAAAAGCAATCAGAGA; Ptprz1, fwd 
GCCAGTTGTTGTCCACTGC, rev CCTTTGAGAACGAATGTGCTT; Cd44, fwd 
CTCCTTCTTTATCCGGAGCAC, rev TGGCTTTTTGAGTGCACAGT. 
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Supplementary figure 2: Tumors are replaced by hair follicles and keratin in mice treated with pre-
emptive LGK974. Relates to Figure 2. 
 (A) H&E stained sections from 3 different tumors of mice treated with vehicle previous to UV-irradiation to 
induce tumors (see Figure 2A). 
LGK974
Vehicle
Supplementary Figure 2
A
B
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	(B) H&E stained sections from 3 different UV-irradiated patches from mice treated with LGK974 previous to 
UV-irradiation (see Figure 2A). 
This experiment was performed once with groups consisting of 4 untreated and 5 treated mice, representative 
images are shown.  
Protocols were as described for the main figures. 
 
WNTs promote progression of HPV-driven cSCC  
Since preemptive inhibition of WNT secretion significantly reduced the development of 
HPV-driven cSCC, we investigated whether blocking WNT-secretion also interferes with 
tumor progression in established tumors (Fig 3A). We observed a marked reduction of 
nuclear staining for b-catenin in response to LGK974 treatment, indicative of reduced 
WNT/b-catenin signaling. This finding was corroborated by a reduction in Axin2 expression, 
especially at the tumor-stroma interphase (Fig. 3B). 
Although LGK974-treament did not macroscopically reduce tumor size, analysis of H&E-
stained sections revealed that LGK974-treated tumors displayed a more differentiated 
morphology than vehicle-treated tumors (Fig. 3C). A good indicator of reduced malignancy 
and the differentiation status of cSCCs is the increased presence of keratin whorls (Yanofsky 
et al., 2011) and a reduced density of invasive cones (Wicki and Christofori, 2007). LGK974-
treated tumors showed both: an increased density of keratin whorls and a loss of invasive 
cones (Fig. 3C). Furthermore, and in line with increased differentiation, LGK974-treated 
tumor cells proliferated less than control tumors as visualized by significantly reduced 
staining for Ki67 (Fig. 3D and supplementary Figure 3A). Together, our findings indicate 
that blocking WNT secretion promotes differentiation, and reduces proliferation as well as 
invasive potential of established HPV-driven cSCC. 
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	Figure 3: WNTs promote HPV-driven cSCC progression. 
(A) Experimental design. Treatment with LGK974 (6 mg/kg) was started 12 days after tumor induction by UV-
irradiation. Mice were treated daily until the endpoint at day 28. Control mice were treated with vehicle. 
 (B) b-catenin staining of vehicle- and LGK974-treated tumors. Nuclear b-catenin is reduced upon treatment. 
Middle panels show a magnification of the boxed area. Right panels show an in situ hybridization for Axin2 
(red), indicating a reduction of its expression upon treatment, nuclei are counterstained with hematoxylin (blue). 
Scale bars = 50 µm.  
(C) Keratin whorls (grey arrowheads in lower panel) and loss of invading cones (black arrowheads in upper 
panel) indicate differentiation in H&E stained sections of vehicle- and LGK974-treated cSCC. Scale bar = 100 
µm.  
(D) Sections stained for Ki67 (red) as marker for proliferation and β-catenin (green) to outline the cells, nuclei 
are counterstained by DAPI. The staining shows a clear reduction of proliferating Ki67 positive cells upon 
treatment. Lower panels show a magnification of the boxed area. Scale bar = 100 µm. 
 (E) HMGA2 (red) is strongly reduced upon treatment in the tumors. β-catenin in green marks the cells, DAPI 
counterstains the nuclei in blue. Scale bar = 100 µm.  
MMP13 expression is lost upon LGK974 treatment. Scale bar = 50 µm. 
(F) Flow cytometric analysis of the percentage of CSC in comparison to live cells (EpCAM+ CD34+ CD31-) in 
vehicle- and LGK974-treated cSCC. Unpaired Student’s t-test, **p<0.01. Groups consisted of 5 vehicle treated 
and 6 LGK974 treated mice. This experiment was performed twice with similar results.  
Protocols were as described for Figure 1. For HMGA2 staining, the same protocol as for PORCN was used, for 
the MMP13 staining, the protocol for nuclear b-catenin staining was used.  
 
PORCN inhibition decreases the malignant potential of HPV-driven cSCCs 
To clarify the downstream effects of PORCN inhibition in HPV-driven cSCCs, we performed 
RNA-sequencing of LGK974- and vehicle-treated tumors (supplementary Figure 3B). Gene 
ontology analysis (The Gene Ontology Consortium, 2015) of the top deregulated transcripts 
(p<0.05) showed “regulation of keratinocyte migration” as the primary hit, which confirms 
our findings of reduced invasiveness and malignancy of the tumors upon LGK974 treatment 
(supplementary Figure 3D). In particular, we observed a significant downregulation of 
transcripts for matrix metalloproteinases (Mmp9, Mmp10, Mmp13) and upregulation of 
Timp4, which is an inhibitor of them (Wang et al., 1997), (supplementary Figure 3C).  
Because we performed RNA sequencing on whole tumor tissues, we cannot draw conclusions 
about whether LGK974-treatment affects tumor cells, tumor infiltrating cells or both. To 
confirm some findings from the RNA-sequencing, as well as to clarify the cell type in which 
the changes occur, we used immunohistochemistry. Our observation that LGK974-treatment 
reduced the expression of HMGA2 in tumor cells suggested a tumor-intrinsic effect of 
PORCN-inhibition (Fig. 3E) but does not exclude that tumor-extrinsic effects occur. This was 
38
	demonstrated by the stark reduction of MMP13 in tumor as well as stromal tissue upon 
LGK974 administration (Fig. 3E). On the other hand, WNT secreted by PORCN positive 
cells may affect the expression of WNT target genes in the stromal compartment and the 
stromal MMP13 could of course be secreted from the tumor cells. 
To check the effects of PORCN inhibition on CSCs in control and LGK974-treated tumors, 
we analyzed the cellular composition of tumors by flow cytometry.  Blocking WNT-secretion 
resulted in the reduction of the CD34+ EpCAM+ CD31- CSC population (Schober and Fuchs, 
2011), (Fig. 3F, supplementary Figure 3F). This was confirmed by antibody stainings for 
CD34 on tumor sections (supplementary Figure 3E), again underscoring the importance of 
WNT-secretion for CSC maintenance and thus tumor growth and malignancy.  
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	Supplementary figure 3: Treatment of HPV-driven cSCC with LGK974 reduces proliferative and 
invasive capacity of the tumors. Relates to Figure 3.  
(A) Proliferation in epithelial areas of five LGK974- and four vehicle-treated tumors indicated by Ki67 staining 
(Figure 3D) and quantified using the Vectra 3.0 system (PerkinElmer). Unpaired Student’s t-test, *p<0.05. 
(B) Clustering analysis (average linkage, Pearson distance measurement) showing the differentially expressed 
genes (general linear model with negative binomial distribution, (quasi-likelyhood F-test) *p<0.05) from an 
RNA-sequencing experiment comparing four LGK974- with four vehicle-treated tumors. 
(C) Heatmap showing selected differentially expressed genes associated with SCC malignancy in RNA-
sequencing of four LGK974- and four vehicle-treated tumors.  
(D) Gene ontology analysis of RNA-sequencing data comparing vehicle- and LGK974-treated HPV-driven 
cSCCs. Four independent samples for each condition were sequenced and analyzed. 
(E) Staining for CD34 (red) and Keratin-6 (green) in LGK974- and vehicle- treated tumors. CD34 staining is 
lost upon treatment along the tumor-stroma interphase. Sections are counterstained with DAPI (blue). Scale bar 
= 100µm. 
(F) FACS analysis of 6 LGK974- and 5 vehicle-treated tumors. Cells were stained for live/dead, CD45.1 
(leukocytes), EpCAM (epithelial cells including tumor), CD31 (vascular endothelial cells) and CD34 (CSC). 
The EpCAM+ CD34+ CSC population is clearly reduced upon treatment (see also Figure 3G). 
This experiment was performed twice with similar results. 
The protocols used were as described for the main figures. 
 
Conclusion 
We investigated the pathways involved in tumorigenesis and growth of cSCCs that are driven 
by HPV. Our finding, that WNT-signaling is crucial for tumorigenesis is in line with work on 
cSCCs induced by chemical carcinogenesis (Malanchi et al., 2008b). Of note, in the case of 
cSCCs, no prominent activating mutations downstream of the WNT/b-catenin pathway 
components were found (Nassar et al., 2015), in contrast to classical WNT/b-catenin-
dependent cancers like colon carcinomas (Nusse and Clevers, 2017). WNT/b-catenin 
activation in HPV-driven cSCC seems rather to be reached by upregulation of WNTs and 
factors such as PORCN that are required for their secretion. The combination is apparently 
crucial to maintain a proper CSC niche. Compelling evidence in support of this theory comes 
from a study by (Tammela et al., 2017), where they show that the CSC niche of lung 
adenocarcinomas is maintained by cells expressing high levels of PORCN. By using PORCN 
inhibitor on HPV-driven cSCCs, we show the addiction of these cancers for WNT secretion. 
Since inhibiting WNT secretion severely hampers tumorigenesis, PORCN inhibition might 
thus be a valuable preventive measure against cSCCs after organ transplantation and 
subsequent immunosuppression. The fact that not only cSCCs, but also lung 
41
	adenocarcinomas seem to upregulate PORCN to maintain a CSC niche asks for further 
investigation into this matter in further epithelial tumor types. It also draws attention towards 
the necessity to not only check the mutational landscape in tumors but also to carefully check 
changes in the transcriptome. 
In conclusion, our results provide novel insights into the molecular details of HPV-driven 
cSCCs. They also reveal a possible therapeutic approach to prevent and treat this type of 
cancers.  
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Bcl9 and Bcl9l (Bcl9/9l) encode Wnt signaling components
thatmediate the interaction between b-catenin and Pygopus
(Pygo) via two evolutionarily conserved domains, HD1
and HD2, respectively. We generated mouse strains lacking
these domains to probe the b-catenin-dependent and
b-catenin-independent roles of Bcl9/9l and Pygo during
mouse development. While lens development is critically
dependent on the presence of the HD1 domain, it is not
affected by the lack of the HD2 domain, indicating that
Bcl9/9l act in this context in a b-catenin-independent
manner. Furthermore, we uncover a new regulatory circuit
in which Pax6, the master regulator of eye development,
directly activates Bcl9/9l transcription.
Supplemental material is available for this article.
Received May 26, 2014; revised version accepted August 8,
2014.
Pygopus (Pygo) and Legless (Lgs) were discovered as
dedicated Wnt signaling components in Drosophila
(Kramps et al. 2002; Parker et al. 2002; Thompson et al.
2002) and Xenopus (Belenkaya et al. 2002). In Drosophila,
pygo and lgs are classified as segment polarity genes, and
mutations in their coding sequences lead to a dramatic
developmental arrest, reminiscent of wingless mutations
(Kramps et al. 2002; Parker et al. 2002; Thompson et al.
2002). They are considered to serve as dedicated and
essential b-catenin transcriptional coactivators. Lgs simul-
taneously binds Pygo and Arm/b-catenin via two evolu-
tionarily conserved homology domains, HD1 and HD2,
respectively (Kramps et al. 2002). The prevailing model is
that Pan/TCF >Arm/b-catenin > Lgs > Pygo serially recruit
each other to the DNA in order to efficiently activate Wnt
target gene expression, forming a ‘‘chain of adaptors.’’ In
this model, the sole function of Lgs is to recruit Pygo to
b-catenin (St€adeli and Basler 2005).
Vertebrates feature two pygo genes, PYGO1 and PYGO2,
and two lgs homologs, BCL9 and BCL9l (BCL9/9l). In
contrast to b-catenin loss-of-functionmutants, Pygo1/Pygo2
double-knockout mice proceed normally throughout gas-
trulation and die later during embryonic development
from a series of tissue-specific defects. Pygo1 knockout
mice are viable and fertile, with no apparent phenotype.
Compound Pygo1/Pygo2 knockout mutants are indistin-
guishable from Pygo2 knockout, suggesting that Pygo2
plays the more important role during development (Li
et al. 2007; Schwab et al. 2007; M Aguet, unpubl.). Unlike
in Drosophila, in mice, Pygo1 and Pygo2 are now consid-
ered to be tissue-specific Wnt pathway components.
Bcl9/9l are necessary for the expression of Wnt targets in
normal intestinal epithelia (Deka et al. 2010) and the
myogenic progenitors during muscle regeneration, where
a reduction of Bcl9/9l inhibits the Wnt-driven myogenic
differentiation (Brack et al. 2009): This indicates that Bcl9/9l
are required for the expression of key subsets of b-catenin
target genes. Consistent with this, mutating b-catenin
such that it cannot bind Bcl9/9l (b-catenin-D164A) results
in embryonic lethality at mid-gestation, around embry-
onic day 10.5 (Valenta et al. 2011). In addition, a growing
body of evidence indicates that Bcl9/9l and their interac-
tion with b-catenin are important not only for normal cell
functions but also in different types of tumors (Mani et al.
2009; Deka et al. 2010; Brembeck et al. 2011; Takada et al.
2012).When their interaction is abrogated in these tumors,
an attenuated migratory potential is observed, accompa-
nied by a decrease in the expression of the Lgr5+-associated
stem cell genes (de la Roche et al. 2012; Kawamoto et al.
2012; A Moor, P Anderle, C Cant!u, N Wiedemann, F
Baruthio, P Rodriguez, J Deka, S Andr"e, T Valenta, B
Gy€orffy, et al., in prep.). The conclusion from these studies
was that, in mammals, Bcl9/9l retains a critical global
function for b-catenin-mediated target gene control, at least
in a tissue-specific manner. Based on comparison with the
Pygo2 knockout situation, this role can be considered, at
least in part, Pygo-independent. However, the molecular
function of Bcl9/9l during mammalian development and
tissue homeostasis remains largely unexplored.
Here we present an analysis of a series of Bcl9/9l knock-
in mouse strains in which, via the deletion of the HD1 or
HD2 domains, Bcl9/9l lose the ability to bind Pygo or
b-catenin, respectively. We found that both interactions
are relevant for development, and their individual disrup-
tion leads to embryonic lethality. Unexpectedly, however,
we found that Bcl9/9l contribute in a Pygo-dependent, but
b-catenin-independent, fashion to eye lens formation, re-
vealing for the first time that Bcl9/9l have functions that
are separate from canonical Wnt signaling. Moreover, we
provide molecular evidence for a novel genetic circuit
containing Bcl9/9l and Pygo that does not involve b-catenin:
Pax6, the master regulator of eye differentiation, directly
activates Bcl9 and Bcl9l transcription. Pygo2 is required
for the function of Bcl9/9l, and the Bcl9/9l–Pygo2 com-
plex appears to sustain Pax6 expression. This reveals that,
independently of canonical Wnt signaling, Bcl9/9l and
Pygo2 constitute a critical molecular unit that responds
to tissue-specific regulators, such as, in the lens, the Pax6
transcription factor.
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Results and Discussion
Pygo2 is assumed to be recruited by Bcl9/9l to promote
the output of the Wnt signaling pathway. However, clear
evidence that the Bcl9/9l–Pygo2 interaction is relevant
during mammalian development is lacking. To specifi-
cally investigate this, we generated constitutive knock-in
Bcl9 and Bcl9l alleles that carry an in-frame deletion of
the conserved HD1 (Fig. 1A; Supplemental Fig. S1), the
domain responsible for binding to Pygo proteins (Kramps
et al. 2002; St€adeli and Basler 2005; Fiedler et al. 2008).
This deletion abrogates the recruitment of Pygo proteins to
the b-catenin transcriptional complex (Fig. 1A; Mosimann
et al. 2009). Indeed, via GST pull-down assays, we con-
firmed that a Bcl9 protein lacking theHD1,when incubated
with total protein extracts obtained from 12.5-d post-
coitum (dpc) embryos, fails to bind Pygo2 but still binds
b-catenin (Fig. 1B), supporting the validity of the rationale
and indicating that a deletion of this domain does not lead
to improper folding of the protein. Pygo1was not detectable
in our experiments, consistent with the previous finding
that it is only weakly expressed later during embryonic
development (Li et al. 2004). For this reason, in our study, we
only considered the contribution of Pygo2.
Double-heterozygous knock-in mice (Bcl9DHD1/+;
Bcl9lDHD1/+) develop normally and do not display any
obvious defect. Interestingly, mice homozygous mutant
only in either Bcl9 or Bcl9l (that is, Bcl9DHD1/DHD1;
Bcl9l+/+ and Bcl9+/+; Bcl9lDHD1/DHD1) are born in ;50% of
the expectedMendelian ratios. This indicates a substantial
redundancy between Bcl9 and Bcl9l, at least concerning the
functions mediated by the HD1. In contrast, no double-
homozygous mutants (Bcl9DHD1/DHD1; Bcl9lDHD1/DHD1)
were ever found later than 13.5 dpc (Fig. 1D), indicating
embryonic lethality at this stage. Throughout the study, to
simplify the analysis and strengthen the validity of the
conclusion drawn, we investigate the effects of the simul-
taneous deletion in both genes and refer to these mice as
Bcl9/9l-DHD1.
Of note, the complete loss of Bcl9/9l (Bcl9/9l knockout)
causes an earlier lethality, occurring between 9.5 and 10.5
dpc (Supplemental Fig. S2; M Aguet, unpubl.); this suggests
the interesting notion that, between 9.5 and 13.5 dpc, Bcl9/9l
have Pygo-independent functions. Bcl9/9l-DHD1 mutant
embryos at 13.5 dpc are slightly smaller than the control
embryos (Fig. 1C); the cause of the lethality is currently
under investigation. Remarkably, the timing of the em-
bryonic lethality of Bcl9/9l-DHD1 mice is similar to that
of Pygo1/Pygo2 knockout embryos (Supplemental Fig. S3).
The time point differs slightly from that previously
reported (Li et al. 2007; Schwab et al. 2007). This minor
difference may be due to an influence of the genetic
background or a difference between the independently
generated genomic manipulations. These results indicate
that an important aspect of Bcl9/9l function ismediated by
the HD1 domain. With the caveat that other, so far
unrecognized proteins may also interact with Bcl9/9l via
the HD1 domain, the results show that the Pygo2–Bcl9/9l
interaction is required for mouse development as of 13.5
dpc.
An aspect in which the Bcl9/9l-DHD1 embryos are
identical to the Pygo2 knockout ones is that they display
an obvious eye defect: The lens is absent (Fig. 2). Of note, the
developing eye is one of the head structures displaying
a marked expression of both Bcl9 and Bcl9l (Supplemental
Fig. S4). The lens defect also often appears in triple-mutant
mice, which retain only one wild-type allele of Bcl9 or Bcl9l
(that is Bcl9+/DHD1; Bcl9lDHD1/DHD1 and Bcl9DHD1/DHD1;
Bcl9l+/DHD1). Interestingly, such genetic combinations
most often lead only to a unilateral lens loss, a further
indication that Bcl9 and Bcl9l are highly redundant with
respect to the functions mediated by Pygo2 binding.
During eye development, the surface head ectoderm
thickens to form the lens placode and at 10.5 dpc invaginates
to generate the lens pit (Lang 2004). In Bcl9/9l-DHD1
embryos, lens development is blocked at this stage: The
surface head ectoderm does not form the eye placode, the
first morphological sign of lens development (Fig. 2, bottom
panels), indicating that the Bcl9/9l–Pygo2 complex is re-
quired early at the onset of lens formation. Also, in Bcl9/9l
knockout embryos, lens development is arrested at this
stage (Supplemental Fig. S2E,F).
Interestingly, a positive role of Bcl9/9l in lens forma-
tion is in contradiction with the notion that Wnt signal-
ing must be turned off during lens development (Smith
et al. 2005; Machon et al. 2010). Therefore, we reasoned
Figure 1. The Bcl9/9l–Pygo2 interaction is necessary during mouse
embryonic development. (A) Wild-type and DHD1 mutant Bcl9 and
Bcl9l proteins; at the right is presented the variation in the ‘‘chain of
adaptors’’ induced by the deletion of the HD1 domain. (WRE) Wnt-
responsive element; (PHD) plant homeodomain; (NHD) N-terminal
homology domain. (B) A GST-Bcl9-DHD1 protein, when incubated
with protein extracts obtained from 12.5-dpc wild-type embryos, loses
the ability to interact with Pygo2 but maintains the ability to pull
down b-catenin; nonspecific signal (n.s.), obtained with Pygo2 anti-
body, was used as a loading control. (C) Crossings between double-
heterozygous mice: All of the possible genetic combinations are
grouped based on the number of wild-type alleles of Bcl9/9l, from
four out of four to zero out of four. Double-homozygous DHD1
mutant mice (Bcl9/9l-DHD1) are never found after 13.5 dpc, in-
dicating embryonic lethality. (D) Bcl9/9l-DHD1 mice at 13.5 dpc
appear slightly smaller but do not display any obvious developmental
defect, apart from an eye malformation (see Fig. 2), when compared
with control littermates (wild type [WT]).
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that Bcl9/9l might not act as Wnt signaling components
in this tissue. This hypothesis predicts that, if Bcl9/9l can
still bind Pygo2 but not b-catenin, the lens will develop
correctly. To assess this possibility, we created a knock-in
mouse strain carrying an in-frame deletion of HD2
(DHD2) in Bcl9 and Bcl9l (Fig. 3A; Supplemental Fig.
S5): We and others have previously shown that, in the
absence of the HD2 domain, Bcl9/9l can still bind to
Pygo2 but not to b-catenin (Fig. 3B; Kramps et al. 2002;
St€adeli and Basler 2005).
Of note, double-mutant embryos (Bcl9DHD2/DHD2;
Bcl9lDHD2/DHD2, referred to as Bcl9/9l-DHD2), die at
;10.5 dpc, earlier than Bcl9/9l-DHD1 mutants (Fig. 3C).
This is consistent with the lethality caused by the
b-catenin-D164A mutation, which also abrogates the
Bcl9/9l–b-catenin interaction (Valenta et al. 2011). A
corollary of this is that early Bcl9/9l functions are in-
dependent of Pygo2 but are mediated by b-catenin; in
other words, a truncated ‘‘chain of adaptors’’ lacking
Pygo2 can sustain mouse development until at least
embryonic day 13.5.
In order to investigate whether the loss of the Bcl9/9l–
b-catenin interaction also blocks lens formation at 10.5
dpc, we compared eye development in Bcl9/9l wild-type,
Bcl9/9l-DHD1, and Bcl9/9l-DHD2 embryos (Fig. 3E). In
wild-type embryos at 10.5 dpc, the lens pit is clearly
distinguishable. In Bcl9/9l-DHD1 mutants, the lens pit is
not forming. Importantly, in Bcl9/9l-DHD2 embryos, the
lens pit is developing normally (Fig. 3E, right panel). This
result indicates that, during lens formation, the Bcl9/9l–
Pygo2 complex functions independently of the physical
interaction with b-catenin.
In addition, we incorporated the lens-cre transgene,
a widely used lens-specific Cre recombinase driver (Ashery-
Padan et al. 2000), to generate Bcl9DHD1/flox; Bcl9lDHD1/flox;
lens-creTg/+ (lens-DHD1) and Bcl9DHD2/flox; Bcl9lDHD2/flox;
lens-creTg/+ (lens-DHD2) mice. Compared with control
animals, at birth, lens-DHD1 mice have smaller lenses.
The same effect is obtained upon the complete loss of
Bcl9/9l in the lens in Bcl9flox/flox; Bcl9lflox/flox; lens-creTg/+.
This is in agreement with data from Song et al. (2007), who
found that lens-cre-driven Pygo2 deletion does not entirely
recapitulate the lens loss induced by constitutive deletion
of Pygo2. Importantly, however, lens-DHD2 pups have
normally shaped lenses and are in all cases indistinguish-
able from control littermates (Supplemental Fig. S6). This
indicates that the Bcl9/9l–Pygo2 complex does not require
b-catenin to mediate its role during lens development.
To our knowledge, this is the first report demonstrating
that Bcl9/9l act outside the canonical Wnt signaling
cascade. A growing body of evidence indicates that, in
Figure 2. Bcl9/9l has a role in early lens development. (Top panels)
Bcl9/9l-DHD1 double-mutant embryos display an eye defect highly
reminiscent of the one previously described for Pygo2 loss of
function (Song et al. 2007). (Middle panels) The dissection of the
eye structure at this stage (i.e., 13.5 dpc) shows a complete absence
of the lens accompanied by an enlarged developing retina, a feature
that resembles the lens-specific conditional loss of Pax6 (Ashery-
Padan 2000). (Bottom panels) Bcl9/9l-DHD1 mutant embryos at 10.5
dpc fail to induce eye placode thickening and subsequent lens pit
formation. A square bracket indicates the lens vesicle in the wild-
type (WT) eye and the region of the surface head ectoderm that, in
Bcl9/9l-DHD1 mutants, despite lying close to the optic vesicle, fails
to form a lens placode.
Figure 3. Bcl9/9l act independently from b-catenin during lens
development. (A) Wild-type (WT) and DHD2 mutant Bcl9 and Bcl9l
proteins; at the right is presented the variation in the ‘‘chain of
adaptors’’ induced by deleting the HD2 domain: The interaction
between Bcl9/9l and b-catenin is abrogated, and the complex Bcl9/
9l–Pygo2 can act independently from canonical Wnt signaling. (B) A
GST-Bcl9-DHD2 protein loses the ability to interact with b-catenin
but maintains the ability to pull down Pygo2. (C) No double-
homozygous DHD2 mutant mice are ever scored after birth, suggest-
ing embryonic lethality. (D) The few embryos found at 12.5 dpc
displayed an evident developmental block at 10.5 dpc. (E) At 10.5
dpc, wild-type surface head ectoderm invaginates to form the lens
pit; in Bcl9/9l-DHD1 embryos, this process is arrested (cf. themiddle
and left panels). At the same stage, Bcl9/9l-DHD2 embryos have
a correctly shaped lens pit, demonstrating that, in this process, Bcl9/
9l function is independent from b-catenin.
b-Catenin-independent function of Bcl9/9l
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mice, Pygo2 has tissue-specific, Wnt-independent
functions in the testis (Nair et al. 2008; Cant!u et al.
2013) and lens (Song et al. 2007). Also, inDrosophila,
Pygo was recently reported to act in a b-catenin-
independent manner during heart development
(Tang et al. 2013, 2014). It will be critical to
establish whether other Wnt-independent func-
tions of Pygo2 require the interaction with Bcl9/9l
and whether these functions are conserved among
species.
Our finding that the Bcl9/9l–Pygo2 complex
functions independently of b-catenin in eye de-
velopment implies that, in this tissue, these
factors also act independently from upstream
canonical Wnt signals. The abrogation of the
Bcl9/9l–Pygo2 interaction causes a lens arrest very
reminiscent of Pax6 loss in this tissue (Ashery-
Padan et al. 2000). Therefore, we reasoned that
Pax6 might lie upstream of Bcl9/9l function. To
test whether Pax6 controls Bcl9, Bcl9l, and Pygo2
expression, we exploited the mouse-derived lens
cell line aTN4, a widely used model for lens cell
differentiation. This cell line expresses Pax6 and its
direct transcriptional target, aA-crystallin, encoded
by the Cryaa gene (Yang and Cvekl 2005); impor-
tantly, Bcl9/9l and Pygo2 are also expressed
(Fig. 4A), making this cell line a suitable model for
studying their regulation.
We identified in silico Pax6 consensus se-
quences between !5 kb and +1 kb of the tran-
scriptional start site (TSS) of Bcl9, Bcl9l, and
Pygo2. To determine whether any of these serve
as bona fide Pax6-binding sites, we performed
chromatin immunoprecipitation (ChIP) experi-
ments. We designed PCR primers to amplify the
Pax6-binding sites located within evolutionarily
conserved regions (Supplemental Fig. S7). Indicative
of Pax6 binding, we found that specific regions
upstream of Bcl9 and Bcl9l are enriched in our ChIP
assay when using an anti-Pax6 antibody (Fig. 4B).
Note that theCryaa promoter, our positive control,
displays a comparable enrichment, while no enrich-
ment is observed in several other genomic regions
(e.g., Prm2 promoter) (Fig. 4B). To probe the rele-
vance of Pax6 binding within these regions, we
treated aTN4 cells with siRNA against Pax6
(siPax6): Pax6 mRNA levels were reduced to <5%
of normal expression, causing a down-regulation of its
target aA-crystallin (Fig. 4C). Of note, Pax6 depletion
also resulted in the down-regulation of both Bcl9 and
Bcl9l transcripts.
To test whether Pax6 also affected Bcl9/9l
expression in vivo, we monitored Bcl9/9l expres-
sion in the developing eye in the absence of Pax6
function. To this end, we exploited Small eye (Sey)
mice that bear a Pax6-truncating mutation, a good
model to investigate Pax6 loss of function in vivo
(Hogan et al. 1986; Hill et al. 1991). Homozygous
Pax6Sey/Sey embryos can be distinguished as early
as 10.5 dpc by the phenotype that, at this stage,
the ectoderm does not invaginate to form a lens pit
(Hogan et al. 1986). In wild-type mice, we found
Bcl9l (Fig. 4D) and Bcl9 (Supplemental Fig. S4) proteins to
be highly expressed in the invaginating surface head
ectoderm, overlapping with the Pax6 expression domain
(Callaerts et al. 1997). In Pax6Sey/Sey embryos, the ectoder-
mal Bcl9l expression appears to be strongly reduced
compared with wild-type controls (Fig. 4D, cf. top and
Figure 4. Bcl9 and Bcl9l are direct transcriptional targets of Pax6. (A) The mouse-
derived lens cell line aTN4 expresses Bcl9, Bcl9l, and Pygo2 together with lens-
specific genes such as Pax6 and Cryaa. (B) ChIP performed on the chromatin
extracted from aTN4: Specific regions upstream of Bcl9 and Bcl9l are enriched
when the chromatin is immunoprecipitated with an anti-Pax6 antibody, indicative
of Pax6-binding events. No such enrichment was scored within the Pygo2
promoter. Cryaa and Prm2 promoters constitute the positive and the negative
controls, respectively. The enrichment is expressed as a ratio between anti-Pax6
and control IgG immunoprecipitation reactions. (TTS) Transcriptional start site.
(C) When aTN4 is treated with siRNA against Pax6, Pax6 mRNA is reduced to
<5% of the control. As its direct target, Cryaa, Bcl9 and Bcl9l levels are also
reduced upon Pax6 depletion. Of note, Pygo2 transcription is not altered. (D) A
loss-of-function mutation of Pax6 in vivo leads to a diminished Bcl9l expression in
the surface head ectoderm at the onset of lens pit formation. Arrows mark the
surface head ectoderm (already forming the lens pit in the wild-type [WT] embryo);
the asterisks indicate the diencephalic protrusion that constitutes the presump-
tive retina. DAPI is in blue and marks cell nuclei; Bcl9l is in red. (E) If aTN4 cells
are treated with siRNA against Pygo2, Pax6 is down-regulated. In such experi-
ments, Bcl9 and Bcl9l, together with Cryaa, are also affected, very likely due to
a secondary effect of Pax6 down-regulation. (AU) Arbitrary units. (F, left panel) At
10.5 dpc, the surface head ectoderm that forms the lens pit expresses high levels of
Pax6; at this stage in wild-type embryos, Pax6 appears to be stronger in the surface
ectoderm (white arrows) than in the presumptive retina (asterisks). In Pygo2
knockout (Pygo2-KO) and Bcl9/9l-DHD1 embryos, this ratio is inverted. Please note
that to detect the scant Pax6 within the surface head ectoderm, the signal must be
enhanced; this explains the apparent brighter signal in mutant retinas. In Bcl9/9l-
DHD2 embryos, the developing lens pit displays a Pax6 expression comparable with
the wild type. Statistically significant values are evidenced by asterisks, which
indicate a P-value < 0.05 calculated using an unpaired one-tail t-test.
Cant!u et al.
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bottom panels). The same is true for Bcl9 (data not shown).
Taken together, our in vitro and in vivo results strongly
suggest that Pax6 is required for Bcl9 and Bcl9l transcrip-
tion in developing lens cells, making them downstream
effectors in this cascade. Of note,Bcl9lwas also reported as
a putative Pax6 target based on ChIP experiments from
lenses of newborn mice combined with high-density
oligonucleotide array hybridizations (ChIP–chip) (Xie
et al. 2013); this is an independent validation of our
findings.
In Pygo2-null mice, Pax6 levels are reduced in the
surface head ectoderm at 10.5 dpc; on the other hand,
when Pax6 function is lacking, Pygo2 expression is un-
affected (Fig. 4C; Song et al. 2007, N Vilain and M Aguet,
unpubl.). Therefore, Pygo2 appears to be genetically
upstream of Pax6. We observed that abrogating the
interaction between Bcl9/9l and Pygo2 leads to a very
similar decrease of Pax6 expression in the surface head
ectoderm at 10.5 dpc (Fig. 4F), indicating that Bcl9/9l not
only are Pax6 targets but also act together with Pygo2
upstream of Pax6. The effect on Pax6 expression is not
observed in the Bcl9/9l-DHD2 developing lens, lending
further support to the notion that, in this context, Bcl9/9l
act in a b-catenin-independent fashion. The epistatic
hierarchy between Bcl9/9l–Pygo2, Pax6, and Bcl9/9l
raises the prediction that, if Pygo2 expression was
altered in lens cells, Pax6 and Bcl9/9l expression would
be affected accordingly. To test this, we treated aTN4
cells with siRNA targeting Pygo2 (siPygo2): Consis-
tently, Pygo2 down-regulation causes a decrease in
Pax6 mRNA level and diminished levels of its target
genes, Cryaa, Bcl9, and Bcl9l (Fig. 4E). Taken together,
our results reveal the existence of a novel genetic
regulatory circuit in which Bcl9/9l–Pygo2 act upstream
of Pax6, which in turn activates Bcl9 and Bcl9l. Thus,
in a b-catenin-independent manner, a Bcl9/9l–Pygo2
complex sustains correct lens formation during mouse
development (Fig. 5).
Bcl9 and Bcl9l, in a manner requiring Pygo2 binding,
thus emerge as new downstream effectors of Pax6 during
lens development. In this context, their action does
not appear to be modulated by upstream canonical Wnt
signals but by a tissue-specific transcription factor, Pax6,
the master regulator of the lens-specific differentiation
program. The molecular mechanism by which the Bcl9/
9l–Pygo2 complex achieves its tissue-specific function in
lens differentiation is an interesting line of future investi-
gation. One possibility is that the main function of the
Bcl9/9l–Pygo2 complex is to sustain Pax6 expression.
Consequently, by activating Bcl9/9l, Pax6
would buttress its own expression, creating
a positive feedback loop, a very common mech-
anism in biological systems, instrumental to
produce an all-or-none response to a signal
(Brandman et al. 2005).
It is currently widely accepted that, in the
lens, the Wnt pathway must be turned off
(Smith et al. 2005), and a recent study dis-
covered that this inhibition is mediated at least
in part by Pax6 (Machon et al. 2010). It is
therefore tantalizing to speculate that Bcl9/9l
and Pygo2 not only act independently from
b-catenin but, together with Pax6, are involved
in the inhibition of the Wnt-induced genetic
program, thus ensuring that lens development
proceeds correctly. To test this speculation, a more de-
tailed understanding of the timing and nature of Wnt
signaling and its targets in the developing lens is needed.
Our results provide a novel circuit and a novel paradigm
(a b-catenin-independent Bcl9/9l–Pygo2 module) that
need to be integrated into the emergent picture.
Materials and methods
Generation of Bcl9/9l knock-in mouse strain
Knock-in mutants in Bcl9 and Bcl9l were generated by standard
techniques (inGenious Targeting Laboratory). Briefly, the targeting
vector was electroporated into BA1 (C57BL/6 3 129/SvEv) hybrid
embryonic stem cells. After selection with the antibiotic G418, surviv-
ing clones were expanded for PCR and Southern blotting analyses to
confirm recombinant embryonic stem cell clones. Mouse embryonic stem
cells harboring the knock-in allele were microinjected into C57BL/6
blastocysts. Resulting chimeras were bred to wild-type C57BL/6N mice
to generate F1 heterozygous offspring. Neo cassette excision was obtained
by crossing heterozygous knock-in animals with mice expressing Flp
recombinase. All mouse experiments were performed in accordance with
Swiss guidelines and approved by the Veterinarian Office of the Kanton of
Zurich, Switzerland.
Cell culture and quantitative RT–PCR
The aTN4 cell line was cultured in DMEM supplemented with 10% FBS
at 37°C. Total RNAwas extracted using TRIzol (Invitrogen). Quantitative
real-time SYBR Green-based PCR reactions were performed in triplicate
and monitored with the ABI Prism 7900HT system (Applied Biosystem).
All primers are listed in the Supplemental Material.
ChIP
aTN4 were fixed with 1% formaldehyde for 10 min at room temperature
and lysed in a nuclei lysis buffer (1% SDS, 50 mM Tris, 10 mM EDTA,
protease inhibitors). Chromatin was sonicated to a size between 200 and
1000 base pairs using a Covaris focused ultrasonicator (10 times for 1 min,
10% duty cycle, 5% intensity, 100 cycles per burst). The antibodies and
the primers used are listed in the Supplemental Material.
Immunofluorescence
Previously fixed cryosections were blocked with 10% goat serum and
0.3% Triton-X-100 in PBS and incubated overnight at 4°C with the
following antibodies: a-Pax6 (Millipore), a-Bcl9 (Abcam), a-Bcl9l
(Abnova), and a-b-catenin (Cl. 14, BD Transduction Laboratories). Slides
were then incubated with a fluorescently labeled secondary antibody
(Alexa 488 goat anti-mouse or Alexa 555 goat anti-rabbit; 1:500). Nuclei
were stained with DAPI (1:1000; Sigma).
Figure 5. Our data indicate that Pax6 is required for the transcription of Bcl9/9l.
Bcl9/9l then assemble with Pygo2 to ensure a correct lens development; the lens
development is arrested when the Bcl9/9l–Pygo2 interaction is abolished. The
complex Bcl9/9l–Pygo2 also lies genetically upstream of Pax6, possibly with the
function of sustaining its expression.
b-Catenin-independent function of Bcl9/9l
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Highlights 	
• Mutations in the genes encoding for Bcl9, Bcl9l, Pygo1 and Pygo2 lead to severe 
cardiac malformations both in zebrafish and in the mouse 
• Bcl9 and Pygo drive the Wnt signaling-dependent transcription in heart progenitor 
cells 
• The b-catenin-Bcl9-Pygo module directly controls the expression of important 
regulators of cardiac and neural crest development 
• The zebrafish and mouse mutants we generated constitute powerful models to study 
human congenital heart conditions 
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	Summary (147 words) 
Congenital heart diseases are the most frequent defects at birth, often lethal even after 
surgical intervention. Discovering novel mechanisms of heart development is the 
prerequisite to generate new diagnostic and therapeutic strategies. Here, via a 
CRISPR/Cas9 genetic screen in zebrafish, we identified a role for the Wnt//b-catenin 
cofactors Bcl9, Bcl9l and the histone code-reader Pygo2 during cardiac development. We 
show that loss-of-function of these proteins, or the sole abrogation of their interaction with b-
catenin via in vivo small-domain deletion, induce heart malformations, both in fish and in 
mouse, that recapitulate human CHDs. We find that the Bcl9-Pygo complex acts in specific 
cell populations of the developing heart, where it directly activates a previously unrecognized 
tissue-specific transcriptional program. Collectively, our results uncover a new role of Wnt/b-
catenin signaling during heart development, and implicate mutations in BCL9 and PYGO as 
potentially causative in the formation of human CHDs. 
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	Introduction 
Understanding heart development at the molecular level is imperative for discovering the 
causes of congenital heart diseases (CHDs). CHDs are the most frequent birth defects, 
affecting ca. 0.8% of live births, and often result in perinatal lethality or life-long 
complications, even after sophisticated surgical interventions (Zaidi et al., 2013). A number 
of mutations in cardiac transcription factors have been linked to genetic forms of congenital 
heart disease (Andersen et al., 2014), but the developmental pathways that drive the onset 
of specific cardiac phenotypes remain unclear. 
 
Wnt signaling is a key determinant of several developmental processes in metazoans, 
including heart formation (Nusse and Clevers, 2017; Woudstra et al., 2017). Studies on the 
role of Wnt signaling in cardiac development have been challenging to interpret, with reports 
supporting both promoting and restricting functions on cardiac progenitor specification, 
depending on the developmental stage (Gessert and Kühl, 2010). Canonical, b-catenin-
mediated Wnt signaling has been shown to play a role in mesodermal cardiac progenitor 
expansion (Buikema et al., 2013) and in the proliferation of cardiac neural crest (CNC) cells 
(Kioussi et al., 2002). Defects in these cell populations are associated with malformations 
such as outflow tract (OFT) defects, persistent truncus arteriosus (PTA), double outlet right 
ventricle (DORV), commonly present in patients with tetralogy of Fallot and genetic 
syndromes, such as DiGeorge syndrome (Neeb et al., 2013). How defects in Wnt/β-catenin 
signaling contributes to these disease conditions is currently unknown. 
 
Nuclear β-catenin orchestrates target gene expression by recruiting a host of co-factors to 
cis-regulatory elements occupied by the TCF/LEF transcription factors (Mosimann et al., 
2009; Nusse and Clevers, 2017). In Drosophila, the coupling of the histone code-reader 
plant homology domain (PHD) finger protein Pygopus (Pygo) via the adaptor protein Legless 
(Lgs) to the β-catenin N-terminal Armadillo repeats was shown to be necessary for virtually 
all canonical Wnt signaling-dependent processes (Kramps et al., 2002a; van Tienen et al., 
2017; Townsley et al., 2004a). The genomes of common vertebrate model organisms 
encode for two paralogs of lgs, Bcl9 and Bcl9l (Bcl9/9l), and two of pygo, Pygo1 and Pygo2 
(Pygo1/2). In vertebrates their relevance has been debated, and they appear to participate in 
the b-catenin-mediated transcription in a context-dependent manner (Brembeck et al., 
2004a; Kennedy et al., 2010; Schwab et al., 2007). Additionally, they have evolved tissue-
specific b-catenin-independent functions (Cantù et al., 2013, 2014a, 2017; Li et al., 2007).  
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	Here, via a CRISPR/Cas9-mediated genetic screen in zebrafish, we identify mutations in 
bcl9 as being potentially causative of developmental heart malformations. Subsequently, we 
generated a series of zebrafish and mouse loss-of-function mutants for Bcl9, Bcl9l, as well 
as for Pygo1 and Pygo2 (the only known Bcl9/9l-interacting proteins), and present genetic 
and molecular evidence for an evolutionarily conserved role of the b-catenin-Bcl9/9l-Pygo1/2 
transcriptional module during vertebrate heart development. In both model organisms, when 
the b-catenin>Bcl9/9l>Pygo1/2 complex formation is abrogated, the resulting embryos 
display severe heart defects reminiscent of human CHDs, associated with forelimb and 
cartilage defects. The heart phenotype is recapitulated, in the mouse, by both constitutive 
and heart-specific conditional loss of Bcl9/9l or Pygo1/2, or by simultaneous impairment of 
the Bcl9/9l-b-catenin and Bcl9/9l-Pygo2 interactions achieved via in vivo small domain 
deletions. Transcriptomics studies (RNA-seq) and chromatin immunoprecipitation followed 
by deep sequencing (ChIP-seq) revealed that the b-catenin>Bcl9>Pygo complex lies 
functionally upstream of a heart-specific genetic program that includes several important 
regulators of cardiac and neural crest development. Collectively, our results suggest a 
causative link between mutations in BCL9, BCL9L, and perhaps in PYGO1 and PYGO2, and 
human CHDs, as result of a tissue-specific perturbation of canonical Wnt signaling. 
 
Results 	
CRISPR/Cas9-mediated genetic screen in zebrafish reveals a potential role for Bcl9 
during heart development		
With the aim of identifying novel genes involved in heart formation, we developed a genetic 
screen in zebrafish in which, via Cas9 RNP-mediated mutagenesis (Burger et al., 2016), we 
introduced specific loss-of-function mutations in a series of genes that have not previously 
been functionally implicated in heart development. We injected Cas9 protein together with 
target-specific guideRNAs (gRNA) into zebrafish embryos, and screened for impaired heart 
development between 56-72 hours post fertilization (hpf). Among other candidates, we 
identified specific heart defects upon mutations in bcl9, a gene encoding for a Wnt/b-catenin 
signaling cofactor. Mutations in bcl9 lead to highly penetrant pericardial edema appearing 
before 72 hpf. To validate this observation, and to exclude possible off-target effects, we 
generated a new set of gRNAs targeting the 5’ region of its coding sequence. We 
established heterozygous mutant strains carrying frameshift 5’ deletions within the region 
encoding for the HD1 and HD2, the domains of Bcl9 that allow functional interaction with the 
only known interactors, Pygo and b-catenin, respectively. We refer to this new allele as 
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	bcl9Δ29 (Figure 1A, B). Homozygous mutant embryos for bcl9Δ29, despite growing normally 
until 48 hpf, develop a pericardiac edema between 56-72 hpf (with an incidence of 25-90%), 
(Supplementary Figure 2 A-C), and mis-expression of the cardiac valve marker vcana 
(Supplementary Figure 2 F,G). At 5 days post fertilization (dpf), lightsheet imaging of 
homozygous bcl9Δ29; drl:EGFP+ [that marks cardiovascular lineages (Mosimann et al., 2015)] 
larvae, revealed an underdeveloped cardiopharyngeal vasculature, vascular defects at the 
cardiac inflow tract, and a miss-looped heart with miss-aligned atria and ventricles, when 
compared to wildtype or heterozygous sibling mutants (Figure 1F-I). bcl9Δ29 mutants also 
displayed other selective phenotypes with high penetrance, such as cartilaginous 
craniofacial defects consisting of deformed pharyngeal skeletons with abnormal Meckel’s 
and palatoquadrate cartilage development, and fusion defects of the ceratohyal and 
ceratobranchial 1 cartilage (Figure 1 J-M). Importantly, homozygous bcl9Δ29-mutant larvae 
die at around 11 dpf, possibly due to a failure in properly inflating the swim bladder already 
apparent at 5dpf (Figure 1 C-E).  
To assess for a potential redundant role between Bcl9 and the paralog protein Bcl9l, we 
generated mutant alleles also for the latter (we refer to this allele as bcl9lΔ4, Supplementary 
Figure 2 A, B). Interestingly, and contrary to previous conclusions based on morpholino-
mediated knockdowns (Brembeck et al., 2004b), homozygous bcl9lΔ4 mutants were viable 
and fertile with no obvious phenotypes (observed for at least 4 generations) (Supplementary 
Figure 2 C-G). In addition, bcl9/9l double-mutant embryos (i.e. homozygous for the bcl9Δ29 
and bcl9lΔ4 alleles) look indistinguishable from bcl9Δ29 (Figure 1 E), corroborating the non-
essential function of bcl9l and establishing that no significant compensation (Rossi et al., 
2015) by the paralog bcl9l occurs upon bcl9 perturbation in bcl9Δ29;bcl9lΔ4 mutants. 
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	Supplementary Figure 1 
 
Supplementary Figure 1: Variable cardiac phenotypes in bcl9Δ29 mutants between 2-3 dpf. (A,-
C) At 48 hpf, bcl9Δ29 develop pericardiac edema with a variable penetrance. Scale bar 500 µm. (D,E) 
The hearts of bcl9Δ29 are patterned into atria and ventricle as visualized by drl:EGFP. The two 
chambers are, however, miss-aligned revealing a looping defect caused by the bcl9 mutation. Scale 
bar 500 µm. (F,G) Whole mount ISH for vcana reveals reduced expression specifically in the heart 
suggesting a defect in valve formation. Scale bar 200 µm. 
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	Figure 1 
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	Figure 1: A homozygous 29 bp deletion between HD1 and HD2 leads to severe cardiac and 
craniofacial defects in zebrafish. (A) CRISPR-Cas9-mediated mutagenesis via NHEJ in coding 
exon 6 between HD1 and HD2 of the zebrafish bcl9 gene. Gene locus represented as per genome 
annotation Zv10 with two isoforms that differ in the first coding exon and the untranslated regions 
(UTRs). The green dotted box represents a zoomed region of the gene locus, with the red line 
representing the location of the sgRNA used for mutagenesis; black boxes mark coding exons (CDS), 
white boxes mark UTRs, the blue boxes represent the part of the CDS that will contribute to HD1 and 
purple boxes to HD2. Note that the schematic is not to scale. (B) CrispRVariants panel plot depiction 
of the germline allele with a 29 bp deletion at the CRISPR cutting site. Top shows genomic reference 
with the bcl9:g.176663_176691 (bcl9Δ29) allele shown below. bcl9Δ29 results in an out-of-frame 
deletion introducing a frameshift in the CDS. The black box over genomic reference sequence 
indicates sgRNA sequence, the smaller box the 5’-NGG-3’ PAM sequence, and the black line the 
predicted Cas9-induced double-strand break position. (C-E) Brightfield images of 5 dpf homozygous 
bcl9Δ29 and bcl9Δ29;bcl9lΔ4 larvae and their wildtype siblings. Mutant larvae do not inflate their swim 
bladder (arrows) presumably due to a failure to gasp air because of craniofacial malformations (black 
arrow heas). Moreover, mutant larvae show heart looping defects (asterisks). Scale bar 500 µm. (F-I) 
SPIM images of drl:EGFP+ wildtype and bcl9Δ29 larvae. Mutant larvae show craniofacial vasculature 
(asterisks and arrow head) and heart looping (dotted line outlines the atrium and ventricle) defects. 
Scale bar 200 µm. (J-M) Alcian blue stainings of the pharyngeal cartilage of 5 dpf wildtype and bcl9Δ29 
larvae shown in ventral (J,K) and lateral (L,M) view. bcl9Δ29 larvae show malformations of the 
pharyngeal apparatus with fusions defect of the ceratohyal (ch) and ceratobranchial 1 (cb1) arches 
and miss-shaped Meckel’s (m) and palatoquadrate (pq) cartilage. Scale bars 100 µm. (N-Q) 
Fluorescent images of TCF-siam:Red bcl9Δ29 and wildtype larvae. TCF reporter activity is severely 
reduced in the cardiac outflow tract (of), nose (no), and craniofacial apparatus (asterisks P,Q) and 
altered in the atrio-ventricular valve (arrow heads N-Q). Scale bars N,O 500 µm; P,Q 200 µm.  
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	Supplementary Figure 2 
 
Supplementary Figure 2: MZbcl9l∆4 mutants are viable and fertile. (A,B) Schematics showing the 
mutation induced in bcl9∆4 mutants. Analogous to bcl9 mutants (see Figure 1 A, B), we designed a 
sgRNA that binds between the HD1 and HD2 domain. (A) Gene locus represented as per genome 
annotation Zv10 with two isoforms that differ in the first coding exon and the untranslated regions 
(UTRs). The green dotted box represents a zoomed region of the gene locus, with the red line 
representing the location of the sgRNA used for mutagenesis; black boxes mark coding exons (CDS), 
white boxes mark UTRs, the blue boxes represent the part of the CDS that will contribute to HD1 and 
purple boxes to HD2. (B) A 4 pb deletion at the CRISPR cutting side leads to a frame-shift allele with 
a premature STOP codon before HD2. (C-G) Homozygous bcl9l∆4 mutants were viable and fertile. 
Thus, we could analyze maternal zygotic mutants (MZbcl9l∆4) by crossing two adult homozygous 
bcl9l mutants. (C) MZbcl9l∆4 mutants did not show any gastrulation defects in contrast to bcl9l 
morphant phenotypes reported in the literature, lateral views. Scale bar 500 µm. (E,F) At 5 dpf we 
could not detect any cardiac and craniofacial phenotypes as observed in zygotic bcl9∆29 mutants (see 
Figure 1), lateral views, anterior to the left. Scale bar 500 µm. (G) Representative image of a five 
month old (5 mo) MZbcl9l∆4  F4 mutant. 
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pygo mutant zebrafish recapitulate bcl9 loss 
Bcl9 has been shown to act, during Drosophila and vertebrate development, via functional 
coupling with the histone-code reader Pygopus (Kramps et al., 2002)(Thompson et al., 
2002). To test for a potential role of Pygo1 and Pygo2 during zebrafish heart development 
we generated, with a similar Cas9 RNP-mediated approach, pygo1 and pygo2 loss-of-
function mutant alleles. These alleles harbor frameshift mutations within the essential NH2-
terminal homology domain (NHD) and result in a premature STOP codon before the Bcl9-
binding C-terminal PHD domain; we refer to these alleles as pygo1Δ5 and pygo2Δ1 
(Supplementary figure 3 A-C). Surprisingly, homozygous pygo1Δ5 and homozygous pygo2Δ1 
mutant strains were indistinguishable from wild-type siblings throughout development, and 
homozygous pygo1Δ5 animals were viable and fertile. In contrast, embryos that were 
homozygous for the pygo2Δ1 alleles and concomitantly carried a homozygous or 
heterozygous pygo1Δ5 mutation displayed cardiac and cartilaginous defects that 
recapitulated those observed in bcl9Δ29 homozygous mutants (Supplementary Figure 3 D-F). 
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	Supplementary Figure 3 
68
	Supplementary Figure 3: Zygotic pygo1/2 mutants phenocopy bcl9Δ29 zebrafish mutants. (A) 
Schematic representation of the zebrafish pygo1 and pygo2 genes with annotated NHD and PHD 
domains and the CRISPR cutting site to generate mutants. Gene locus represented as per genome 
annotation Zv10 with the main isoforms of both genes shown. The red line represents the location of 
the sgRNA used for mutagenesis; black boxes mark coding exons (CDS), white boxes mark UTRs, 
the blue boxes represent the part of the CDS that will contribute to NHD and purple boxes to PHD. 
Note that the schematics are not to scale. (B,C) CrispRVariants panel plot depictions of the germline 
alleles with a 5 bp or 1 bp deletion in pygo1 and pygo2, respectively. Top shows genomic reference 
with the pygo1∆5: g.2924_2928del and pygo2∆1: g.3191del alleles shown below. Both alleles result in 
an out-of-frame deletion introducing a frameshift in the CDS. The black box over genomic reference 
sequence indicates sgRNA sequence, the smaller box the 5’-NGG-3’ PAM sequence, and the black 
line the predicted Cas9-induced double-strand break position. (D,E) Brightfield images of live and 
Alcian blue stained pygo1Δ5;pygo2Δ1 double mutants reveal cardiac edema (asterisks) and 
craniofacial defects (arrow heads), and aberrant swim bladder inflation (arrows) as detected in bcl9Δ29 
mutants (see Figure 1), lateral or ventral views, anterior to the left. Scale bars 250 µm. (F) 
Quantification of phenotypes in four individual pygo1Δ5/wt x pygo2Δ1/wt crosses reveal defects in 7-18% 
of all larvae. Genotyping of phenotypic larvae revealed phenotype occurrence in homozygous 
pygo2Δ1 mutants in combination with homozygous or heterozygous pygo1Δ5 mutation.  
 
Bcl9 is required for selective developmental processes 
As a next step, we set out to identify the gene expression changes that accompanied the 
phenotypic defects occurring upon mutations in bcl9. To this end, we performed RNA 
extraction followed by deep sequencing (RNA-seq) on combined zebrafish trunk and head 
regions - where the ensemble of phenotypic defects was manifest -, including the heart, 
pharyngeal arches, pectoral fins, and craniofacial structures, and compared homozygous 
bcl9∆29 mutants and wild-type siblings derived from heterozygote bcl9∆29 in-crosses at 54 hpf. 
Our aim was to capture the gene-expression changes leading to the cardiac and 
cartilaginous craniofacial defects occurring later at 5 dpf (Figure 1). At 54 hpf, we detected 
deregulation of 178 genes (124 genes down, cut-off: 2x downregulation, FC <0.5; 54 genes 
up, cut-off: 2.5x upregulation, FC>2.5) in homozygous bcl9∆29 mutants compared to the wild-
type siblings. Among the deregulated genes, 37 have been associated with zebrafish heart, 
pharyngeal arches, pectoral fins, and cranial neural crest development (Supplementary 
Table 1). A number of the downregulated genes (e.g. vegfa, cdh5) have been linked to 
epithelial-to-mesenchymal transition (EMT), and to morphogenetic processes occurring 
during cardiac valve formation (Supplementary Table 1). Considering this set of genes, we 
performed a Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, 
Szklarczyk et al., 2015) analysis, and found that they assembled in a medium-to-high 
confidence protein-protein associations cluster that implies their cooperative action during 
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	cardiac valve formation (Supplementary Figure 4). Overall, these data strongly supported 
the notion that Bcl9, in zebrafish, acts during selective developmental processes, including 
fin formation, craniofacial cartilage specification likely via a cell-autonomous role in neural 
crest cells and, most importantly, during cardiac valve morphogenesis. 
 
Supplementary Figure 4 
 
Supplementary Figure 4: Cardiac genes de-regulated in bcl9∆29 mutants cluster in a network 
guiding valve development. (A) STRING analysis of mouse orthologues of de-regulated genes in 
bcl9∆29 zebrafish mutants with kmeans clustering analysis (numbers of clusters 4). Five out of seven 
down-regulated genes assemble in one cluster with medium to high confidence protein-protein 
interactions reflecting their interactive involvement in cardiac valve formation as reviewed from the 
literature. All up-regulated genes assemble a separate cluster reflecting their potential involvement in 
cardiomyocytes actino-myosin and sarcomere assembly. Permalink to analysis: http://bit.ly/2wmba7z. 
 
Pygo1/2 and Bcl9/9l loss in mouse causes lethal heart malformations 
The observation that Bcl9 and Pygo proteins have a prominent role during cardiac 
development in zebrafish, prompted us to test their role in the mouse, a model closer to 
human physiology. 
In the mouse, the compound deletion of Pygo1 and Pygo2 (Pygo1/2) leads to embryonic 
lethality at 13.5/14.5 dpc for undetermined reasons (Cantù et al., 2013; Li et al., 2007). We 
found that Pygo1/2 mutant embryos, between 13.5 and 14.5 days post coitum (dpc), display 
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	severe heart defects such as malformed atrio-ventricular valves resulting in substantial 
regurgitate flow and dilated atria, hypoplastic ventricular myocardium and aberrant chamber 
septation (Figure 2 A-D). In addition, Pygo1/2 mutant embryos displayed outflow tract (OFT) 
anomalies such as transposition of the great arteries (TGA, with a penetrance of ca. 80%) 
(Figure 2 E-F) and a hypotrophic ductus arteriosus, with a penetrance of 90% (Figure 2 G-
H). Strikingly, some of these defects are reminiscent of those present in human CHDs such 
as, for example, Valvular Heart Disease, or DiGeorge syndrome (Racedo et al., 2017). 
Defects in atrioventricular (AV) valve formation in mice have been found to cause lethality 
between 13.5 and 16.5 dpc (Combs and Yutzey, 2009; Ranger et al., 1998), suggesting that 
the cardiac defects likely cause the death of Pygo1/2-mutant embryos. 
Subsequently, we tested the requirement of Bcl9/9l proteins for this function of Pygo1/2 by 
making use of Bcl9/9l alleles with a deletion in HD1, the domain responsible for Pygo1/2 
binding (Bcl9/9l-DHD1, Cantù et al., 2014). Bcl9/9l-DHD1 homozygous embryos died at the 
same stage (13.5 - 14.5 dpc), and histological sections revealed heart defects resembling 
those observed upon Pygo1/2 loss (Figure 2Q). This suggests that the cardiac defects 
observed in our mutant mice arise from a cooperative Bcl9-Pygo function. The finding that 
Bcl9/9l-Pygo1/2 have a role in mouse and zebrafish heart development suggests a 
conserved tissue-specific function of this complex. Discovered as apparently obligate 
players in Drosophila Wnt signaling, in vertebrates Bcl9/9l and Pygo1/2 act together in 
several developmental processes independently of b-catenin (Cantù et al., 2013, 2014a, 
2017; Song et al., 2007). As a next step, we therefore sought to establish if the zebrafish 
and mouse phenotypes described here constitute other examples of b-catenin independent 
processes or if they are connected to Wnt/b-catenin signaling. 
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	Figure 2: Cardiac defects in Pygo1/2 and Bcl9/9lDHD1 mutant mouse embryos. (A-D) 
Haematoxylin/eosin stained sagittal sections of the heart at 10.5 (A, B) and 14.5 dpc (C,D). At 10.5 
dpc the development of heart and heart cushion was still largely normal in the mutants. At 14.5 dpc 
the mutants displayed markedly smaller and thinner valves, highly dilated atria, and the atrial septum 
was missing. (E,F) Gross anatomical view of heart and great vessels at 13.5/14.5 dpc as revealed by 
India ink injection. (G) While normally the aorta (Ao) arises from the left (L) and the pulmonary artery 
(Pa) from the right ventricle (R), mutants had a classic TGA (H) in addition to a hypoplastic aortic arch 
(Aa) and ductus arteriosus (Du). (I) Schematic representation of the Bcl9/9l-Pygo1/2 interaction 
(upper left) and the molecular configuration of this interaction when the HD1 domain in Bcl9/9l is 
deleted in Bcl9/9l-∆HD1 mice (upper right). The abrogation of this interaction leads to a delayed 
chamber septation, hypoplastic myocardium and velves deficiency. 
 
The Bcl9/9l-Pygo1/2 complex drives Wnt/b-catenin signaling in the developing heart 
Wnt signaling is required for the formation of both the AV valves, the OFT (Bosada et al., 
2016; Liebner et al., 2004), and the activity of Pax3 and Pitx2 during cardiac neural crest 
(CNC) migration and expansion (Bang et al., 1999; Kioussi et al., 2002). Since Bcl9/9l 
function as linker proteins connecting b-catenin and Pygo1/2 (Bienz, 2006), we aimed at 
specifically testing the concurrent requirement of connecting these two interaction partners 
for Wnt/b-catenin dependent outputs in the mouse. We combined mouse Bcl9/9l alleles in 
which either the HD1 (Pygo binding) or the HD2 (b-catenin binding) domains are deleted 
(Figure 3A, B) (Cantù et al., 2014). Double-heterozygous mice for the HD1 (Bcl9ΔHD1/+; 
Bcl9lΔHD1/+, referred to as Bcl9/9l-DHD1/+) or the HD2 (Bcl9ΔHD2/+; Bcl9lΔHD2/+, referred to as 
Bcl9/9l-DHD2/+) deletions are viable and fertile. Crosses between Bcl9/9l-DHD1/+ and 
Bcl9/9l-DHD2/+ must lead to trans-heterozygous embryos (1/16) in which both domain 
deletions are present (Bcl9ΔHD1/ΔHD2; Bcl9lΔHD1/ΔHD2, referred to as Bcl9/9l-D1/D2): this allelic 
composition would not allow for a single molecule of Bcl9/9l to simultaneously bind b-catenin 
and Pygo. In fact, in Bcl9/9l-D1/D2 mice, the resulting protein products can form Bcl9-b-
catenin and Bcl9-Pygo complexes, but not the full tripartite transcriptional complex (Figure 
3B), thereby enabling us to precisely test the developmental requirement of the b-catenin-
Bcl9-Pygo complex. 
From such crosses, we never recovered Bcl9/9l-D1/D2 pups (Figure 3B), indicating 
embryonic lethality. Bcl9/9l-D1/D2 embryos reached the 13.5-14.5 dpc stage, even though in 
a smaller proportion than the expected Mendelian ratio (Figure 3B). Bcl9/9l-D1/D2 embryos 
displayed heart defects including ventricular myocardium hypoplasia and aberrant cardiac 
valves and OFT formation (Figure 3C-F). In addition to cardiac defects, we observed severe 
underdeveloped limbs (Figure 3I, L), and several skeletal malformations (Figure 3M-R) 
including shortened radius and ulna bones, incorrect specification of digit number (Figure 3 
73
	M,N and P,Q), and bifid ribs (Figure 3M,O and P,R). Suggestive that the observed defects 
are related to perturbed canonical Wnt signaling. Bcl9/9l-D1/D2-mutant mouse embryos also 
displayed a reduced expression of the in vivo BATgal reporter transgene in the cardiac 
cushions (Figure 3D, F), craniofacial structures, and limbs (Figure 3G-L). 
To confirm that the heart defects induced by the loss of Bcl9 or Pygo function are caused by 
a tissue-specific perturbation of Wnt signaling also in zebrafish, we treated wild-type 
embryos with LH-2-40, a recently developed selective inhibitor of the β-catenin/Bcl9 
interaction (Wisniewski et al., 2016). LH-2-40 was administered at concentrations ranging 
from 10 to 25 µM, at different time-points: 4 cell-stage, shield stage, or 18 somite stage. LH-
2-40-treated embryos recapitulated the bcl9Δ29-mutant phenotypes at 5 dpf (Figure 4A-H). In 
addition to the craniofacial and cardiac defects found in bcl9Δ29 mutants, we frequently 
scored fin defects, characterized by the formation of an aberrant angle between the fin and 
the trunk, and a deformation of the proximal fin tissue (Figure 4C-H). We monitored the Wnt 
signaling activation status via Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 (Moro et al., Dev Biol 
2012) (referred to as TCF-siam:Red it is a canonical Wnt signaling in vivo reporter). Both in 
LH-2-40-treated embryos and in bcl9Δ29 mutants (Figure 1N-Q), we could measure a specific 
alteration of TCF-siam:Red expression in the atrio-ventricular valve, in the craniofacial 
structures, and in the pectoral fins, at 3 and 5 dpf (Figure 4M-T). 
While we cannot rule out that Bcl9 and Pygo proteins possess additional functions that are 
independent of Wnt/β-catenin signaling, these results provide compelling genetic evidence 
that they are simultaneously required during vertebrate heart development for b-catenin-
dependent transcription. 
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	Figure 3: The abrogation of the tripartite b-catenin-Bcl9-Pygo complex leads to selective heart 
and skeletal defects.  
(A) Schematic representation of the β-catenin transcriptional complex. Bcl9/9l simultaneously interact 
with Pygo1/2 and β-catenin via the domains HD1 and HD2, respectively. (B) In the Bcl9/9l-D1/D2 
mice, no Bcl9/9l molecule can simultaneously bind Pygo1/2 and β-catenin; the deletion of the HD2 or 
HD1 domains abrogates Bcl9/9l binding to β-catenin (left panel) or Pygo1/2 (right panel), respectively. 
Bcl9/9l-D1/D2 embryos are never found after stage 14.5 dpc (table). (C-H) In vivo BATgal reporter 
expression at 13.5 dpc: mutant embryos have a slightly decreased reporter expression, but it is 
generally retained in most tissues (compare C and F, or D and G). Bcl9/9l-D1/D2 embryos display 
severe limb defects accompanied by a complete loss of canonical Wnt signalling activity as reported 
by the lack of BATgal expression (compare E with H). (I-N) Alcian blue cartilage staining reveals loss 
of digits in Bcl9/9l-D1/D2 embryos (compare I-J with L-M). Other cartilage malformations are present, 
for example rib bifurcations (K, N). (O, P) H&E staining of heart sections at 13.5 dpc. Bcl9/9l-D1/D2 
embryos sport pronounced heart defects, in particular in the ventricle walls, the forming septum, the 
AV valves and outflow tract. (X,Y) The expression of BATgal in the outflow tract region is completely 
lost in Bcl9/9l-D1/D2 mutant hearts. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left 
ventricle. 
 
 
 
 
 
 
 
 
76
	Figure 4 
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	Figure 4: The Bcl9 inhibitor LH-2-40 induces phenotypes mimicking bcl9Δ29 mutants.  
(A-B) Treatment with 10 µM LH-2-40 from 2-4 cell stage does not result in gastrulation defects. Scale 
bar 500 µm. (C-H) Phenotypes in LH-2-40 treated embryos become visible at 5 dpf, comparable to 
phenotypes observed in bcl9Δ29 mutants. LH-2-40 treated embryos show a variable phenotype 
expressivity with mild to strong swim bladder inflation defects (arrow heads E,G) caused variable 
craniofacial defects (asterisks C,E,G). Additionally, Bcl9 inhibited larvae with medium or strong 
phenotype expressivity are characterized by readily observable fin phenotypes (arrow heads D,F,H). 
Scale bar 200 µm. (I-K) Similar dose-dependent phenotype penetrance and expressivity can be 
observed after Bcl9 inhibition at 4-cells, shield and 18 ss stage suggesting that the observed 
phenotypes result from Bcl9 function in craniofacial, fin, and heart development after somitogenesis. 
Mild phenotypes are characterized by mild craniofacial and swim bladder defects without observable 
fin defects. Partial phenotypes show strong craniofacial defects and a complete failure to inflate the 
swim bladder, but no fin defects. Medium and strong phenotypes as described in (E-H). (L-S) 
Fluorescent and brightfield images of TCF:siamRed Bcl9 inhibited and DMSO treated wildtype 
siblings. TCF reporter activity is severely reduced in the atrio-ventricular valve at 3 dpf (asterisks L,N) 
and altered in the craniofacial cartilage (arrow heads L,N). At 5 dpf, TCF is miss-expressed in the 
atrio-ventricular valve (asterisks P,R) and fins (arrow heads P,R). Scale bars 200 µm. 
 
 
Bcl9-Pygo act in neural crest cells and cardiac heart progenitors 
The zebrafish and mouse phenotypes described above suggest a potential role for the Bcl9-
Pygo complex both in neural crest cells as well as in mesodermal cardiac progenitors. We 
set out to test this by using mouse genetics, and combining conditional alleles of Pygo1/2 
and Bcl9/9l with tissue-specific Cre-drivers (Figure 5A,B). When we combined the 
conditional Pygo1/2 and Bcl9/9l alleles (Pygo1flox/flox;Pygo2flox/flox, referred to as Pygo-flox; 
Bcl9 flox/flox;Bcl9l flox/flox, referred to as Bcl9/9l-flox) with the neural crest-specific Cre-driver 
Wnt1-Cre, we observed embryonic lethality at 13.5/14.5 dpc, and heart malformations that 
morphologically recapitulated the constitutive loss of Pygo1/2 (Figure 2Q, Figure 5A). 
The transcription factors Pax3 and Pitx2 are required for the migration and expansion of 
CNC cells at 10.5 dpc (Bang et al., 1999; Kioussi et al., 2002). We observed decreased 
expression of Pax3 and Pitx2 transcripts in migratory CNC cells in Pygo1/2-mutant embryos 
at 10.5 dpc, (Figure 2I-P). In addition, cultured primary neural crest cells, isolated from the 
pharyngeal arches at 10.5 dpc from Pygo-flox embryos, displayed signs of impaired 
differentiation into smooth muscle actin (SMA)-positive non-neuronal cells (Achilleos and 
Trainor, 2012), when Pygo1/2 conditional alleles were recombined via transduction of 
Adeno-CreEGFP viral particles (Figure 5C). This provided strong evidence that the OFT 
valves and septation defects we observed might be due to aberrant CNC cell differentiation. 
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	Defective myocardium and cardiac valve formation in Pygo and Bcl9 mutant mice and fish 
could be a secondary consequence of failed OFT morphogenesis, due to perturbed 
communication of colonizing extra-cardiac neural crest lineages with cardiac and 
endocardial progenitors (Neeb et al., 2013). To test for earlier heart field defects contributing 
to cardiac malformations upon Bcl9/9l-Pygo1/2 perturbation, we combined Pygo-flox and 
Bcl9/9l-flox with a Cre-recombinase driven by the regulatory regions of the cardiac 
homeobox gene Nkx2-5, activated in heart progenitors at early cardiac crescent stages (ca. 
7.5 dpc) (Stanley et al., 2010). Nkx2.5-Cre-mediated Bcl9/9l recombination led to embryonic 
lethality around 13.5 dpc, with obvious myocardial malformations, such as thinner 
myocardium and aberrantly enlarged atrio-ventricular valves (Figure 5B), indicating a cardiac 
mesoderm-specific requirement of the b-catenin-Bcl9-Pygo mediated transcription. 
Additionally, siRNA-mediated downregulation of Pygo2 in cultured murine embryonic 
cardiomyocytes lead to enhanced signs of differentiation (Figure 5D), consistent with the 
known role of canonical Wnt signaling in preventing cardiomyocyte differentiation (Naito et 
al., 2006). We conclude that the Bcl9-Pygo complex is required both in migrating CNC cells 
and the early mesodermal Nkx2.5-expressing cardiac progenitors, whose interplay is crucial 
during heart development (Brade et al., 2013).  
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	Figure 5 
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	Figure 5: Neural crest specific deletion of Pygo1/2 as well as cardiac mesoderm deletion of the 
same genes leads to similar defects as total loss of the protein.   
(A) Schematic of the cells deleted upon Wnt1-Cre mediated recombination (red dots) and 
Haematoxilin/Eosin staining of heart section from wild-type (left panel) or neural crest-specific 
conditional Pygo1/2 mutant mice (right panel). (B) Schematic of the cells deleted upon Nkx2.5-Cre 
mediated recombination (green dots). Akin to neural crest-specific loss of Pygo1/2, deletion of Bcl9/9l 
in Nkx2.5-expressing ALPM-derived cardiac progenitors disturb heart formation, in particular causing 
septal and valve defects (arrow) and highlighting important functions of the chain-of-adaptors in both 
mesodermal and neural crest lineages during cardiac morphogenesis. (C) Branchial arch cell explants 
from Pygo1/2-flox mice were treated with adenoCre viral particles and TGFβ to induce differentiation. 
Neural crest differentiation potential was markedly reduced upon treatment as indicated by the loss of 
smooth muscle actin (Acta2) fibers. (D) Cardiomyocyte cultures showed increase of differentiation 
markers upon siRNA mediated knock-down of Pygo2, consistent with a role for Pygo2 in these cells 
as well. (E, F) Whole mount ISH showing expression of the neural crest cell markers Pax3 in 
representative 10.5 dpc wild-type (E) and mutant (F) embryos. (G, H) Pax3 expression in the region of 
branchial arches (insets of I and J, respectively). (I, J) Whole mount ISH of Pitx2 expression in 10.5 
dpc wild-type (I) and mutant (J) embryos. Pitx2 expression was drastically reduced in mutant 
embryos, particularly in periocular mesoderm, oral ectoderm, branchial arches and anterior somites. 
(K, L) Pitx2 expression in the region of branchial arches. 
 
The b-catenin-Pygo2 transcriptional complex directly activates a heart-specific 
genetic program 
To get insights into the molecular mechanism that explains the previously described gene 
expression changes, we set out to discover the full ensemble of target genes directly 
controlled by the b-catenin-Bcl9-Pygo transcriptional module in the combined mesodermal 
heart progenitors and CNC cells. 
In a first experiment, we dissected embryonic branchial arches 3-6, through which CNC 
progenitor cells migrate dorso-ventrally toward the heart cushion and OFT structures 
(Gessert and Kühl, 2010) together with the developing heart tube, from constitutive Pygo1/2 
mutant and control siblings at 10.5 dpc, and performed RNA-seq (N=4, Figure 6A). Pygo1/2-
mutant embryos featured a reproducible set of 127 deregulated genes (p-value<0.05), 84 of 
which were downregulated and 53 upregulated (Figure 6B). Gene Ontology (GO) analysis 
(http://www.geneontology.org/) revealed that deregulated genes were associated with 
biological processes such as cardiac ventricle development, embryonic limb morphogenesis, 
skeletal system development and determination of bilateral symmetry, recapitulating the 
biological processes perturbed upon bcl9 mutations in zebrafish (Figure 6D). Notably, the 
down-regulated genes included several genes encoding for transcription factors crucial for 
heart development, such as Pitx2, Hand2, Msx1 and Prrx1 (Andersen et al., 2014; Chen et 
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	al., 2007; Kioussi et al., 2002; Ocaña et al., 2017), indicating that Wnt/b-catenin lies 
functionally upstream of a heart-specific genetic program. Although the statistical power of 
the RNA-seq was low, possibly due to the differences between samples caused by the 
manual dissection or individual variability, we could confirm the downregulation of the most 
relevant genes by in situ hybridization (ISH) (Figure 6E). STRING analysis of the 
differentially expressed genes revealed two Pygo-dependent clusters of important regulators 
of heart and limb development (Figure 6F). Because some of the differentially expressed 
genes found before the onset of cardiac defects at 11.5, such as Pitx2, Hand2, Msx1 and 
Prrx1, are known important regulators that activate tissue-specific gene regulatory networks 
(Chen et al., 2007; Kioussi et al., 2002; Laurent et al., 2017; Nadadur et al., 2016; Ocaña et 
al, 2017), we interpret the phenotypes observed at 13.5 as a consequence of the early 
perturbation of these genes. These data raised the hypothesis that, at around 10.5 dpc, b-
catenin-Bcl9/9l-Pygo1/2 activates several heart-specific effectors, whose combined 
deregulation produces the complement of heart defects we described at later stages. To test 
this, we collected ca. 250 wild-type mouse embryos at 10.5 dpc and carefully dissected the 
looping heart tube and pharyngeal arches 3-6, exactly as carried out for the RNA-seq 
experiment, and performed chromatin immunoprecipitation for b-catenin and Pygo2, 
followed by deep DNA sequencing (ChIP-seq, Figure 7A). This assay, performed in 
duplicate, revealed a total of 982 high-confidence genomic loci occupied by b-catenin, and 
5252 by Pygo2 (Figure 7B). Of note, co-occupancy of b-catenin and Pygo2 was observed at 
a large fraction of the total b-catenin peaks (577/982), implying their in vivo interaction on a 
substantial number of regulatory genomic locations in developing cardiopharyngeal 
structures. Of interest, in line with its known role as chromatin code-reader (Bienz, 2006; 
Fiedler et al., 2015) and its Wnt-independent functions (Cantù et al., 2013), Pygo2 displayed 
a much broader spectrum of targets than b-catenin (Figure 7B). We focused our attention on 
the overlapping peaks (i.e. chain-of-adaptors targets): we found binding events in the vicinity 
of classical Wnt targets such as Axin2 and Lef1 (Figure 7D). These correspond to previously 
described Wnt-regulatory-elements (WRE) at these loci (Hovanes et al., 2001; Jho et al., 
2002). Furthermore, we found heart specific genes like Prrx1 and Six1 (Figure 7D, lower 
panels). This, while constituting a strong validation of our experiment, indicated that 
mainstream Wnt target genes are mechanistically regulated via the b-catenin-Bcl9-Pygo 
interaction, in this context. Importantly, and consistent with the phenotypes and the gene 
expression profile described above, GO analysis of the targets revealed a striking 
enrichment of genes that control heart development and morphogenesis, cardiac chamber 
septation, and skeletal development (Figure 7C, E). 
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	Figure 6 
Figure 6: Pygo1/2 control a set of heart regulator genes, explaining the observed heart 
malformations. 
(A) Artificial depiction of the dissected structures to extract the sequenced RNA from. (B) Heatmap 
showing the up- and down- regulated genes in Pygo1/2 mutant versus wilt-type E10.5 branchial 
arches and hearts. (C) Table showing the GO terms associated with the misregulated genes. (D) 
Selected targets that are misregulated upon loss of Pygo1/2. (E) Whole mount ISH for Msx1 in E10.5 
embryos shows strong downregulation of the transcript especially in the branchial arches (arrows), as 
well as parts of the forelimbs in Bcl9/9l-∆1/∆2 mutants (upper 2 panels). Lower 4 panels: ISHs of 
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	sections from E13.5 embryos. Hand2 expression is reduced upon loss of Pygo2 especially in the 
valves. Pitx2 expression is reduced upon ablation of Pygo in the neural crest cells via a Wnt1 Cre 
driver.  
 (F) STRING analysis network of the differentially expressed genes shows two heart specific cluster 
as well as a histone cluster of genes.  
 
The intersection between the data deriving from the RNA-seq and the ChIP-seq, revealed 
that b-catenin, in this context, is an upstream regulator of important cardiac genes. Among 
these, Msx1, that governs CNC cell proliferation and migration, OFT formation, and EMT 
during AV valves formation (Chen et al., 2008, 2007), and Prrx1, a mesodermal homeobox 
transcriptional regulator of the neural crest-derived mesenchyme, whose function is highly 
conserved between fish and mammals (Braasch et al., 2014), and that activates a genetic 
program required for the formation of the heart asymmetry (Ocaña et al., 2017). Other direct 
targets include Nr2f2, mutations in which are causative of congenital AV septal defects (Al 
Turki et al., 2014), and Six2, a marker of the SHF progenitors, whose ablation leads to 
hypoplastic RV and pulmonary atresia (Zhou et al., 2017). Collectively, these data implicate 
that the b-catenin-dependent transcription, via the action of the transcriptional activators 
Bcl9/9l and Pygo1/2, is an upstream governor of a heart-specific genetic program, and that it 
acts by directly regulating a series of important heart-specific transcription factors. 
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	Figure 7: Pygo and b-catenin co-occupy selective regulatory regions  
(A) Illustration showing the upper body of a mouse embryo at 10.5 dpc. Dashed lines delineate the 
region dissected to perform ChIP-seq experiments. (B) Venn diagram depicting the peak overlap 
between β-catenin and Pygo2 occupancy. (C) 30 direct β-catenin-Bcl9/9l-Pygo2 target genes have 
been already implicated in heart development. (D) ChIP peaks on the Axin2 (left panel) and Lef1 
(right panel) loci; these are prototypical Wnt target genes. Red bars indicate the position of previously 
described WREs. ChIP-seq custom tracks are visualized in the UCSC genome browser 
(https://genome.ucsc.edu). The lower 4 panels show the same tracks for Prrx1 and Six1, two genes 
known to be crucial for heart development (E) Gene Ontology analysis of the common β-catenin and 
Pygo2 target genes reveals the direct regulation of processes associated with heart development. 
 
Discussion 
 
Bcl9/9l and Pygo1/2: new players in heart development 
 
A role for Wnt signaling during cardiac morphogenesis was previously established: waves of 
activation and inhibition of Wnt/b-catenin signaling were shown to be essential for second 
heart field (SHF) progenitor proliferation (Ai et al., 2007; Cohen et al., 2007; Kwon et al., 
2007; Qyang et al., 2007; Tian et al., 2010), for endocardial invagination and EMT and 
neural crest migration during cardiac valve formation (Liebner et al., 2004; Augustine et al., 
1993; Bosada et al., 2016b; Hurlstone et al., 2003; Kirby and Hutson, 2010).  
 
Here, by using genetics, genome engineering, chemical genetics, and biochemical 
approaches in the mouse and in zebrafish, we identify Bcl9/9l and Pygo1/2 as regulators of 
Wnt/b-catenin signaling during heart development. Of note, the cardiac defects induced by 
loss-of-function mutations in these genes include defective aortic arch, truncus arteriosus, 
incomplete chamber septation and aberrant valvulogenesis. Tantalizingly, BCL9 and BCL9L 
have been recently connected to human congenital heart defects: BCL9 has been reported 
as a frequently de novo mutated gene in innate CHD (Andersen et al., 2014; Zaidi et al., 
2013), while loss of BCL9L has been genetically linked to heterotaxia (HTX), a human 
syndrome in which left-right asymmetry of various organs, including the heart, is perturbed 
(Saunders et al., 2012). Our study confirms this hypothesized connection, and shows that 
the consequence of the mutations in BCL9 and BCL9l are due to perturbed canonical Wnt 
signaling. This is important, as the heart defects induced by mutations in Bcl9 and Pygo 
genes resemble those commonly found in patients with different CHDs. 
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	Notably, by combining RNA-seq and ChIP-seq studies, we found that Bcl9 and Pygo 
orchestrate the correct expression of mesodermal heart and neural crest regulators such as 
Msx1, Prrx1, Hand2, Pitx2,  as well as members of the FGF signaling cascade (Lee et al., 
2006; Li et al., 2016). We wish to point out that, among these genes, Msx1 and Prrx1, 
display b-catenin and Pygo2 enrichment in their regulatory regions (Figure 7D) and can 
therefore be considered as new direct Wnt/b-catenin targets. Importantly, deregulation of 
these genes per se could lead, in principle, to the series of heart defects we observed: Msx1 
was previously implicated in CNC cell proliferation, OFT formation and EMT during AV 
valves formation (Chen et al., 2007, 2008), while Prrx1 encodes for a mesodermal 
homeobox transcription factor that contributes in establishing the left-right asymmetry in 
zebrafish, and its downregulation causes heart looping defects (Ocaña et al., 2017). Other 
master regulators of heart development, such as Hand2 and Pitx2, were found deregulated 
upon mutations of Bcl9/9l and Pygo1/2, but did not appear to be associated to any ChIP-seq 
peak, indicating that they are likely secondary targets. Notably, Hand2 controls cardiac 
development by triggering a gene regulatory network (GRN) of effectors with known 
functions in EMT processes and AVC cardiac cushion formation (Laurent et al., 2017), while 
Pitx2 modulates a Tbx5-dependent GRN necessary to proper adult heart function (Nadadur 
et al., 2016). The perturbation of Hand2 and/or Pitx2 activity is associated with several heart 
defects accordant with the phenotypes caused by loss of b-catenin-Bcl9-Pygo signaling 
(Andersen et al., 2014; Gessert and Kühl, 2010; Kioussi et al., 2002; Neeb et al., 2013). The 
observation that the b-catenin>Bcl9/9l>Pygo1/2 lies upstream of these mechanisms thrusts 
forward the notion that canonical Wnt/b-catenin signaling triggers a broad heart-specific 
GRN, via the direct activation of important regulators such as Msx1 and Prrx1 that, in turn, 
leads to the subsequent regulation of a plethora of other genes encoding for crucial heart 
regulators, among which the relevant Hand2 and Pitx2 transcription factors are included.  
 
Of note, the human diseases DiGeorge Syndrome (DGS) and Holt-Oram Syndrome (HOS) 
present cardiac features resembling those identified in Bcl9 and Pygo mutant mice. DGS is 
known to be caused by loss of TBX1 function (Papangeli and Scambler, 2013; Yagi et al., 
2003). Interestingly, it has been recently suggested that perturbation of b-catenin function 
causes DGS-like defects in murine hearts by affecting Fgf8-Tbx1 pathways activity, and that 
the unbalance of this mechanism might result in the variable expressivity observed in DGS 
patients (Racedo et al., 2017). Moreover, the combination of heart and limb defects is 
remarkably similar to the human genetic condition HOS, caused by mutations in TBX5 (Al-
Qattan and Abou Al-Shaar, 2015; Mori et al., 2006). Intriguingly, our data does not seem to 
suggest direct regulation of Tbx1 or Tbx5 by b-catenin. However, both Tbx1 and Tbx5 are 
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	mildly downregulated at 12.5 dpc in the mouse, suggesting that they might be secondary 
targets, or that the interplay between these factors and the b-catenin transcriptional complex 
occurs at the protein level.  Exploring the role of a Wnt/b-catenin dependent transcriptional 
network mediated in the context of a TBX factor-guided regulatory network presents a 
promising avenue of the project, and could potentially uncover new mechanistic insights into 
the molecular causes of DGS and HOS. 
 
Canonical Wnt signaling is executed, in specific cell populations, via the b-catenin-Bcl9-Pygo 
chain of adaptors complex 
 
Intriguingly, we found that in zebrafish as in the mouse, mutations in Bcl9 and Pygo lead to a 
location-specific downregulation of in vivo Wnt signaling reporters, as evidenced by the 
reduction of TCF-siam:Red, in bcl9∆29 mutants and LH-2-40-treated zebrafish embryos 
(Figure 1N-Q, Figure 4L,N,P,R), or of the widely used BatGal reporter transgene in the 
mouse (Figure 3D,F,G-L). Of note, the decrease in Wnt signaling was not ubiquitous but 
occurred in a tissue-specific manner. This is important, as these proteins have been 
discovered in Drosophila as constitutive transducers of the Wnt/Wg cascade (Kramps et al., 
2002a; Townsley et al., 2004b), but their in vivo relevance as general b-catenin cofactors in 
other organisms has been the matter of a long debate (Cantù et al., 2014b, 2017; Mosimann 
et al., 2009; van Tienen et al., 2017). To understand the tissue-specific molecular 
mechanism of action of the Wnt/b-catenin-Bcl9-Pygo complex, we studied the effects of their 
mutation on the transcriptome (RNA-seq) and their genome-wide physical association to the 
DNA (ChIP-seq). The combination of these data sets established a new tissue-specific list of 
direct b-catenin transcriptional targets. Among these, we found not only classical Wnt 
targets, but also genes associated with tissue-specific differentiation programs, such as that 
of the heart, limbs and neural crest cells. Therefore, this study indicates that Wnt/b-catenin 
orchestrate cell fate in a tissue-specific manner, and invite revisiting the precise mechanisms 
of Wnt signaling-dependent transcription in other tissues. 
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	 Methods 
 
Zebrafish husbandry and transgenic strains 
All zebrafish embryos were raised and maintained in E3 medium at 28.5°C without light 
cycle essentially as described (Westerfield, 2007). All experiments were performed on 
embryos and larvae up to 5 dpf and older larvae only kept for raising mating pairs in 
agreement with procedures mandated by the veterinary office of UZH and the Canton of 
Zürich. Embryo staging was done according to morphological characteristics corresponding 
to hours post fertilization (hpf) or days post fertilization (dpf) as described previously (Kimmel 
et al., 1995). Previously established transgenic zebrafish lines used for this study include 
Tg(-6.35drl:EGFP) (Mosimann et al., 2015) and Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 (Moro et 
al., 2012).  
 
CRISPR-Cas9 mutagenesis  
CRISPR-Cas9 mutagenesis was essentially performed as described in Burger et al. 
2016(Burger et al., 2016). Oligo-based sgRNA templates (Bassett et al., 2013) were 
generated by PCR amplification using the the invariant reverse primer 5’-
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGC CTT-3’ and 
forward primers of the sequence 5’-GAAATATTTAGGTGACACTATA-(N20-22)-
GTTTTAGAGCTAGAAATAGC-3’ with N representing the 20 nucleotides of the sgRNA 
target sequence plus up to 2 Gs at the 5’-end for successful T7 in vitro transcription. sgRNA 
(plus added 5’Gs in brackets) sequences were: i) bcl9 5’-(G)GCCTGACTGCGCTACTTTAG-
3’; ii) bcl9l 5’-(G)GATTTAGGTGTGCCAATCGG-3’; iii) pygo1 5’-
GGACTTCCCAGTAGCAGCCC-3’ ; iv) pygo2 5’-(G)GCCGATGGTTGACCACCTGG-3’.  
 Crispants were raised to adulthood and crossed to wildtypes to make F1 germline mutants. 
All analyses and experiments were taken out on F2 mutant generations and beyond. 
Genotyping primers were designed to either amplify target regions of mutated alleles that 
were subsequently analyzed via sequencing (for pygo1∆1) or high-percentage gel 
electrophoresis (for bcl9∆29) or allele-specific primers were designed to bind to mutated vs. 
wildtype sequences specifically (for bcl9l∆4 and pygo1∆5). Primers used were: i) bcl9 5’-
GGTGGAAAGCCCCAACTCC-3’ (fwd), 5’-CGTGTGCCAACTGCTGGTGG-3’ (rev); ii) bcl9l 
5’-	 CACTTGCAGGTGCTGCATGG-3’ (fwd), 5’-	 CTTTGAGATTTAGGTGTGCCGG-3’ (rev); 
iii) pygo1 5’-CACTTTTACTGACCCCCACAC-3’ (fwd), 5’-GGACTTCCCAGTAGCAGGA-3’ 
(rev); iv) pygo2 5’-	 GCCCAGAGAAAAAGAAGAGG-3’ (fwd), 5’-	
GCTGTCCACTTCCAGGTCC-3’ (rev). Genotyping results were analyzed and alleles 
visualized using CrisprVariantsLite as described in Lindsay et al., 2016(Lindsay et al., 2016).  
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	Chemical treatments 
Wildtype and Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 embryos were treated with LH-2-40 to 
globally perturb Bcl9∆HD2-β-catenin interaction at the respective developmental stages. LH-
2-40 was kindly received from the laboratory of Dr. Haitao Ji at the Moffitt Cancer Center, 
Tampa/FL, USA. Single-use LH-2-40 stocks were kept at a concentration of 100 mM in 
DMSO at -80°C and thawed and diluted in E3 to a working concentration indicated in 
individual experiments directly before administration to the embryos.  
 
Alcian Blue staining 
Wildtype, bcl9, and pygo1/2 mutant larvae were fixed in 4% Paraformaldehyde (PFA) 
overnight at 4°C and after washing in 0.1% PBS-Tween (PBST) stained in Alcian blue 
staining solution (0.1 g Alcian blue, 70 mL ethanol, 30 mLl glacial acetic acid) overnight at 
room temperature. Embryos were washed in Ethanol and transferred through an Ethanol 
series to PBST and subsequently bleached in hydrogen peroxide (3% H2O2 in 1% KOH in 
PBS) for 1 hour or until pigments of specimens became transparent. 
 
Whole-mount in situ hybridization 
Antisense RNA probes were designed for the genes vcana. First-strand complementary 
DNA (cDNA) was generated from pooled zebrafish RNA isolated from different 
developmental stages using Superscript III First-Strand Synthesis kit (Invitrogen). DNA 
templates were generated using first-strand cDNA as PCR template and following primers 
5’-TTACGTATGCAGCCTTCTCG-3’ and 5’-GGTTCATGGGGTAACTGTGG-3’). For in vitro 
transcription initiation, the T7 RNA polymerase promoter 5'-TAATACGACTCACTATAGGG-
3’ was added to the 5’-end of reverse primers. PCR reactions were performed under 
standard conditions using Phusion High-Fidelity DNA Polymerase (ThermoFisher Scientific). 
RNA probes were generated via overnight incubation at 37°C using T7 RNA polymerase (20 
U/µl) (Roche) and Digoxigenin (DIG)-labeled dNTPs (Roche). The resulting RNA was 
precipitated in lithium chloride and Ethanol.  
 Embryos were fixed in 4% PFA overnight at 4°C, transferred into 100% methanol and 
stored at -20°C. ISH of whole mount zebrafish embryos was performed essentially according 
to standard protocols (Thisse and Thisse, 2008). 
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	Microscopy and data processing 
Brightfield (BF), basic fluorescence, and ISH imaging was performed using a Leica M205FA 
equipped with a DFC450 C camera. Detailed fluorescent embryo imaging of drl:EGFP-
expressing bcl9 mutants was performed by Single Plane Illumination Microscopy (SPIM) 
with a Zeiss Lightsheet Z.1 microscope. Prior to imaging, embryos were embedded in a rod 
of 1% low melting agarose in E3 with 0.016% Ethyl 3-aminobenzoate methanesulfonate salt 
(Tricaine, Sigma) in a 50 µL glass capillary.  
Image processing was done with Leica LAS, Zeiss Zen Black, ImageJ/Fiji and Adobe 
Photoshop and Illustrator CS6 according to image-preserving guidelines to ensure unbiased 
editing of the acquired image data. Quantitative data analysis was performed using 
GraphPad Prism 5.0. Data are presented as mean ± SEM. A lower case “n” denotes the 
number of embryos, while a capital “N” signifies the number of replicates.  
 
Mouse lines 
Knock-in mutants in Bcl9 and Bcl9l were generated by standard techniques (inGenious 
Targeting Laboratory). Briefly, the targeting vector was electroporated into BA1 (C57BL/6 × 
129/SvEv) hybrid embryonic stem cells. After selection with the antibiotic G418, surviving 
clones were expanded for PCR and Southern blotting analyses to confirm recombinant 
embryonic stem cell clones. Mouse embryonic stem cells harboring the knock-in allele were 
microinjected into C57BL/6 blastocysts. Resulting chimeras were bred to wild-type 
C57BL/6N mice to generate F1 heterozygous offspring. Neo cassette excision was obtained 
by crossing heterozygous knock-in animals with mice expressing Flp recombinase. All 
mouse experiments were performed in accordance with Swiss guidelines and approved by 
the Veterinarian Office of the Kanton of Zurich, Switzerland.  
 
Histological analysis  
Embryos between day E9.5 and E14.5 were fixed overnight in 4% paraformaldehyde at 4°C, 
dehydrated and embedded in paraffin. Sections were stained with haematoxylin and eosin 
for histological analysis. The same paraffin embedded material was sectioned under RNase 
free conditions for in situ hybridization.  
 
Mouse in situ hybridization  
Whole-mount in situ hybridization was performed as described previously (Piette et al., 
2008). Digoxigenin-labeled probes (Roche) were detected by enzymatic color reaction using 
alkaline phosphatase-conjugated anti-digoxigenin Fab fragments (1:1000, Roche) and BM 
purple alkaline phosphatase substrate (Roche). In situ hybridization on paraffin sections was 
performed as described (Gregorieff et al., 2005). Digoxigenin-labeled RNA probes were 
91
	detected with peroxidase-conjugated anti-digoxigenin Fab fragments (1:500, Roche) 
followed by fluorescence detection using Tyramide Signal Amplification (PerkinElmer). 
Mouse antisense RNA probes were as described in supplementary materials.  
 
Intracardiac injection of India ink  
For the analysis of the cardiovascular system, india ink was injected into the left ventricle of 
mouse embryos at E14.5 using a finely drawn glass pipette. The embryos were fixed in 4% 
paraformaldehyde and hearts were dissected for the anatomic examination.  
 
RNA sequencing 
Zebrafish samples (poly A selection): 
Zebrafish embryos from bcl9∆29/wt crosses were dissected at 56 hpf: a cut was made 
between the anterior part of the embryo (containing the head, pharyngeal and cardiac 
structures) and the posterior part starting from the beginning of the yolk extension. The 
anterior tissues were directly snap-frozen in liquid nitrogen in single tubes of PCR 8-tube 
strips. The posterior trunks and tails were transferred in 50 mM NAOH and genomic DNA 
was extracted. Single embryos were genotypes using the target sequence primers listed 
above and PCR products were separated through high-percentage gel electrophoresis 
leading to a separation of the wildtype allele and mutant allele with the following outcome: i) 
a low running band in bcl9∆29 mutants; ii) a high running band in wildtypes; iii) two bands in 
bcl9∆29/wt heterozygous mutants. All snap-frozen anterior parts of bcl9∆29 mutants and of 
wildtypes were pooled in two separate tubes and RNA isolation performed with the RNeasy 
Plus Mini Kit (Qiagen). The whole procedure was repeated for a total of three clutches 
making three independent replicates.  
The TruSeq mRNA stranded kit from Illumina was used for the library preparation with 250 
ng of total RNA as input. The libraries were 50-bases sequenced on an Illumina HiSeq 2500 
sequencer. The quality control of the resulting reads was done with FastQC and the reads 
mapped to the UCSC Danio rerio danRer10 genome with the TopHat v.2.0.11 software. For 
differential expression analysis the gene features were counted with HTSeq v.0.6.1 (htseq-
count) on the UCSC danRer10 gene annotation. The normalization and differential 
expression analysis were performed with R/Bioconductor package EdgeR v. 3.14. The p-
values of the differentially expressed genes are corrected for multiple testing error with a 5 
% false discovery rate (FDR) using Benjamini-Hochberg (BH). 
 
Mouse samples (ribo depletion): 
The Illumina TruSeq stranded Total RNA library Prep kit with RiboZero was used for the 
library preparation with 300 ng of total RNA as input. The libraries were 100-bases 
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	sequenced on an Illumina HiSeq 4000 sequencer. The quality control of the resulting reads 
was done with FastQC and the reads mapped to the UCSC Mus musculus mm10 genome 
with the TopHat v.2.0.11 software. For differential expression analysis the gene features 
were counted with HTSeq v.0.6.1 (htseq-count) on the UCSC mm10 gene annotation. The 
normalization and differential expression analysis were performed with R/Bioconductor 
package EdgeR v. 3.14. The p-values of the differentially expressed genes are corrected for 
multiple testing error with a 5 % false discovery rate (FDR) using Benjamini-Hochberg (BH). 
 
qRT-PCR 
Quantitative real-time SYBR Green-based PCR reactions were performed in triplicate and 
monitored with the ABI Prism 7900HT system (Applied Biosystem).  
 
ChIP 
Ca. 200 branchial arches of E10.5 embryos were fixed with EGS (5mM) for 40 minutes, then 
1% formaldehyde was added for another 20 min at room temperature. Cells were then lysed 
in a nuclei lysis buffer (1% SDS, 50 mM Tris, 10 mM EDTA, protease inhibitors). Chromatin 
was sonicated to a size between 200 and 1000 base pairs using a Covaris focused 
ultrasonicator (10 times for 1 min, 10% duty cycle, 5% intensity, 100 cycles per burst). The 
antibodies used were anti IgG (Santa Cruz), anti-Pygo2 (Novus Biological, NBP1-46171 ) 
and anti-b-catenin (Cl. 14, BD Transduction Laboratories, 610154).  
 
Immunofluorescence 
FFPE sections were blocked with 5% hings, % BSA and 0.1% Tween in PBS and incubated 
overnight at 4°C with the following antibodies: mouse anti p53 5E2 (NovusBio), rabbit anti 
Sox9 (Millipore), Troponin type2 (novus biologicals), Acta2 (Sommer lab), GFP (Aves). 
Slides were then incubated with a fluorescently labeled secondary antibody (Alexa 488 goat 
anti-mouse or Alexa 555 goat anti-rabbit, Alexa 594 goat anti-chicken; 1:500). Nuclei were 
stained with DAPI (1:1000; Sigma).  
 
Branchial arch explants 
Pharyngeal apparatus was dissected in PBS and resuspended in digestion mix (0.5mg 
collagenase/ml, 0.1% Trypsin) and incubate at 37 °C for 15min. Digestion was inactivated 
with 750ul of DMEM 10%FCS and plated in fibronectin coated wells in medium according to 
(Zhao et al., 2006), medium 2. 
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	Supplementary Table 1 
 
Supplementary Table 1: De-regulated genes in bcl9∆29/∆29 mutants with expression in 
cardiopharyngeal and/or pectoral fin precursors/derivatives as per Zfin annotations and selected 
publications. 
 
 
Gene name FC Zfin ID Expression 
mcu 0.46 ZDB-GENE-061013-24 heart, heart tube 
nos2b 0.44 ZDB-GENE-080916-1 mandibular arch skeleton 
zgc:56699 0.46 ZDB-GENE-040426-2099 pharyngeal arches, pectoral fin 
vegfaa 0.49 ZDB-GENE-990415-273 heart, pharyngeal arch 
hoxc1a 0.45 ZDB-GENE-000822-2 pectoral fin bud, pharyngeal arch 
plaub 0.36 ZDB-GENE-030619-15 heart 
cyp3a65 0.43 ZDB-GENE-050604-1 heart 
arhgap17a 0.31 ZDB-GENE-050417-56 pharyngeal arch 
cdh5 0.43 ZDB-GENE-040816-1 heart, heart primordium, lateral mesoderm 
adora2aa 0.46 ZDB-GENE-080723-28 heart 
rspo1 0.50 ZDB-GENE-040718-44 heart 
met 0.37 ZDB-GENE-041014-1 liver, pharyngeal arch 
wtip 0.36 ZDB-GENE-050419-261 heart 
tgfbr1a 0.44 ZDB-GENE-051120-75 pharyngeal arch 
hoxb4a 0.41 ZDB-GENE-990415-105 pharyngeal arch 
vwf 0.40 ZDB-GENE-070103-1 pharyngeal arch 
rbck1 0.51 ZDB-GENE-040704-3 pharyngeal arch 
mtf1 0.46 ZDB-GENE-020424-1 heart 
mcoln1a 0.42 ZDB-GENE-040426-2704 heart 
lepr 0.50 ZDB-GENE-080104-1  heart 
fgfr1b 0.48 ZDB-GENE-060503-14 pharyngeal arch, fin bud 
sema3ga 0.43 ZDB-GENE-050513-3 pharyngeal arch 
cldn15la 0.46 ZDB-GENE-010328-12 heart 
ucp3 0.46 ZDB-GENE-040426-1317 heart 
cldng 0.48 ZDB-GENE-010328-7 lateral mesoderm, heart 
erbb2 0.47 ZDB-GENE-031118-121 neural crest 
grhl2b 0.43 ZDB-GENE-060503-719 otic vesicle, pectoral fin 
ltk 0.48 ZDB-GENE-030616-115 neural crest 
wnt1 0.50 ZDB-GENE-980526-526 neural crest 
matn1 2.68 ZDB-GENE-050307-3 pharyngeal arch 
gnrh3 8.96 ZDB-GENE-030724-4 heart 
slc4a3 3.40 ZDB-GENE-141006-1 fin bud 
pdlim3b 3.43 ZDB-GENE-060130-104 heart, heart tube, mandibular arch skeleton 
srfb 2.87 ZDB-GENE-040426-1294 heart rudiment, primitive heart tube 
fabp10a 3.24 ZDB-GENE-020318-1 heart 
optc 2.74 ZDB-GENE-030131-1798 pharyngeal arch 
myoz2a 2.92 ZDB-GENE-040426-1880 heart 
    
100
	A	regulatory	receptor	network	directs	range	and	output	of	the	Wingless	signal 
	
	
Sabine	Schilling1,	2	Sarah	Steiner1,	Dario	Zimmerli1	and	Konrad	Basler	
	
	
Institute	of	Molecular	Life	Sciences,	University	of	Zurich,	Switzerland	
1		Co-first	authors	
2		Current	address:	Institute	of	Molecular	Systems	Biology,	ETH	Zurich,	Switzerland	
 
 
 	
	
 
 
	
 
 
 
 
 
  
101
RESEARCH ARTICLE
A regulatory receptor network directs the range and output of the
Wingless signal
Sabine Schilling*,‡, Sarah Steiner‡, Dario Zimmerli‡ and Konrad Basler§
ABSTRACT
The potent activity of Wnt/Wingless (Wg) signals necessitates
sophisticated mechanisms that spatially and temporally regulate their
distribution and range of action. The two main receptor components
for Wg – Arrow (Arr) and Frizzled 2 (Fz2) – are transcriptionally
downregulatedbyWgsignaling, thus forminggradients that oppose that
of Wg. Here, we analyze the relevance of this transcriptional regulation
for the formation of the Wg gradient in the Drosophila wing disc by
combining in vivo receptor overexpression with an in silico model of
Wg receptor interactions. Our experiments show that ubiquitous
upregulation of Arr and Fz2 has no significant effects on Wg output,
whereas clonal overexpression of these receptors leads to signaling
discontinuities that have detrimental phenotypic consequences. These
findings are supported byour in silicomodel forWg diffusion and signal
transduction, which suggests that abrupt changes in receptor levels
causes discontinuities in Wg signaling. Furthermore, we identify a
200 bp regulatory element in the arr locus that can account for the Arr
gradient, and we show that this is indirectly negatively controlled byWg
activity. Finally,weanalyze the roleofFrizzled3 (Fz3) in thissystemand
find that its expression, which is induced by Wg, contributes to the
establishment of the Arr and Fz2 gradients through counteracting
canonical signaling. Taken together, our results provide a model in
which the regulatory network ofWgand the three receptor components
account for the rangeandshapeof thisprototypicalmorphogensystem.
KEY WORDS: Wingless receptors, Wnt pathway, Model for Wg
diffusion
INTRODUCTION
Communication between the cells in a tissue depends on extracellular
signaling molecules. The vast majority of these are produced by
defined subsets of cells. This restricted production provides spatial
information that is needed for the signals to orchestrate patterning and
growth. The signaling output is dependent on the range of action and
level of activity of the secreted signaling protein – determinants that
depend not onlyon the biochemical nature of the signal but also on the
receptor systems that are employed by the receiving cells. The
glycoproteins of the Wnt family serve as an interesting model to
understand the interplay between these determinants.
Mechanisms that precisely and tightly control Wnt signal reception
and transduction, both spatially and temporally, are absolutely
necessary – Wnt signaling is crucial in many developmental
processes, and improper activation of the canonical signaling cascade
can have severe pathological consequences, such as cancer (Clevers,
2006). Altering receptor levels is often the first step in attenuating the
cellular response to a signalingmolecule. Receptor downregulation can
be achieved on the transcriptional level through repression of the
receptor-encoding gene, or on the protein level through internalization
and subsequent lysosomal degradation. Both processes lead to a
diminution of active receptors from the cell membrane and, thereby, to
an attenuation of the signaling output.
Wingless (Wg), the founding member of the highly conservedWnt
family, plays an important role in the primordium of the Drosophila
melanogaster wing (Zecca et al., 1996; Neumann and Cohen, 1997).
In this tissue, Wg is expressed in a thin stripe at the dorsal-ventral
boundary fromwhere it spreads to either side, producing a symmetrical
concentration gradient. The canonical Wnt/Wg transduction pathway
is initiated by the binding of Wnt/Wg ligands to a receptor of the
Frizzled familyandaco-receptor, the low-density lipoprotein receptor-
related LRP5/6 [Arrow (Arr) in D. melanogaster]. This binding
transduces the extracellular signal into an intracellular cascade that
ultimately results in the cytoplasmic stabilization and nuclear
localization of β-catenin/Armadillo (Arm) and its subsequent
association with TCF/LEF [Pangolin (Pan) in D. melanogaster]
DNAbinding proteins. The activation ofWnt target genes is promoted
by the interaction of the bipartite Arm-Pan complex with various
auxiliary co-factors (Mosimann et al., 2009).
In Drosophila, the genes encoding the Wg receptor Fz2 and the
co-receptorArr are transcriptionally downregulated byWg signaling
(Cadigan et al., 1998; Wehrli et al., 2000). However, the details
of the underlying molecular mechanism, and an understanding of
its physiological significance, are still lacking. Wnt-induced
transcriptional repression could be either direct or indirect; only a
detailed analysis of the cis-regulatory elements (CREs) and the
corresponding transcription factors can distinguish between these
modes of repression (Affolter et al., 2008). In addition to signaling-
induced transcriptional downregulation, there is evidence for a
collateral post-transcriptional layer of regulation of Wg receptors.
Both Fz2 and Arr contain endocytosis signals and have been shown
to localize to endocytic compartments together with their ligandWg
(Rives et al., 2006), which suggests that both the receptor and
co-receptor are internalized upon Wg binding. The contribution of
this to Wg internalization, however, is less clear, as it can also occur
in their absence (Baeg et al., 2004).
Here, we experimentally address the contribution of the
transcriptional regulation of the Wg receptors Arr and Fz2 to wing
development andWg gradient formation.We show thatWg-mediated
patterning is, remarkably, unaffected by a ubiquitous upregulation of
the levels of the receptor. However, local interruptions of the
transcriptional gradient of arr and fz2 lead to detrimental outcomes
caused by an imbalance between receptor and ligand levels at the
borders of signaling discontinuity. Furthermore,we uncover a second,
but less important, layer of control – in high-signaling regions the
decoy receptor Fz3 is expressed, dampening the signal. By dissectingReceived 7 February 2014; Accepted 24 April 2014
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*Present address: Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich,
Switzerland.
‡These authors contributed equally to this work
§Author for correspondence (basler@imls.uzh.ch)
2483
© 2014. Published by The Company of Biologists Ltd | Development (2014) 141, 2483-2493 doi:10.1242/dev.108662
D
E
V
E
LO
P
M
E
N
T
102
the regulatory control regions that are responsible for arr and fz3
expression, we find fz3 to be a direct positive, and arr an indirect
negative, target of the Wg pathway.
RESULTS
Transcriptional downregulation of Arr and Fz2 by Wg
signaling
In the Drosophila melanogaster wing imaginal disc, the expression
pattern of Arr and the inferred Wg protein gradient are inverse
(Fig. 1A-C) – low Arr levels close to the Wg source are contrasted
by high Arr levels at sites of little or no Wg. We explored the
potential relevance of the Arr expression pattern by experimentally
perturbing it, by using a heterologous ubiquitously active promoter.
Surprisingly, animals that expressed Arr under the control of the
tubulinα1 promoter (tubArr) were viable and did not show any wing
phenotypes. To monitor Arr expression in tubArr animals, we used
an antibody against Arr for immunohistochemical analysis. Arr
expression was elevated in tubArr wing pouches, but still graded,
with reduced levels towards the Wg expression domain (Fig. 1D-F).
We quantified the fluorescent intensities of Arr in tubArr and
Fig. 1. Wg represses its receptors Arrow and Frizzled 2 – graded
expression of the receptors is maintained upon tubulinα1
promoter-mediated misexpression. In all panels showing imaginal
discs, the posterior compartment is oriented towards the top, the
anterior compartment is towards the bottom of the image. The green
(D,P) and red (E,Q) rectangles displayed on these example discs show
the ROI, sized 100 µm×16 µm, that was used to quantify the level of
receptor in F and R. (A-C) Wingless (Wg) and Arrow (Arr) exhibit an
inverse relationship in their expression levels. Immunofluorescence
staining for Wg (green in A and C) and Arr (gray in B and red in C)
revealed the inverse expression levels of the two proteins (C). (D,E)
Graded Arr expression was maintained in Arr-overexpressing discs.
Wild-type wing discs (D), and wing discs that misexpressed Arr,
controlled by the tubulinα1 promoter (tubArr) (E), were stained for Arr.
(G-L) Wg represses arr transcription. The transcriptional arr reporter
arr-lacZ (arrZ) (gray, H) was repressed in Wg-expressing areas of the
wing imaginal disc. It was also repressed in randomly induced
somatic clones (gray, K), as revealed by immunostaining against
β-galactosidase (β-Gal), that overexpressed membrane-attached
NRT-Wg [marked by green fluorescent protein (GFP) in J]. (M-O)
Dominant-negative pan (panDN) derepresses Arr. Expression of
dominant-negative UAS-panDN with dppGAL4 (M), marked by GFP,
led to derepression of the arrZ reporter (gray, N). (P,Q) Graded Fz2
expression is maintained in Fz2-overexpressing discs. tubFz2-
expressing wing discs (Q) that were immunostained for Fz2 showed a
higher intensity profile of Fz2 than that of wild-type controls (P). Note
that the receptor upregulation in tubFz2 was much stronger than in the
corresponding tubArr discs. (F,R) Receptor level intensity plots. In
both panels, intensities of four wild-type (wt, green-shaded crosses)
and four receptor-overexpressing discs (OE, red-shaded crosses) are
projected on the longer axis of the ROI, perpendicular to the dorsal-
ventral compartment boundary. The corresponding moving averages
(defined by a half window size of three micrometer) are denoted by
solid green (wt) and red (overexpression) lines. Green- and red-shaded
areas denote standard deviations of the mean of the data from wild-
type and mutant imaginal discs, respectively. Intensity plots were
normalized to the maximum of the moving average of the wild-type
discs. a.u., arbitrary units.
2484
RESEARCH ARTICLE Development (2014) 141, 2483-2493 doi:10.1242/dev.108662
D
E
V
E
LO
P
M
E
N
T
103
control animals. The absolute Arr levels in tubArr animals were
higher, whereas the shapes of the gradients were similar to those in
the wild type (Fig. 1F; supplementary material Table S1).
In order to further analyze the arr transcriptional gradient, we
used the recessive lethal lacZ P-element insertion l(2)k08131, which
we refer to as arrZ (Wehrli et al., 2000) and is uncharacterized at the
molecular level. We mapped the insertion site and found that it is
positioned in the 50UTR region of arr in the short first untranslated
exon (data not shown). Owing to its insertion site and its expression
pattern, arrZ can be used as a molecular read-out to study the
transcription of the arr gene. arrZ is expressed in a graded manner
and is inactive in areas of high Wg signaling (Fig. 1G-I). To
investigate this negative regulation of arr by Wg, we clonally
overexpressed NRT-Wg, which is a membrane-tethered non-
diffusible fusion protein of Wg (Zecca et al., 1996). All over the
wing imaginal disc, clones that expressed NRT-Wg showed
repression of arrZ, as did adjacent wild-type neighboring cells
(Fig. 1J-L). We next asked whether the nuclear mediator of Wg
signaling Pan is involved in arrZ repression. Overexpression of a
dominant-negative form of Pan (UAS-panDN-HA), which lacks the
Armadillo-binding domain and was tagged with hemagglutinin
(HA), resulted in a strong and strictly cell-autonomous derepression
of arrZ expression (Fig. 1M-O). Hence, arrZ is a negative target of
Wg signaling in the wing pouch and is repressed as a consequence
of signaling events downstream of Pan.
Negative transcriptional regulation byWg signaling has also been
reported for the fz2 gene, which encodes the main Wg receptor
(Cadigan et al., 1998). To study the physiological relevance of this
regulation, we misexpressed Fz2 under the control of the tubulinα1
promoter (tubFz2) in the wing imaginal disc. Similar to the case of
tubArr, tubFz2 animals had wings that appeared wild type. Also, as
observed for Arr, Fz2 protein levels were elevated in tubFz2
animals, but remained graded with a slightly steeper slope, as
observed for that in corresponding wild-type discs (Fig. 1P-R;
supplementary material Table S1). Although weaker, a gradient
could still be observed in larvae that harbored tubFz2 but lacked
endogenous Fz2 (supplementary material Fig. S1A-D and
Table S1). These observations suggest that post-transcriptional
regulation plays a rather minor role in gradient formation.
Modeling Wg receptor interactions
To formalize, and systematically study, the mechanisms of
Wg-receptor interaction, we developed an in silico model that
reproduces the negative regulation of Arr and Fz2 by Wg in cells of
the wing pouch (Fig. 2). We first reduced the complexity of the
system by summarizing the similar biological roles of the receptor
Arr and its co-receptor Fz2 into the receptor entity ‘ArrFz2’. Next,
we set up a system of coupled ordinary and partial differential
equations that described the production and decay of the Wg ligand
and its receptors, the reverse complex formation between ligand and
the receptor entity, the diffusion ofWg, as well as the transcriptional
downregulation of the receptor entity by Wg (Fig. 2).
A simplified analytical model suggests that most Wg is not
bound to its receptors
Neglecting the Wg-induced transcriptional receptor repression
(ktWg!ArrFz2¼0 in Fig. 2) allowed us to study the effect of receptor
upregulation analytically in one dimension (Schwank et al., 2011;
details in the supplementary methods). Supplementary material
Fig. S2 shows the dependence of the amplitude of total Wg (black)
in regions that overexpressed the receptor on the relative amount of
ligand that was not bound to the receptor, a¼½Wg$=½WgT $. In such a
simplified model, the higher the value of a, the less the amplitude of
the total Wg distribution is affected by changes in receptor levels.
To study the consequences of apposing wild-type and receptor-
overexpressing cells, as well as to have a direct comparison of
the Wg distribution in receptor-overexpressing cells to wild-type
cells in the same disc, we generated tubulinα1>CD2,y+>arr and
tubulinα1>CD2,y+>fz2 transgenes that harbored flp-out cassettes
between the promoter and coding region. Exposure to Flp
recombinase during development leads to clones that overexpress the
corresponding receptor. In discs, where the receptor overexpression
was compartmental (Fig. 3; supplementary material Fig. S3 and
Table S1), we found no significant difference between the Wg
amplitudes in wild-type compartments and those that overexpressed
the receptor. If the staining revealed the total amount of Wg, then the
analytical model (supplementary material Fig. S2 and supplementary
methods) suggests that the majority of Wg is not receptor bound.
A simplified analytical model predicts narrowing of Wg
distribution upon receptor overexpression
Assuming further that Wg decay occurs only in complex with its
receptors (leading to kWg¼0), the analytical model predicts a
narrowing of the Wg gradient in regions of receptor overexpression –
an n-fold upregulation of the receptor would lead to a decrease in the
Wg decay length (the distance from the Wg source, where the Wg
concentration is reduced by a factor of 1/e from its maximal value)
by a factor 1=
ﬃﬃﬃﬃﬃﬃ
ðnÞ
p
in the receptor-overexpression (OE) region
(supplementary methods). Remarkably, theory and experiment
coincided within the measurement error for compartmental Arr
Fig. 2. Model representing Wg-induced negative regulation of Arr and Fz2. (A) Dotted arrows denote the first order decay of either single molecules or
complexes of molecules; the reversible formation of complexes is denoted by groups of arrows. This mechanistic model can be translated into a set of differential
equations (B).
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overexpression experiments; we found lOE;Arr=lwt¼0:7+0:1
(Fig. 3M; supplementary material Table S1), whereas the simple
model predicted lOE;Arrth =l
wt
th ¼1=
ﬃﬃﬃ
n
p
¼1=
ﬃﬃﬃ
2
p
¼0:7 for the
upregulation of Arr by a factor of n=2.
Receptors hinder diffusion of Wg
Extending our Wg receptor interaction model to two dimensions,
we numerically solved the corresponding system of differential
equations (displayed in Fig. 2) on a mesh, which resembled the cell
shapes at the apical side of the wing disc. The vertex model
describes cells and their contact surfaces as polygons that are
composed from connected vertices with positions that are defined
by the local minimum of an energy function (Farhadifar et al.,
2007). Using these polygons as local control volumes, we
discretized the diffusion of Wg by using the Finite Volume
Method. Our modeling approach allowed us to study the
consequences of changing receptor levels with cellular resolution
in patches of cells, disc compartments or the entire wing pouch.
Simulating receptor overexpression in entire compartments (Fig. 4)
led to a narrower Wg distribution than that in the corresponding
wild-type compartments (Fig. 4B,C,F; supplementary material
Table S1). These findings are also supported by our measurements
of the extracellular Wg gradients (Fig. 3J-L; supplementary material
Fig. S3). In our model, cells that overexpressed ArrFz2 hindered the
spreading of Wg, the only diffusing protein of the model; thus, these
cells serve as a ‘sink’ forWg if placed next towild-type cells (Fig. 3) –
cells that overexpressed ArrFz2, positioned immediately adjacent to
wild-type cells, exhibited pathway activity (simulated by the amount
of Wg-ArrFz2 complex formation) further away from the Wg source
than the overexpressing cells that were not adjacent to wild-type cells
(Fig. 4E). In our model, these cells receive unbound Wg from
neighboring wild-type cells (see Discussion).
Abrupt changes in receptor levels lead to detrimental
phenotypic effects
The clonal abrupt upregulation of the receptor levels by using
tubulinα1>CD2,y+>arr or tubulinα1>CD2,y+>fz2 transgenes
caused detrimental phenotypic defects in the wings and legs of
adult flies; in wings, we detected clones that caused typical Wg gain-
of-functionphenotypes, such asblistering and ectopic sensory-margin
Fig. 3. Compartmental misexpression of Arr and Fz2 leads to
accumulation of Wg at the edge that is shared between wild-type
and receptor-overexpressing cells and to a slightly decreased
distribution of Wg. The posterior (towards the top of the image) and
anterior compartments of the wing imaginal discs are marked by the
absence and presence of CD2, respectively. Arrowheads indicate
the point of Wg accumulation. (A-C) Expression of tubFz2 in the P
compartment led to an accumulation of extracellular Wg, exactly at the
boundary between the A and P compartments. (D-I) Expression of
tubArr in the P compartment, or tubArr and tubFz2 together, led to a
similar extracellular Wg accumulation. (J-L) Wg level intensity plots in
discs that compartmentally overexpressed Arr (J, n=4), Fz2 (K, n=4)
and simultaneous overexpression of Arr and Fz2 (L, n=9), where n
denotes the number of discs. Green-shaded crosses denote Wg
intensities in the A compartment, red-shaded dots denote Wg
intensities in the receptor-overexpressing P compartment. The moving
average and standard error are defined as described in Fig. 1. a.u.,
arbitrary units. (M) Quantification of the change in Wg decay length (λ)
and amplitude (y) upon receptor overexpression. Within each disc, we
calculated the ratio between the decay length (white) and amplitude
(green) in the receptor-overexpression (OE) and wild-type (wt)
compartments. The bar charts display the mean and standard deviation
for each experimental set up. We tested the null hypothesis, that decay
length and amplitude were unchanged upon receptor overexpression,
***P<0.001, **P<0.01.
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bristles (Fig. 5A). In legs, we found limb bifurcations that created
supernumeraryappendages (Fig. 5B), oran absence of tarsal segments
and claws (Fig. 5C).
Asanadditional lineof experimental validation, and to reachahigher
level of reproducibility, we obtained clones that overexpressed Arr and
Fz2 simultaneously through the activation of the tubulinα1>CD2,
y+>fz2 and tubulinα1>CD2,y+>arr cassettes upon a hedgehog-driven
Flp recombinase, which was specifically expressed in the posterior
compartment. They showed similar defects to the flies described above.
Accordingly, when probed with an antibody against the prototypical
Wg target gene Senseless (Sens), cells that co-overexpressed tub>fz2
and tub>arr and were adjacent to wild-type cells displayed ectopic
expression of Sens (Fig. 5D-F). We observed a similar phenotype
with tub>fz2 flp-out clones (Fig. 5G-I), but not with tub>arr clones
(Fig. 5J-L). If we induced clones overexpressing Arr with the stronger
GAL4-UAS expression system (Fig. 5M-O), again, we observed
upregulation of Sens at the dorsal-ventral compartment border. Thus,
we conclude that perturbations of Wg receptor levels cause ectopic
pathway activity in cells with high amounts of receptor, if juxtaposed
with cells that have lower levels of receptor levels.
Receptor-overexpressing cells neighboring wild-type cells
act as a Wg sink
To test our model – that the receptor-overexpressing cells apposed to
wild-type cells, indeed, serve as a Wg sink and benefit from this
situation by increased signaling – we monitored extracellular Wg in
discs that misexpressed the receptors in all posterior (P) compartment
cells.Consistentwithourmodel, suchdiscs exhibited an accumulation
of extracellular Wg, exactly at the border between wild-type anterior
(A) and misexpressing P cells (arrows in Fig. 3A-I). These findings
also explain the very restricted upregulation of Sens, noted above,
exactly at the border between wild-type cells and cells that
overexpressed the receptor.
The dual role of Fz3 – stabilization of Wg, and attenuation of
Fz2 and Arr
Although Arr and Fz2 constitute the mainWg receptors, Fz3 has also
been implicated in modulating the Wg response. Fz3 is expressed in
the wing pouch (Sivasankaran et al., 2000) and has been proposed to
serve as a negative-feedback regulator of theWg pathway (Sato et al.,
1999).UnlikeFz2 andArr, however, the expression ofFz3 seems tobe
positively regulated byWg signaling (Sivasankaran et al., 2000; Sato
et al., 1999). To clarify the role of Fz3 in Wg gradient formation, we
overexpressed Fz3 in the P compartment andmonitored Sens levels as
a read-out for Wg pathway activity. Indeed, we observed decreased
Sens levels in the P territory, suggesting that overexpressed Fz3
attenuates Wg signaling (Fig. 6A-C). Consistent with this finding,
Sens levels are enhanced in fz3mutant mitotic clones (Fig. 6D-F).We
wonderedwhether the alterations in Sens levels in fz3mutant tissue, or
tissue that overexpressed fz3, were mediated by changes in the levels
of Wg, Fz2 or Arr. We first monitored extracellular Wg protein in
compartments that overexpressed Fz3 and observed a notably
enhanced and broadened extracellular distribution of the Wg protein
(Fig. 6G-J). Interestingly, Fz2 and Arr levels were reduced in such
Fig. 4. Modeling reveals ectopic pathway activation in receptor-overexpressing cells juxtaposed with wild-type ells. (A) Schematic view of a wing disc.
The posterior (P) compartment of thewing pouch ismarked in dark blue, and the anterior (A) compartment is marked in light blue. (B) An example simulation result
shows the total Wg concentration of a disc, where the ArrFz2 production rate was increased by a factor n=3 in all cells of the upper (P) compartment.
Concentrations are displayed using Matlab’s jet algorithm, where red corresponds to high, and blue corresponds to low concentrations. All concentrations
were normalized to themaximum value of the receptor entity ArrFz2 in wild-type discs and are given in arbitrary units. Thewhite square corresponds to a zoomed-
in region of 80 µm×80 µm centered around the intersection of the dorsal-ventral and anterior-posterior compartment boundaries. (C-E) Wg (C), ArrFz2
(D) and Wg-ArrFz2 (E) distributions of the zoomed-in region of B. Wg-expressing cells are marked by white cell edges, the anterior-posterior compartment
boundary is marked by a white (horizontal) line. Note the narrowing of the total Wg distribution in the receptor-overexpressing compartment. (C) The model
predicted reduced levels of diffusible Wg in anterior cells that were adjacent to the compartment boundary. (E) The distribution of Wg-ArrFz2 broadened in
posterior cells that were adjacent to the compartment boundary. (F) The total ArrFz2 concentrations (defined as the sum of free andWg-bound receptor) in a wild-
typewing disc (green) and in an ArrFz2-overexpressing wing disc (red) was projected onto the anteroposterior axis. Each cell in the tissue corresponds to one dot
in the graphic. Total Wg levels in a wild-type simulation are shown in blue and in an ArrFz2-overexpression simulation in gray. a.u., arbitrary units.
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tissue (supplementarymaterial Fig. S4A-F); however, the activity of a
transcriptional arr reporter (ArrC19, described below and in
supplementary material Fig. S7) did show a small increase in the
area overwhich itwas expressed (supplementarymaterial Fig. S4G-I),
suggesting that Fz3 post-translationally regulates the levels of Fz2 and
Arr. By contrast, fz3 mutant wing discs exhibited increased levels of
Fz2 and, to a lesser extent, Arr (supplementary material Fig. S4M-N),
but no discernible effect on the distribution of Wg was observed
(Fig. 6K). Remarkably, we only observed the downregulation of Arr
and Fz2 upon overexpression of Fz3, if the overexpressing cells
included the Wg source (supplementary material Fig. S4A-F). In
Fz3-overexpressing clones that were distant from the Wg source, Arr
levels were higher, as we expected for a negative target, following
attenuation of signaling (supplementary material Fig. S4J-L). This
also suggests that downregulation of the receptor is not the primary
cause for the observed attenuation ofWg signaling.We did not detect
any upregulation of Fz2 levels in this situation. We conclude from
these findings that the binding ofWg to Fz3 mediates the degradation
of Arr and Fz2, presumably lowering receptor levels at the
Wg-expressing stripe even further (supplementary material Fig.
S4M-N), as well as broadening the area of Wg distribution through
stabilizing the protein (Fig. 6G-J). These findings are supported by the
observation that compartmental Fz3 overexpression, combined with
RNA interference against Wg, reduces the downregulation of Arr in
this compartment (data not shown).
To further define and rationalize the above observations, we
incorporated Fz3 into our in silico model (supplementary material
Fig. S5). We modeled Fz3 production to depend on the concentration
of the Wg-ArrFz2 complex (our approximation of Wg pathway
activity). Furthermore we assumed – as in the case of the receptor
entity ArrFz2 – a reversible complex formation between Wg and
Fz3. Our experimental data (supplementary material Fig. S4J-L)
suggest that the Fz3-induced repression of Arr and Fz2 is mediated
by Wg (albeit the exact mechanism still has to be investigated).
Therefore, we assume in our model that Fz3 represses Arr and Fz2
expression only when Fz3 is interacting with Wg. The resulting
extended set of differential equations is provided in the
supplementary methods. Scanning the corresponding parameter
Fig. 5. Clonal overexpression of Arr and Fz2 leads to severe border
effects. (A) Adult wing phenotypes that arose from random clones
that expressed tubFz2 or tubArr showed Wg gain-of-function defects,
such as blistering and ectopic sensory bristles (arrowheads).
(B,C) Random tubFz2- and tubArr-expressing mitotic clones resulted
in bifurcations and truncations in legs. (D-F) Third-instar imaginal discs
that contained hhGal4, UAS-Flp, tubFz2, tubArr clones (D-F) showed
ectopic expression of the Wg target Sens (gray in E, red in F),
predominantly in cells that were adjacent to wild-type neighbors at the
border of the clone, close to theWg source [tubFz2- and tubArr-expressing
clones were marked by the absence of CD2 (green in D and F)]. (G-I)
Similar to cells that expressed both receptor components, cells that only
expressed tubFz2 exhibited ectopic expression of Sens at the border of the
clone (gray in H, red in I). CD2 expression is shown in green in G and I.
(J-O) hhGal4, UAS-Flp, tubArr clones did not show strong Sens
upregulation at the border with wild-type cells (J-L); however, in random
heatshock-induced UAS-GFP, UAS-Arr-expressing clones (M-O), ectopic
Sens expression at the border of the clone facing the Wg source was
observed (arrowhead). CD2 staining is shown in green in J and L; Sens
staining is marked by gray in K and N, and by red in L and O; GFP in M
represents the Arr expression domain; the red outline in N marks the clone
outline shown in M.
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space (supplementary methods), we identified a parameter set that
qualitatively reproduced the experimentally observed Wg and
receptor distributions in the wild-type and receptor-misexpression
conditions (the exact parameters are shown in supplementary
material Table S1). Remarkably, the parameter exploration
suggested that the complex that was formed by Wg and Fz3 might
be more stable than the corresponding Wg-ArrFz2 complex (see
supplementary material Table S2 in the supplementary methods),
confirming the role of Fz3 in stabilizing Wg.
In summary, we show that Fz3 acts as an attenuator of Wg
signaling in the wing pouch. We propose that Fz3 reduces the
amount of Arr and Fz2 protein close to the Wg source and mediates
a broader distribution of Wg.
Wg signaling indirectly represses arr and directly
activates fz3
The existence of the transcriptional gradients of Arr and Fz2 prompted
us to analyze by which mechanism(s) Wg signaling represses the
transcription of their genes. Many feedback regulatory mechanisms of
signaling pathways use direct transcriptional regulation. However,
signaling-mediated transcriptional repression (as opposed to
activation) has rarely been described (Affolter et al., 2008). Thus, we
sought to isolate and characterize the regulatory DNA elements of arr
and fz2 that are responsible for the Wg input. The similar expression
patterns and regulatory roles of arr and fz2 led us to speculate that
both genesmight be transcriptionally controlled by the samemolecular
mechanism. Hence, we chose the arr locus as a case study and
Fig. 6. Fz3 acts as an attenuator of Wg signaling.
(A-C) Overexpression of Fz3 in the P compartment (A), marked with
GFP, results in a prominent reduction of Sens levels (gray in B, red in C).
(D-F) Fz3 loss-of-function clones (fz3G10), marked by the absence of
GFP (clones induced with an FRT19, ubiGFP chromosome) (D), led to
an enhancement of Sens expression at the dorsal-ventral compartment
boundary (gray in E, red in F). (G-I) Ectopic expression of Fz3 in the P
compartment (G) resulted in an enhancement and broadening of the
extracellular Wg gradient, revealed by immunostaining of the
extracellular (ex) Wg levels (gray in H, red in I). GFP marks the
P compartment. (J) Intensity profile of the Wg gradient in Fz3-
overexpressing (OE) P compartments (red) and wild-type (wt)
compartments (green) in a ROI of 100 µm×20 µm. n=8. Note the higher
and broader Wg gradient in Fz3-overexpressing compartments.
(K) Intensity profile of the Wg gradient in fz3 mutant wing discs (red,
fz3−) and wild-type wing discs (green) in a ROI of 100 µm×20 µm. n=8.
fz3mutant wing discs showed reduced levels of Wg and a narrower Wg
distribution. (L) Results of the simulation model showed the total Wg
levels (defined as the sum of free and receptor-boundWg) in a wild-type
(green), fz3 mutant (dark red) and Fz3-overexpression simulation (light
red). As in the experimental intensity profiles (J,K), Wg levels were
normalized to the maximum of the wild-type expression. The simulation
qualitatively reproduced the behavior of the experimental situations (J,K;
supplementary material Table S1). a.u., arbitrary units. (M) A simulated
profile of Senseless (red) distribution in wild-type (lower compartment)
and fz3− cells (upper compartment). The ROI was the same as that
described in Fig. 4. Wg-expressing cells are marked by white edges,
and the compartment boundary is marked by a white line. We modeled
Wg-expressing cells as being deficient for Senseless expression. It was
assumed that all other cells with Wg-ArrFz2 concentrations higher than
95% of the maximal Wg-ArFz2 concentration expressed Senseless.
A, anterior; P, posterior.
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systematically dissected its regulatory region. Seven overlapping
fragments (A to G) covering 25 kb were cloned into a placZ-attB
reporter vector, 50 to an hsp70 minimal promoter. Each construct was
integrated into the same attP landing site on the second chromosome
(Bischof et al., 2007) and the expression of lacZ in imaginal discs was
analyzed. Fragment arrC recapitulated the endogenous arr expression
pattern (Fig. 7A) and also properly reacted to experimentally increased
and decreased Wg pathway activity, as assessed in clones that
expressedNRT-Wg and panDN, respectively (data not shown).We next
narrowed down the regulatory activity of arrC by using an extensive
series of reporter constructs (supplementarymaterial Fig. S7), resulting
in a 200 bp fragment termed arrC19, which could not be shortened
further without compromising activity. Clones that expressed a
constitutively active version of Arm (Armact) repressed arrC19
reporter expression, confirming that it retained the element(s)
responsible for the negative Wg input (Fig. 7B-D). To check if this
regulatoryWg inputwasmediated directly byPan,wemutated the four
highly conserved Pan binding sites in the arrC19 enhancer. The
expression pattern of the resulting arrC19_Tcf_mut transgenewas not
derepressed, suggesting that Pan is not directly involved in regulating
arrC19 (Fig. 7I). Thus, we conclude that Wg-mediated repression of
arrC19 occurs independently of the direct binding of Pan.
Furthermore, we analyzed the nature of the Wg input on fz3 by
using a similar approach – dissecting the fz3 locus into seven
overlapping fragments, A to G. The expression pattern of fragment
Fz3G was the only one that was reminiscent of the pattern of fz3.
Further dissection yielded fz3G5, a fragment of approximately
290 bp that retained fz3-like expression (Fig. 7E). Clones that
expressed Armact (Fig. 7F-H) caused upregulation of fz3G5 reporter
gene activity. This regulation seems to be directly exerted by the
canonical Wg pathway because it was completely abrogated upon
mutation of the Pan-binding site (Fig. 7I).
We conclude that Wg signaling indirectly regulates arr (and
presumably fz2), whereas fz3 is a direct positive-target gene of the
pathway. Thus, the sign of regulation by Wg of arr and fz2 differs
from that of fz3 (to impact negatively and positively on their
expression, respectively), as well as the mode of regulation (indirect
versus direct).
Fig. 7. arr is an indirect negative Wg target, and fz3 is a direct
positive Wg target. A map of the genomic region of arr (A). Translated
exons are shown in red, untranslated regions in yellow. Fragments A-G
were tested for their ability to activate a heterologous promoter driving
lacZ expression (blue stain). Only fragment C recapitulated the arr
expression pattern in the wing imaginal disc. Insertion of the P-element
arrZ is shown on top. Further dissection of fragment C revealed the
minimal enhancer fragment arrC19 (see supplementarymaterial Fig. S4
for further details). (B-D) Randomly induced clones that overexpressed
the constitutively active UAS-Armact, marked with GFP in (B), led to a
cell-autonomous repression of arrC19 expression, revealed by
immunostaining of β-galactosidase (gray in C, red in D) (C,D). (E) Amap
of the genomic fz3 locus. Fragments A-G were tested for their ability to
activate a heterologous promoter driving lacZ expression. Only
fragment G recapitulated the fz3 expression pattern in the wing pouch.
(F-H) Overexpression of UAS-Armact (green) (F) results in a cell-
autonomous derepression of fz3G, as shown by by immunostaining
of β-galactosidase (gray in G, red in H) (G,H). (I) Mutation of TCF sites
in conserved regions of arrC19 did not affect the expression of the
reporter. By contrast, mutation of TCF sites in the fz3G5 reporter
completely abolished reporter expression (J).
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DISCUSSION
During the development of a metazoan organism, signaling events
are precisely regulated. One frequently employedmode of regulation
is feedback loops. Here, we analyzed a network of feedback loops in
the Drosophila wing pouch that regulate receptor abundance, and
thus the range of distribution and signaling output of Wg.
Receptors sequester their ligands and, thereby, impact upon the
range of the signal (supplementarymaterial Fig. S6). A transcriptional
regulatory link between receptor expression and signaling activity,
causing up- or downregulation of receptor levels in cells in response
to the signal, can thus restrict or extend the signaling range. For
example, the Hedghog (Hh) signal induces the expression of its
receptor Patched (Ptc), a regulatory link which severely narrows the
Hh activity gradient (Chen and Struhl, 1996). In the case of Wg, we
observed the opposite –Wg signaling appeared to extend the range of
Wg distribution by transcriptionally downregulating expression of arr
and fz2; downregulation of the receptors hinders the formation of
Wg-Arr-Fz2 complexes. This allows superfluous Wg to diffuse
further away from the source without being immobilized by its
receptors. In agreement with this notion, we observed a slightly
narrower distribution of extracellular Wg in discs that expressed
Fz2 or Arr under the tubulinα1 promoter (Fig. 3; supplementary
material Fig. S2). Quantifying these observations in discs that
compartmentally overexpressed the receptor (Fig. 3; supplementary
material Fig. S2 and Table S1), we observed a subtle reduction of the
decay length (corresponding to a slightly steeper Wg distribution) in
compartments that overexpressed the receptor compared with that in
wild-type compartments.
In apparent contradiction, a previous study (Cadigan et al., 1998)
has shown that high levels of Fz2 can stabilize Wg and promote Wg
spreading; accordingly, we observed an accumulation of Wg when
repeating this experiment by overexpressing Fz2 using the GAL4-
UAS system. These contradictory findings can be reconciled by
taking into account the different strength of Fz2 upregulation in the
two experimental setups – Fz2 expression that is driven by the
tubulinα1 promoter leads to a relatively mild upregulation of the
receptor by, approximately, a factor of 2 (Fig. 1; supplementary
material Table S1), whereas overexpression by using the GAL4-
UAS system causes a much stronger overexpression. Presumably,
Arr becomes the limiting factor in UAS-Fz2-overexpressing cells, a
situation that might prevent the surplus Wg-Fz2 complexes from
being internalized, thus causing an extracellular accumulation of
Wg (Marois et al., 2006). If Fz2 is only moderately overexpressed,
sufficient Arr protein might be available to allow this extra Fz2 to
form Wg-Arr-Fz2 complexes, which are subsequently internalized,
leading to a slight narrowing of the gradient because there is less
free and diffusible Wg. Consistent with this notion, simultaneous
strong overexpression of both of the receptors Fz2 and Arr, by
means of Gal4, leads to a reduction of extracellular Wg levels
(Piddini et al., 2005).
Receptors act as a Wg sink
Although Wg signaling transcriptionally represses both Arr and
Fz2, ubiquitous overexpression of Arr, or Fz2, had no phenotypic
consequences. Unexpectedly, however, severe phenotypes arose
upon mosaic expression of the tub>arr or tub>fz2 transgenes.
Theoretical modeling (Fig. 4) and reporter gene analysis indicated
that cells that had elevated receptor levels ectopically activated the
pathway when situated close to wild-type cells. Apparently, the
‘high-receptor-level state’ allows tub-fz2 or tub-arr cells to engage
in ligand-receptor interactions that depend on the ‘low-receptor-
level state’ of their neighbors. One plausible explanation might be
that tub-fz2, or tub-arr, cells bind to Wg that diffuses in from
neighboring wild-type cells.
The different outcome of clonal versus uniform alteration of the
Wg pathway is reminiscent of observations that have been reported
by Piddini and Vincent (Piddini and Vincent, 2009), where loss of
Wg signaling in the entire P compartment had no impact on the
expression of low-threshold target genes but resulted in their
repression, and in patterning defects, when Wg signaling was only
clonally abolished. Piddini and Vincent also used different patterns
of Wg receptor expression for their experiments, and they explained
their findings by postulating that there is a Wg-induced, still to be
identified, inhibitory signal that negatively regulates target gene
expression in surrounding cells.
The negative feedback regulator Fz3
In an additional layer of negative-feedback regulation in the wing
pouch, Wg signaling activates the expression of the Frizzled family
member Fz3 (this work; Sato et al., 1999; Sivasankaran et al., 2000).
Fz3 seems to act as a negative regulator ofWg signaling by repressing
Wg signaling readouts and downregulating Wg receptor levels.
Various models could be envisaged of how Fz3 acts as an inhibitor of
Wg signaling. As it has been demonstrated that Fz3 is able to bindWg
(WuandNusse, 2002), Fz3 couldwork as a decoy receptor that acts as
a molecular trap by binding to Wg without eliciting a signal. Decoy
receptors are often part of negative-feedback mechanisms. In the
Drosophila epidermal growth factor (EGF) system, the pathway
inhibitor Argos is a target of EGF signaling and functions as a decoy
receptor (Klein et al., 2004). In vertebrates, decoy Frizzled receptors
have been identified that modulateWnt signaling – secreted Frizzled-
related molecules (sFRPs) have strong homology to the Frizzled
extracellular domains. sFRPs inhibit signaling by directly binding to
the Wnt ligands (Mii and Taira, 2011). No sFRP gene has been
identified in the Drosophila genome.
In another scenario, Fz3 could work as a negative regulator ofWg
receptors. Its function could be analogous to that of ZNRF3 and
RNF43 in crypt base columnar intestinal stem cells. These related
E3 ubiquitin ligases have been shown to regulate the stability and
levels of cell-surface Fz and LRP5/6, through internalization and
lysosomal degradation of the receptor components in the presence
of Wnt signaling (Hao et al., 2012; Koo et al., 2012). Several of our
experimental findings indicate that Fz3 might work as an inhibitor
ofWg feedback at the receptor level – firstly, we observed decreased
Arr and Fz2 levels in compartments that overexpressed Fz3
(supplementary material Fig. S2B,E), and secondly, Arr and Fz2
levels were increased in fz3 mutant wing discs (supplementary
material Fig. S4M,N). Most probably, Fz3 acts by more than one
mechanism – cells that overexpressed Fz3 in the Wg stripe lead to
Arr downregulation, whereas cells that overexpressed Fz3 outside
of the Wg stripe lead to Arr upregulation (supplementary material
Fig. S4J-L). Furthermore, extracellular Wg was stabilized upon Fz3
overexpression (Fig. 6G-I). In a wild-type situation, this
stabilization of Wg might contribute to a broader Wg gradient and
promote signaling in the outskirts of the wing pouch. Taken
together, these findings suggest that only Wg-bound Fz3 causes
inhibition of the pathway.
The role of transcriptional Wg receptor regulation
The post-translational regulation of Wg receptor levels was not the
focus of this study, but we undertook substantial efforts to further
characterize the transcriptional regulation of the receptor genes. In
particular, we sought to identify the regulatory elements of these
genes that mediated the feedback loops. The isolation of a 200 bp
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fragment of the arr locus and a 300 bp fragment of the fz3 gene –
each of which was responsive to Wg signaling and drove reporter
gene expression in a pattern that was reminiscent of the
endogenous expression pattern – allowed us to investigate
whether the Wg pathway controls these genes directly or
indirectly; fz3 appeared to be a direct target of canonical Wg
signaling, whereas arr did not. Pan-binding sites were dispensable
in the minimal arr enhancer, indicating that either Arm regulates
the transcriptional activity of arr through another DNA-binding
protein, or that Arm and/or Pan transcriptionally induce one (or
more) negative regulators that, in turn, regulate arr expression.
Hence, although the Wg pathway has been reported to possess the
capacity to directly negatively regulate transcription (Blauwkamp
et al., 2008; Affolter et al., 2008), it apparently does not use this
mechanism to attenuate arr expression.
Including transcriptional Wg receptor downregulation in our
model led to a broader distribution of Wg (supplementary material
Fig. S6A) – receptor downregulation by ligand-induced endocytosis
consumes the ligand, this was not the case for transcriptional
repression (supplementary material Fig. S6B). The broadening of
the Wg distribution area under a mechanism of transcriptional
receptor repression might facilitate a robust signaling readout for
high-threshold Wg target genes.
A recent study indicates that the long-rangeWg gradient might be
less important for imaginal disc patterning than assumed previously
(Alexandre et al., 2014). Hence, it is also conceivable that the
receptor gradients are not essential, a notion supported by our
finding that uniform misexpression of Arr or Fz2 in the wing
imaginal disc had no phenotypic consequences. Nevertheless, it
remains to be determined whether the Arr and Fz2 gradients
are dispensable; our tubArr transgene is not able to rescue arr
loss-of-function mutants.
A cell-based ligand-receptor model
So far,most quantitativemodels of theWnt-Wgpathwayhave focused
on intracellular events (reviewed in Kofahl andWolf, 2010), and only
a few models have taken into account the spatial aspects of this
signaling system (Sick et al., 2006; Ramis-Conde et al., 2008; van
Leeuwen et al., 2009; Zhu, 2011). Our model is the first to
systematically study the roles of Wg-receptor complexes – Wg-
ArrFz2 andWg-Fz3 – in the spatial profile ofWg signaling, as well as
being the first to be challenged experimentally bymanipulations of the
receptor levels. Our cell-based modeling approach of ligand receptor
interactions allowed us to vary all parameters in a cell-autonomous
manner, which has not been done in previous studies (Eldar and
Barkai, 2005; Dalessi et al., 2012; Schwank et al., 2011). This
technique is, thus, an ideal tool to predict the impact of clonal
conditions with cellular precision, which have historically formed the
basis of experimental approaches inDrosophila but have also become
increasingly available in vertebrates.
MATERIALS AND METHODS
Quantifying the shape of Wg and receptor distributions
We quantified the Wg intensity projections of each disc, i, by fitting an
exponential decay yi s¼y0 i s"expð$x=li sÞ, where y0 i s is the corresponding
Wg amplitude and li s the decay length, from the center of the region of
interest to both sides (s [ ½left; right') up to 30 µm, omitting the Wg-
producing source region (approximately 4 µm in width).
How well the data fitted to each curve was estimated by calculating the
coefficient of determination, R2is, from the intensity projections and the fit of
the curve. For the two fits, to the left and right within each region of interest
(ROI), of disc number i, we calculated the mean R2i and the mean of the
absolute values of the two decay lengths, li¼ðjli leftjþ jli rightjÞ=2.
We quantified the receptor intensity projections of each disc i by fitting
exponential functions, linear (data not shown) and second order
polynomials yiðxÞ¼aix2þbixþci, where the latter showed the best
overall coefficients of determination. The slope of the receptor
distributions was then defined as the derivation of the second order
polynomial with respect to x. Supplementary material Table S1 displays the
mean fit coefficients of n measurements.
Fly stocks
Transgenic flies were generated by using the PhiC31 transgenesis system
and integrated on the landing sites ZH-51D or ZH-86Fb (Bischof
et al., 2007).
The following stocks were used for genetic and clonal analysis:
Sp/CyO; hhGAL4, UAS-Flp/TM6B (Pérez-Garijo et al., 2009);
yw hsp-flp; UAS-HA-NRT-Wg/SM5^; MKRS/TM6B (Zecca et al., 1996);
yw hsp-flp; UAS-ΔPan-HA/TM6B (van de Wetering et al., 1997);
yw hsp-flp; UAS-Armact (Zecca et al., 1996);
yw hsp-flp; Sp/CyO; dpp-GAL4/TM6B (Entchev et al., 2000);
yw hsp-flp; enGAL4, UAS-GFP, tubGal80ts/CyO; MKRS/TM6B
(individual components are from Bloomington);
yw hsp-flp; act>CD2, y+>GAL4, UAS-GFP (Pignoni et al., 1997);
UAS-Fz3, UAS-Arr, UAS-Fz2 and UAS-PanHA (Bischof et al., 2013);
yw hsp-flp; C765-GAL4 (Nellen et al., 1996);
Tub-flp (Struhl et al., 1993);
P(lacZ) arrk08131 (Bloomington stock 665);
FRT19 (Bloomington stock 1709), Fz3G10 (Sato et al., 1999);
fz2(c1) (Chen and Struhl, 1999);
Df(3L)fz2 (Bloomington stock 6754).
Vectors
For cloning, standard molecular biology cloning methods were used.
To generate hybrid tubArr and tubFz2 constructs, the coding regions of
Arr and Fz2, respectively, were cloned 30 in-frame of the tubulinα1 promoter
and a FRT-flanked >CD2,y+> flp-out cassette in a plasmid that contained
the tubulinα1 30UTR and an attB site for phage-mediated transgenesis.
To generate lacZ reporter constructs, fragments of the genomic arr and
the fz3 locus were amplified from yw genomic DNA by using PCR with
primers that harbored suitable restriction enzymes for subsequent cloning
into placZattB. A detailed list of the primers and constructs that were used is
available upon request.
The sequences of arrC19 and fz3G5 containing mutated TCF sites
(mutated from ttt to ccc, the site is in bold) were synthesized by Entelechon
GmBH as follows: arrC19, 50-CCAACAGCCAGCAGTCTCCCCGTT-
CGACGAATTGCTAATTTATTTCACTCTTGTACCTCGGAACACGCT-
TCCTATCTAGACGTTGGAAAgggACCAATTTAAAGTTTATTTATGG-
CgggTATTAgggTATACCCTCTCTATATTTGGCATTTTTCCTGTTGC-
TCTTTTTTTTTTTGCCTTTTGCAGCTGCCTCTTCGACTGGCGTTTG-
TCAATgggTAACCTGTTGTGCATACTAATTTG-30; fz3G5, 50;-GGTAC-
CCTTTCCCTGCTCTCTGGATGgggGGGCTGCGTCAGAACACGGG-
TAATTGGTATCAACCGAGGCACAATTAAgggGATTGAAGCTGCC-
ACACCGCATGCCGCTCCAACGAACAACGAATCCATCCTACcccTT-
GCCGGCCGTCGTGGCAGGCAACAAGCCGcccCACTGCGGCAACA-
TCGGCACAATAGCAACAGCAACTGTGCAGCAAGCGTGCAATTA-
ACTCTTGTGCGCCAAGATCcccGCGATTAATGCGGCCCCAAGTT-
CCCAGACGAAGGGACTCTAGA-30.
Clone induction
tubArr- and tubFz2-expressing clones were generated by heat-shocking the
larvae for 1 h at 37°C 72 h (±12 h) after egg-laying and dissected 2-3 days after
clone induction. P compartments that expressedUASconstructsweregenerated
by shifting the crosses to 29°C for 2-3 days before dissection. NRT-Wg-
expressing clones were induced 4 days after egg-laying for 15 min at 37°C.
Immunohistochemistry
Immunostainings were performed using standard protocols. Images were
taken by using a Zeiss LSM710 confocal microscope using 40× and 63× oil
objectives and analyzed with the ImageJ software. Maximum z projections
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of ROI were performed for the individual micrographs: Discs were oriented
and processed in Adobe Photoshop, intensities were projected on the longer
axis of the ROI, perpendicular to the dorsal-ventral compartment boundary.
For each condition, we measured at least four independent discs.
The following antibodies were used against the indicated proteins:
β-galactosidase (mouse, 1:2000, Promega); Arrow (rabbit, 1:15,000, a
generous gift from Steve DiNardo, University of Pennsylvania, USA;
Senseless (guinea pig, 1:800, a generous gift from Hugo Bellen, Baylor
College of Medicine, Houston, TX, USA; Wg [mouse, 1:3 (for extracellular
stainings, see Baeg et al., 2001), Developmental Studies Hybridoma Bank];
Fz2 (mouse, 1:30, Developmental Studies Hybridoma Bank); CD2 (rat, Alexa
Fluor 488-conjugated, 1:25, Serotec); HA (rabbit, 1:200, Santa Cruz
Biotechnology).
To detect β-galactosidase activity of the arr reporters, third-instar larvae
were subjected to standard X-Gal reactions. For color detection, we used
standard conditions.
The secondary antibodies used were Alexa Fluor 594-conjugated goat
against mouse IgG, Alexa Fluor 488-conjugated goat against mouse IgG,
Alexa Fluor 594-conjugated against rabbit IgG, Alexa Fluor 488-conjugated
against rabbit IgG, Alexa Fluor 568-conjugated against guinea pig IgG. All
were obtained from Molecular Probes and were used 1:400.
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	Brief	summaries,	discussions	and	outlooks		
	
WNT	 ligands	 control	 initiation	 and	 progression	 of	 human	 papilloma-virus-driven	
squamous	cell	carcinoma	
	
Summary	
Human	papilloma	virus	(HPV)-driven	cutaneous	squamous	cell	carcinoma	(cSCC)	is	the	most	
common	 cancer	 in	 immunosuppressed	 patients.	 Despite	 indications	 suggesting	 that	 HPV	
promotes	 genomic	 instability	 during	 cSCC	 development,	 the	 molecular	 pathways	
underpinning	 HPV-driven	 cSCC	 development	 remain	 unknown.	 We	 compared	 the	
transcriptome	of	HPV-driven	mouse	cSCC	with	normal	skin	and	observed	higher	amounts	of	
transcripts	 for	Porcupine	and	WNT	 ligands	 in	 cSCC,	 suggesting	a	 role	 for	WNT-signaling	 in	
cSCC	progression.	We	 confirmed	 increased	Porcupine	expression	 in	human	 cSCC	 samples.	
Blocking	 the	 secretion	 of	 WNT-ligands	 by	 the	 Porcupine	 inhibitor	 LGK974	 significantly	
diminished	initiation	and	progression	of	HPV-driven	cSCC.	Administration	of	LGK974	to	mice	
with	established	cSCC	resulted	in	differentiation	of	cancer	cells	and	significant	reduction	of	
the	 cancer	 stem	 cell	 compartment.	 Thus,	 WNT/b-catenin	 signaling	 is	 essential	 for	 HPV-
driven	cSCC	initiation	and	progression	as	well	as	for	maintaining	the	cancer	stem	cell	niche.	
Interference	with	WNT-secretion	may	thus	represent	a	promising	approach	for	therapeutic	
intervention.	
	
Outlook	
These	experiments	in	mouse	models	raise	the	question,	if	treating	human	SCC	patients	with	
Porcn	 inhibitors	 might	 be	 a	 suitable	 therapeutic	 approach.	 The	 fact,	 that	 Porcn	 is	 also	
upregulated	 in	human	 tumors	 suggests	 that	 it	 could	have	clinical	 value.	Another	question	
remaining	to	be	answered	is,	 if	Porcn	levels/expression,	have	predictive	value	towards	the	
aggressiveness	of	 the	 cancer.	 Further	experimental	 validation	would	be	needed	 for	Porcn	
113
	inhibitor	 treatments	 to	 be	 ready	 for	 clinical	 trials	 in	 SCC.	 An	 interesting	 line	 of	 future	
investigation	 is	 to	 test	 if	 one	 combines	Wnt/β-catenin	 inhibitors	 together	with	 the	MAPK	
inhibitors.	 Are	 there	 synergies	 between	 the	 two?	 Furthermore,	 an	 alternative	 approach	
might	be	to	apply	the	inhibitors	directly	into	the	tumor	instead	of	giving	them	systemically.	
Thereby,	much	higher	doses	could	be	used,	which	might	be	able	to	kill	an	established	tumor	
instead	of	just	slowing	its	growth.		
Further	confirmation	for	the	feasibility	of	such	a	therapy	might	be	the	use	of	human	primary	
cSCC	cell	lines	in	combination	with	xeno-transplantation.	This	would	enable	us	to	check	the	
ability	of	the	inhibitor	to	block	human	tumor	cell	growth.	In	such	cell	lines,	it	might	also	be	
possible	 to	 use	 the	 Crispr/Cas9	 technology	 to	 test	 some	 possible	 downstream	 effector	
candidates	we	retrieved	from	the	RNA-sequencing	experiment,	such	as	Procr	or	Mmp13.		
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	Pax6-dependent,	but	β-catenin-independent	 function	of	Bcl9	proteins	 in	mouse	 lens	
development	
	
Summary	
Bcl9	 and	 Bcl9l	 (Bcl9/9l)	 encode	 Wnt/b-catenin	 signaling	 components	 that	 mediate	 the	
interaction	 between	 β-catenin	 and	 Pygopus	 (Pygo)	 via	 two	 evolutionarily	 conserved	
domains,	HD1	and	HD2,	respectively.	We	generated	mouse	strains	lacking	these	domains	to	
probe	the	β-catenin-dependent	and	β-catenin-independent	roles	of	Bcl9/9l	and	Pygo	during	
mouse	development.	While	lens	development	is	critically	dependent	on	the	presence	of	the	
HD1	domain,	it	is	not	affected	by	the	lack	of	the	HD2	domain,	indicating	that	Bcl9/9l	act	in	
this	context	in	a	β-catenin-independent	manner.	Furthermore,	we	uncover	a	new	regulatory	
circuit	 in	which	 Pax6,	 the	master	 regulator	 of	 eye	 development,	 directly	 activates	 Bcl9/9l	
transcription.		
	
What	this	work	neglected,	was	the	cause	of	lethality	in	these	embryos,	which	cannot	be	due	
to	the	observed	eye	defect	and	led	to	the	next	project	vide	infra.		
	
	
Mutations	 in	 the	 Wnt/b-catenin	 cofactors	 Bcl9	 and	 Pygo	 Cause	 Congenital	 Heart	
Malformations	
	
Summary	
Congenital	 heart	 diseases	 (CHDs)	 cause	 life-threatening	 conditions	 that	 often	 cannot	 be	
resolved	by	surgical	correction	of	the	structural	defects.	Inspired	by	reports	that	mutations	
in	 the	 Wnt/b-catenin	 cofactors	 BCL9	 and	 BCL9L	 were	 associated	 with	 human	 CHDs,	 we	
sought	to	determine	the	role	of	 these	proteins	 in	 the	onset	of	cardiac	malformations.	We	
show	that	mutations	 in	Bcl9,	Bcl9l	and	 in	the	histone	code-reader	Pygo	 (a	Bcl9-interacting	
protein),	as	well	as	abrogation	of	their	interaction	with	b-catenin	via	small-domain	deletion	
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	induce	 dramatic	 heart	 malformations,	 from	 fish	 to	 mammals,	 that	 recapitulate	 human	
CHDs.	 We	 find	 that	 the	 Bcl9>Pygo	 complex	 transduces	 the	 Wnt/b-catenin-dependent	
transcription	 in	 cardiac	 neural	 crest	 and	 mesodermal	 heart	 progenitor	 cells,	 and	 lies	
upstream	of	heart-specific	master	genes,	 such	as	Prrx1	and	Msx1.	Collectively,	our	 results	
indicate	 that	 Wnt/b-catenin	 orchestrates	 a	 heart-specific	 gene	 regulatory	 network,	 and	
implicate	mutations	 in	BCL9	and	PYGO	as	potentially	causative	 in	the	formation	of	human	
CHDs.	
	
Outlook	
While	the	need	for	the	“chain	of	adaptors”	in	heart	development	is	clear,	there	are	several	
indications	that	Bcl9/9l	also	has	Pygo-independent	functions.	For	instance,	while	Bcl9/9l	KO	
animals	die	at	around	10.5	dpc,	Pygo1/2	KO	mice	survive	until	13.5	dpc.	Furthermore,	we	
observe	severe	limb	defects	(missing	digits)	in	Bcl9/9lDHD1/DHD2	mice,	which	we	never	see	in	
Pygo	mutants.	From	this,	we	must	conclude	that	Bcl9/9l	may	associate	with	another	partner	
in	certain	circumstances.	Certainly,	the	fact	that	the	phenotypes	occur	upon	deletions	in	the	
HD1	and	HD2	domains	suggests	protein-protein	interactions	are	needed	and	makes	a	case	
against	a	direct	interaction	of	Bcl9	with	the	DNA.	The	existence	of	another	partner	of	Bcl9/9l	
is	 further	 supported	 by	 findings	 from	 Andreas	 Moor	 and	 Claudio	 Cantu	 (personal	
communication),	that	the	deletion	of	the	HD1	domain	in	Bcl9/9l	decreases	the	invasiveness	
of	a	mouse	colon	carcinoma	model,	while	the	deletion	of	Pygo1/2	has	no	influence	on	the	
tumors.	Possible	candidates	for	this	alternate	Bcl9	 interaction	partner	are	Tbx	factors.	Not	
only	are	they	associated	with	the	Di	George	syndrome,	which	is	a	human	congenital	disease	
reminiscent	of	our	murine	phenotype,	but	they	are	also	crucial	for	limb	development.	These	
two	 properties	 would	 perfectly	 explain	 a	 role	 for	 them	 in	 facilitating	 b-catenin-Bcl9	
dependent	transcription	in	the	heart	and	limbs.	To	confirm	this	theory,	we	plan	to	perform	
mass	 spectrometry	 on	 limb	 as	 well	 as	 colon	 carcinoma	 samples	 after	 an	
immunoprecipitation	with	Bcl9	as	a	bait.		
Another	 interesting	aspect	of	 the	 limb	defects	we	observed	 in	 the	Bcl9	mutants	was	their	
resemblance	 to	Hedgehog	 loss	 of	 function	 phenotypes,	 in	 fact,	 there	 is	 a	 report	 showing	
very	similar	heart	phenotypes	upon	Hedgehog	signaling	disturbances	(Washington	Smoak	et	
	al.,	2005).	 It	would	be	very	 interesting	to	check	the	interplay	between	Wnt	and	Hedgehog	
signaling	 in	 limb	 and	 heart	 development	 and	 to	 elucidate	 if	Wnt	 signaling	 is	 upstream	of	
Hedgehog	signaling	or	if	they	merely	have	similar	targets	in	this	specific	context.	
	
	 	
	A	regulatory	receptor	network	directs	the	range	and	output	of	the	Wingless	signal	
	
Summary	
The	 potent	 activity	 of	 Wnt/Wingless	 (Wg)	 signals	 necessitates	 sophisticated	 mechanisms	
that	spatially	and	temporally	regulate	their	distribution	and	range	of	action.	The	two	main	
receptor	 components	 for	 Wg	 –	 Arrow	 (Arr)	 and	 Frizzled	 2	 (Fz2)	 –	 are	 transcriptionally	
downregulated	by	Wg	signaling,	 thus	 forming	gradients	 that	oppose	that	of	Wg.	Here,	we	
analyze	the	relevance	of	this	transcriptional	regulation	for	the	formation	of	the	Wg	gradient	
in	 the	Drosophila	wing	disc	by	combining	 in	vivo	 receptor	overexpression	with	an	 in	 silico	
model	of	Wg	receptor	interactions.	Our	experiments	show	that	ubiquitous	upregulation	of	
Arr	and	Fz2	has	no	significant	effects	on	Wg	output,	whereas	clonal	overexpression	of	these	
receptors	leads	to	signaling	discontinuities	that	have	detrimental	phenotypic	consequences.	
These	findings	are	supported	by	our	in	silico	model	for	Wg	diffusion	and	signal	transduction,	
which	suggests	that	abrupt	changes	in	receptor	levels	causes	discontinuities	in	Wg	signaling.	
Furthermore,	we	identify	a	200	bp	regulatory	element	in	the	arr	locus	that	can	account	for	
the	Arr	 gradient,	 and	we	 show	 that	 this	 is	 indirectly	 negatively	 controlled	by	Wg	activity.	
Finally,	we	 analyze	 the	 role	of	 Frizzled	3	 (Fz3)	 in	 this	 system	and	 find	 that	 its	 expression,	
which	 is	 induced	 by	 Wg,	 contributes	 to	 the	 establishment	 of	 the	 Arr	 and	 Fz2	 gradients	
through	counteracting	 canonical	 signaling.	 Taken	 together,	our	 results	provide	a	model	 in	
which	 the	 regulatory	network	of	Wg	and	 the	 three	 receptor	 components	 account	 for	 the	
range	and	shape	of	this	prototypical	morphogen	system.	
	
Outlook	
While	 in	 mammalian	 systems,	 the	 SFRPs	 have	 long	 been	 known	 as	 so-called	 decoy	
receptors,	 dampening	 signaling	 peaks,	 their	 existence	 in	 Drosophila	 was	 never	 shown.	 In	
this	work,	we	showed	that	Fz3	might	take	up	this	function	in	the	fly.	Curiously,	the	loss	of	
Fz3	has	no	apparent	phenotype	 in	D.	melanogaster.	 Therefore,	 it	would	be	 interesting	 to	
test	if	its	loss	might	make	flies	more	prone	to	Wg	induced	tumor	development.		
A	 further	 unanswered	 question	 from	 this	 manuscript	 is,	 which	 transcription	 factors	 are	
responsible	for	the	negative	regulation	of	Arrow	upon	Wg-signaling.	Since	careful	dissection	
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	of	the	Arrow	promoter	and	enhancer	showed	that	Pangolin	does	not	work	as	a	repressor	to	
achieve	 the	described	expression	pattern,	other	 factors	need	 to	be	 responsible.	 Since	 the	
exact	DNA	sequences	where	 these	 factors	bind	are	known,	 immunoprecipitation	with	 this	
stretch	of	DNA	as	bait	followed	by	mass	spectrometry	might	yield	interesting	results.		
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	Conclusion	
	
N-terminal	b-catenin	interactors	have	been	largely	neglected	in	recent	year’s	research	due	
to	 the	 relatively	 weak	 phenotype	 in	 comparison	 to	 the	 full	 β-catenin	 KO	 in	 mammals.	
Further	adding	to	the	confusion	is	the	fact,	that	while	Bcl9	and	Pygo	do	have	an	important	
function	 in	Wnt/β-catenin	 signaling	early	 in	 fly	development,	 it	 is	 not	 known	 if	 they	have	
other	 functions	 later	 in	 development,	 as	 well	 as	 if	 these	 functions	 might	 even	 be	 tissue	
specific	during	 these	 later	stages.	This	 is	quite	 in	contrast	 to	 the	mouse,	where	 they	have	
Wnt-signaling	 dependent	 and	 independent,	 tissue	 specific	 functions.	 With	 this	 work,	 we	
tried	 to	 clarify	 the	 role	 of	 these	 proteins	 as	 Wnt	 signaling	 effectors	 in	 the	 mammalian	
kingdom.	 Specifically,	 we	 wanted	 to	 answer	 the	 question,	 if	 these	 components	 are	 ever	
needed	in	mammalian	development	as	a	tripartite	unit	of	Pygo,	Bcl9	and	b-catenin,	as	was	
described	in	the	fly.		The	intriguing	concept	suggested	by	the	data	described	in	this	thesis	is	
that	this	is	indeed	the	case,	but	in	a	very	specific	way.	These	proteins	add	an	additional	layer	
of	 tissue/cell	 specific	 transcriptional	control,	 that	has	presumably	 the	 function	 to	 regulate	
the	Wnt	 signal	 in	 a	 subset	 of	 cells.	While	most	 cells	 seem	 to	 be	 able	 to	 activate	Wnt/b-
catenin	signaling	without	the	need	for	the	co-factors	Bcl9	and	Pygo,	some	cells	undergoing	
EMT	 and	 interactions	with	 different	 tissues	 need	 these	 factors.	 A	 next	 step	 should	 be	 to	
elucidate	 the	 mechanism	 why	 these	 cells	 need	 those	 co-factors,	 while	 other	 cells	 can	
activate	the	Wnt	signal	to	sufficient	levels	without	them.	One	possibility	that	comes	to	mind	
is,	that	it	is	just	a	problem	of	the	level	of	activation,	but	our	data	indicate	that	this	cannot	be	
the	only	issue,	since	the	downregulation	of	Wnt/b-catenin	reporters	upon	loss	of	Pygo	and	
Bcl9	is	stronger	specifically	in	the	tissues	where	we	also	see	a	phenotype.	
The	discovery	 that	 co-factors	 for	 a	 general	pathway	act	 specifically	 in	 certain	 cell	 types	 is	
also	 of	 interest	 for	 the	 development	 of	 inhibitors	 (e.g.	 Sclerostin,	 (Appelman-Dijkstra	 and	
Papapoulos,	 2016))	 since	 one	 can	 inhibit	 the	 pathway	 in	 a	 specific	 set	 of	 cells	 without	
affecting	the	well-being	of	the	whole	organism.		
In	the	case	of	Wnt	signaling,	inhibitors	targeting	tissue	specific	components	might	be	a	more	
efficient	approach	 than	 targeting	universal	 components,	 such	as	Porcn.	To	avoid	 lethality,	
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	Porcn	 inhibitors	 are	 used	 at	 levels	 where	 the	 pathway	 is	 not	 completely	 abrogated.	 This	
seems	to	work	well	 in	certain	cancers,	but	 it	stands	to	reason	that	where	the	normal	cells	
find	a	way	to	survive	the	inhibition,	cancer	cells	will	find	such	a	way	as	well	at	some	point.		
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	Appendix	
	
β-catenin	 binding	 to	 either	 C-	 or	 N-terminal	 co-factors	 alone	 is	 sufficient	 to	 drive	
Wnt/β-catenin	signaling	in	hair	follicle	regeneration		
	
To	 investigate	 the	 specific	 transcriptional	 outputs	 of	 the	 different	 β-catenin	 interaction	
partners	 in	 the	 skin,	 we	 used	 β-catenin	 alleles	 where	 β-catenin	 binding	 to	 either	 the	
Bcl9/Pygo-axis	 or	 all	 C-terminal	 partners	 was	 abrogated.	 This	 was	 achieved	 by	 i)	 a	 point	
mutation	at	amino	acid	position	164	mutating	a	D	to	an	A,	thus	abrogating	β-catenin	binding	
to	Bcl9	(β-cateninD164A)	and	 ii)	a	deletion	 in	the	C-terminus	of	β-catenin	abrogated	binding	
from	 all	 the	 factors	 of	 the	 transcriptional	 machinery	 binding	 there	 (β-cateninDC).	 A	
combination	of	these	two	mutations	was	also	generated,	which	abrogates	all	transcriptional	
output	 of	 β-catenin,	 while	 retaining	 the	 adherens	 junction	 function	 of	 β-catenin	 (β-
catenindm)	(Valenta	et	al.,	2011).	
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	By	crossing	these	different	β-catenin	alleles	to	β-cateninflox	mice	with	a	Keratin14CreERT	driver	
(active	in	keratinocytes	mostly	of	the	skin),	we	could	study	the	effect	of	specifically	
abrogating	the	binding	of	β-catenin	to	its	C-	or	N-terminal	co-factors,	as	well	as	the	
contribution	of	transcription	and	adherens	junction	function	of	β-catenin	in	the	epidermis	of	
the	skin.	We	could	confirm	that	β-catenin’s	adherens	junction	function	is	negligible	in	the	
epidermis,	as	well	as	Wnt/β-catenin	mediated	transcription	(Huelsken	et	al.,	2001).	This	
contrasts	to	the	role	of	B-catenin	in	hair	follicle	regeneration.	Upon	loss	of	β-catenin,	mice	
slowly	started	to	lose	hair,	primarily	at	sites	with	high	exposure	to	mechanical	stress	like	the	
throat/belly	and	around	the	snout.	Of	note,	they	did	not	lose	the	complete	hair	coat,	as	
would	be	expected	from	loss	of	Wnt/β-catenin	signaling	(Huelsken	et	al.,	2001),	what	can	be	
attributed	to	incomplete	recombination,	as	was	confirmed	by	staining	for	β-catenin	in	skin	
sections	from	such	mice	(Appendix	Figure	4a).	H+E	sections	revealed	the	loss	of	hair	to	be	
accompanied	by	thickening	of	the	epidermis	on	the	belly	(Appendix	Figure	1a)	as	well	as	a	
stark	increase	in	size	of	sebaceous	glands	at	the	cost	of	hair	follicles	(Appendix	Figure	1a,	b).	
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	These	findings	are	in	agreement	with	previous	work	where	β-catenin	was	deleted	in	the	skin	
(Huelsken	et	al.,	2001)(Lim	and	Nusse,	2013).		
Appendix	Figure	1:	A)	Hair	follicles	in	anagen	on	the	back	skin	of	a	mouse	(left	panel,	arrow)	and	catagen	(right	
panel,	arrow)	on	the	throat	of	a	mouse.	B)	shows	the	increase	in	sebaceous	gland	cells	(arrows)	upon	loss	of	β-
cateninenin	signaling	function,	as	well	as	the	thickening	of	the	epidermis	on	the	throat	(right	panel).	
	
The	abrogation	of	β-catenin’s	binding	to	N-terminal	interaction	partners	had	no	discernible	
effect	on	the	mice.	The	hair	coat	looked	normal	and	also	hair	regeneration	after	plucking	did	
not	seem	to	be	affected	in	our	hands.	This	is	contradictory	to	findings,	where	it	was	shown	
that	 loss	 of	 Pygo	 leads	 to	 a	 slowed	 down	 hair	 regeneration	 after	 plucking,	 which	 was	
attributed	to	canonical	Wnt	signaling	(Sun	et	al.,	2014).	One	explanation	for	the	divergent	
results	 could	 be	 recombination	 issues,	 especially	 since	 we	 could	 also	 not	 reproduce	 the	
results	from	the	mentioned	paper	with	our	Pygo	mutants.	A	possible	solution	might	be	the	
use	of	a	different	Cre	driver,	or	even	the	combination	of	two	drivers.	
Control (back)
K14	CreERT,	b-catflox/dm (back)
Control (throat)
K14	CreERT,	b-catflox/dm (throat)
Increase in	sebaceous gland cells upon	loss of b-catenin
a
b
124
	Interestingly,	also	the	loss	of	the	C-terminal	co-activators	did	not	have	dramatic	effects.	The	
mice	still	had	a	quite	complete	hair	coat,	only	around	the	eyes	was	some	bald	skin	observed.	
This	was	somewhat	surprising	because	it	was	shown	that	 in	the	gut,	 loss	of	C-terminal	co-
factors	 mimicked	 the	 complete	 loss	 of	 transcription	 (personal	 communication,	 Tomas	
Valenta).	 H+E	 staining	 on	 skin	 sections	 after	 hair	 plucking	 indicated	 a	 reduction	 in	 hair	
follicle	 numbers	 upon	 loss	 of	 C-terminal	 co-activators	 (Appendix	 Figure	 2).	 To	 further	
investigate	 this,	 we	 used	 immunohistochemistry	 against	 b-catenin	 (antibody	 against	 b-
catenin’s	 C-term)	 to	 check	 recombination	 efficiency,	 which	 was	 around	 60-80%.	 The	
incomplete	recombination	had	the	unintended	advantage	of	giving	us	a	nice	tool	to	analyze	
and	 compare	 clones	of	 cells	with	wild	 type	β-catenin	 to	β-catenindm	or	β-cateninDC	 in	 the	
same	mouse	(Appendix	Figure	4a,	b).	Loss	of	β-catenin	N-terminal	co-factors	in	the	skin	had	
no	significant	effect.	
	
K14	CreERT,	b-cat flox/flox
K14	CreERT,	b-cat flox/dm K14	CreERT,	b-cat flox/dC
b-cat flox/dm (control)
After	anaphase induction,	hair follicle regeneration is severely
hampered upon	b-catenin loss
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	Appendix	Figure	2:	Stark	reduction	of	hair	follicle	numbers	in	anagen	upon	total	 loss	of	β-cateninenin	(upper	
right	panel)	or	its	signaling	function	(lower	left	panel)	after	hair	plucking	in	comparison	to	a	control	(upper	left	
panel,	 arrow).	 The	 loss	 of	 C-terminal	 binding	 partners	 (lower	 right	 panel)	 has	 a	much	weaker	 effect	 on	 the	
reduction	of	hair	follicle	numbers.		
While	we	scored	telogen	stage	hair	follicles	where	only	β-catenindm,	but	no	wild	type	allele	
was	expressed	quite	readily,	we	could	never	find	such	hair	follicles	in	anagen	stage,	which	is	
the	 proliferative	 phase	 (Appendix	 Figure	 4a).	 These	 findings	 are	 in	 line	 with	 previous	
findings	that	Wnt/β-catenin	signaling	is	essential	for	hair	follicle	stem	cells	and	thus	renewal	
of	 the	 hair	 cycle	 (Huelsken	 et	 al.,	 2001).	 Surprisingly	 though,	 we	 did	 find	 hair	 follicles	 in	
anagen,	where	only	β-cateninDC	was	expressed	and	even	some	where	half	 the	 follicle	was	
recombined	while	the	other	half	was	not	(Appendix	Figure	4a).	These	results	suggest,	that	
N-terminal	β-catenin	co-activators	can	be	sufficient	to	carry	out	most	functions	of	β-catenin	
mediated	transcription	in	hair	follicle	regeneration.	Interestingly,	cells	with	a	wild	type	allele	
of	β-catenin	also	do	not	have	a	stark	advantage	in	proliferation,	since	they	seem	not	to	be	
able	to	out-compete	the	mutated	cells.		
Since	β-cateninDC	 cells	were	 also	 still	 able	 to	 induce	 strong	 expression	of	 Lef1,	which	 is	 a	
bona	fide	Wnt/β-catenin	target	gene	in	hair	follicles,	we	can	conclude	that	this	isoform	of	β-
catenin	 is	 indeed	 still	 able	 to	 activate	 Wnt/β-catenin	 signaling	 in	 this	 context	 (Appendix	
Figure	4b).	A	confirmation,	that	recombination	issues	were	responsible	for	the	only	partial	
hair	loss	upon	Tamoxifen	administration	to	β-cateninflox/flox	or	β-catenindm/flox	mice,	was	the	
finding	 that	 upon	Wls	 deletion	 (Bänziger	 et	 al.,	 2006),	 hair	 regeneration	 was	 completely	
abrogated	(Appendix	Figure	3).	
126
		
Appendix	Figure	3:	The	left	panel	shows	hair	follicles	in	anagen	induced	by	hair	plucking,	the	right	panel	the	
same	situation	upon	deletion	of	Wls	and	thus	inhibition	of	Wnt	signaling.	 	
Complete loss of hair follicles upon	deletion of Wntless with an	
ubiquitous Cre driver
Control Rosa26Cre,	Wlsflox/flox
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Appendix	 Figure	 4:	 A)	 shows	 the	 incapability	 of	 hair	 follicles	 to	 enter	 anagen	 upon	 loss	 of	 β-cateninenin’s	
signaling	function	(upper	and	lower	right	panels),	the	only	hair	follicles	in	anagen	are	those	not	recombined	for	
β-cateninenin	 (green	 and	 red	 staining).	 The	 lower	 left	 panel	 shows	 that	 hair	 follicles,	 that	 only	miss	 the	 C-
terminus	but	still	have	the	rest	of	β-cateninenin	intact	(red	staining	only)	can	survive.	These	cells	are	also	not	
outcompeted	by	unrecombined	cells	since	hair	follicles	consisting	of	red	and	green	stained	cells	exist	(arrow).	
B)	shows	that	hair	follicle	cells	without	C-terminal	β-cateninenin	interactor	binding	can	still	express	the	Wnt-
target	gene	Lef1.	
K14	CreERT,	b-cat flox/dm
DAPI
b-cat
b-cat C-termK14	CreERT,	b-cat flox/dC
Hair	regeneration is possible without C-terminal	b-catenin co-
activators
K14	CreERT b-cat flox/flox
DAPI
b-cat
Lef1
K14	CreERT,	b-cat flox/dCb-catflox/+		(control)
b-catflox/+		(control)a
b
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	β-catenin’s	signaling	function	is	necessary	for	HPV-induced	cSCC	growth	
	
Experiments	with	chemically	induced	cSCCs	revealed	the	crucial	role	that	β-catenin	plays	in	
the	establishment	of	these	tumors	due	to	the	necessity	of	Wnt/β-catenin	signaling	in	cSCC	
CSCs	(Malanchi	et	al.,	2008).	
What	 was	 largely	 neglected	 so	 far	 was	 the	 question,	 what	 specific	 outputs	 of	 β-catenin	
signaling	was	 necessary	 for	 cSCC	 establishment	 and	 survival	 and	 if	 the	 adherens	 junction	
function	 of	 b-catenin	 plays	 any	 role	 in	 these	 tumors.	 Therefore,	 we	 used	 the	 above	
described	 alleles	 of	 β-catenin	 (Valenta	 et	 al.,	 2011),	 to	 shed	 light	 on	 the	 specific	
transcriptional	changes,	mediated	by	Wnt/β-catenin	signaling,	 that	ultimately	block	 tumor	
growth.		
To	study	this,	we	used	a	UV	inducible	K14-HPV8-E6	SCC	tumor	model	(Marcuzzi	et	al.,	2009),	
since	 tumor	 induction	 is	 much	 faster	 (around	 2-3	 weeks)	 in	 comparison	 to	 chemical	
induction.	 We	 crossed	 the	 mice	 harboring	 the	 K14-HPV8-E6	 transgene	 to	 mice	 with	 an	
inducible	skin	driver	(Keratin5-CrePR,	inducible	by	a	synthetic	steroid)	(Kasper	et	al.,	2011)	
and	crossed	in	the	β-catenin	alleles	(flox,	dm,	DC	and	D164A).		
Tumor	induction	after	deletion	of	β-catenin	or	abrogating	its	transcriptional	outputs	(via	β-
catenindm)	 completely	 failed.	 This	 was	 somewhat	 surprising,	 since	 immunohistochemistry	
confirmed	 the	 incomplete	 β-catenin	 recombination	 (ca.	 50%)	we	 observed	 already	 in	 the	
experiments	on	hair	follicles	and	skin	(Appendix	Figure	5a).	This	argues	for	the	hypothesis,	
that	 in	 this	 cancer	model,	 there	might	be	a	non-cell	 autonomous	need	 for	Wnt/β-catenin	
signaling	 or	 at	 least	 a	 crucial	 number	 of	 cells	 need	 to	 be	 able	 to	 transduce	 the	Wnt/b-
catenin	signal.	A	ligand,	important	for	tumor	induction,	might	be	needed	to	be	secreted	by	
most	of	 the	 cells	 in	high	enough	amounts,	or	 the	 immune	 system	 recognizes	 recombined	
cells	and	then	blocks	 tumor	 induction.	These	 findings	also	suggest	 that	 tumor	 induction	 is	
most	 likely	not	 from	a	single	cell	 in	 this	model,	otherwise	 the	non-recombined	cells	could	
still	readily	be	tumorigenic.		
We	could	also	show	that	Sox9	as	well	as	the	MAPK	cascade	do	not	seem	to	be	affected	by	
this	loss	of	Wnt	signaling	(Appendix	Figure	5b,	c).	This	is	especially	surprising	in	the	case	of	
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	Sox9,	 since	 it	 was	 recently	 shown	 to	 be	 a	 Wnt	 target	 gene	 in	 Basal	 Cell	 Carcinoma	
(Larsimont	et	al.,	2015).	
The	experiments	using	b-catenin	alleles	which	 lack	the	ability	 to	bind	C-	or	N-terminal	co-
factors	are	currently	being	analyzed.		
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HPV8E6;	K5CrePR;	b-catenin	dm/floxK5CrePR;	b-catenin	dm/flox
(neg.	control)
HPV8E6;	K5CrePR;	b-catenin	flox/flox HPV8E6;	b-catenin	wt
(pos.	control)
b-catenin
DAPI
HPV8E6;	K5CrePR;	b-catenin	dm/flox
(hyperplasia)
K5CrePR;	b-catenin	dm/flox
(healthy	skin)
b-catenin
DAPI
p-Erk
HPV8E6;	K5CrePR;	b-catenin	dm/flox HPV8E6;	b-catenin	wt
b-catenin
DAPI
Sox9
cSCCs do	not	grow	without	b-catenin
a
b
c
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	Appendix	Figure	5:	A)	shows	the	inability	of	cSCCs	to	develop	without	β-cateninenin’s	signaling	function.	The	
lower	right	panel	shows	a	tumor	3	weeks	after	UV-irradiation,	the	upper	left	panel	shows	skin	from	a	mouse	
without	 the	 E6	 transgene	 3	 weeks	 after	 UV-irradiation.	 The	 upper	 right	 panel	 shows	 that	 loss	 of	 β-
cateninenin’s	 signaling	 function	 still	 allows	 some	 hyperplasia	 of	 keratinocytes	 upon	 UV-irradiation,	 but	 no	
proper	tumor	growth.	This	despite	the	fact,	that b-catenin	recombination	is	 incomplete	(green	staining).	The	
same	holds	true	for	complete	loss	of	b-catenin	(lower	left	panel).	
B)	 clarifies	 that	 the	MAPK	 signaling	 cascade	 is	 still	 activated	 upon	 UV-irradiation	 in	 E6	 positive	mice	 (right	
panel),	despite	the	absence	of	b-catenin	signaling.	This	is	not	sufficient	to	allow	tumor	development.		
C)	Sox9	expression	is	not	β-catenin	in	dependent	(left	panel).	
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	Appendix	Materials	and	Methods	
	
Mice	 experimental	 procedures:	 Tumors	 were	 induced	 by	 UVA	 (10 J/cm2) and	 UVB	 (1.5 
J/cm2) irradiation.	The	higher	doses	 in	comparison	to	the	above	described	procedures	was	
necessary	because	C57BL/6	mice	were	used	instead	of	FVB	mice.	Genotyping	was	done	with	
primers	according	to	the	Jackson	lab	and	(Valenta	et	al.,	2011).		
Hair	 plucking	 to	 induce	 anagen	was	 done	 by	 plucking	 hair	 in	 a	 1cm2	 square	with	 forceps	
under	isoflurane	anesthesia.	Mice	were	sacrificed	between	5	and	8	days	after	plucking.	
Recombination	of	β-catenin	alleles	with	the	Keratin14	driver	was	induced	by	10	times	2mg	
Tamoxifen	 applications	 intraperitoneal	 (Tamoxifen	 diluted	 in	 corn	 oil,	 volume	of	 injection	
was	200ul).		
The	 conditional	 Keratin5	 driver	 was	 induced	 by	 intraperitoneal	 Ru486	 injection	 (5	 times	
2mg).	
Stainings	were	done	as	described	in	the	included	manuscripts.	
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